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Preface 
 
Sickle Cell Disease (SCD) is a worldwide health problem with a burden comparable to 
that of communicable diseases and other major global diseases such as diabetes and 
hypertension. Furthermore, over 3/4 of this burden is in sub-Saharan Africa, with limited 
studies investigating the genetic polymorphisms that affect the severity, hematologic 
phenotypes, disease course and less so, the mechanism of action of the only approved 
medication for treatment of SCD, namely hydroxyurea (HU). It was therefore advisable 
to present the current PhD thesis in this format, “with inclusion of publications”, mostly 
reported or submitted in international peer-reviewed journals in order to populate this 
sparse niche in SCD research.  Moreover, the multiple peer reviews by international 
researchers was also intended to improve the quality of the final outcomes in the thesis, 
which will hopefully, contributed significantly to scholarship in this field. In addition, the 
inclusion of published work also aimed to: (i) set a path that would bolster the academic 
career of the candidate and enhance his candidacy for the financial support received 
from the NRF, Oppenheimer Memorial Trust and FirstRand Laurie Dippenaar 
Scholarship; (ii) enable participation in and attendance at academic conferences and 
training workshops: the candidate effectively attended a total of 16 specialised meetings 
in several cities including Cape Town, Johannesburg, Tunis, Kyoto, London, 
Washington DC and Chicago; and lastly (iii) the published works would form integral 
parts of a cohesive body of research that will fit the encouragement policies of the 
Faculty of Health Sciences (UCT) to publish the findings of research projects, 
particularly at the doctoral level, in order to continue to disseminate the knowledge 
generated within the Faculty and enhance the profile of the institution. 
With the advice and guidance of the supervisors, the candidate’s contributions to the 
included publications ranged from conceiving and designing the experiments; recruiting 
and sampling of biological material from participants; execution of all experiments; 
analysis of experimental results; drafting the full manuscripts and incorporating revisions 
from co-authors and journal reviewers. The candidate’s contribution to this project and 
thesis can be detailed as follows: 
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Conception of research: 
The study and all experiments were conceived by the candidate in conjunction with the 
supervisors, primary supervisor Professor Ambroise Wonkam and jointly refined with 
the advice of Dr Shaheen Mowla and Professor Nicolas Novitzky (co-supervisors). 
Data collection: 
All necessary recruitment of participants, obtaining informed consent/assent and 
sampling biological material in this project was executed in its entirety by the candidate. 
All the required DNA, RNA and protein isolation and cataloguing of patient material was 
done by candidate. The clinical information of participants was also retrospectively 
collected from hospital records and patient files by the candidate. 
Experimentation and analysis: 
All experiments; molecular analysis by genotyping and sequencing; and functional 
analysis by tissue culture and expression analysis of messenger transcript, microRNA 
and protein was executed in full by the candidate. The primary analysis of all data was 
performed by the candidate and when additional statistical analysis was required, a 
collaborator was included by the primary supervisor and their contribution to the work 
clearly indicated in each publication. 
Publications: 
Synthesis of all the works and drafting of all manuscripts of the publications included in 
this thesis were executed in full by the candidate, after which revisions from all co-
authors were similarly incorporated before submission to the journal by the primary 
supervisor. After review, all reviewer comments were addressed by the candidate in 
conjunction with the primary supervisor. The detailed role of the candidate in the 
publications included is clearly defined in each chapter. 
This project and thesis is presented with three cohesive elements; (i) genetic modifiers 
of fetal hemoglobin; (ii) mechanisms of HU-induced γ-globin expression and lastly, (iii) 
the southern African perspective of SCD. 
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We have met all requirements and abided by the UCT’s Doctoral Degrees Board, under 
Rules GP6.7 as follows: 
(i) The candidate’s proposal to include publications in the current thesis was 
approved by the UCT Faculty of Health Sciences Doctoral Degrees Board. 
(ii) The thesis contains an adequate Introduction; a chapter on the Aims and 
Objectives; a comprehensive Academic Discussion of the results as a whole, 
forming the basis of the Conclusions and Perspectives drawn from this 
research. 
(iii) Each Results chapter with publications included, is preceded by a synopsis of 
how the publications directly tie to the aims and objectives of the project, as 
well as to the thesis as a whole. 
(iv) All included publications were written and published during the candidate’s 
tenure as a PhD student. 
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Abstract 
 
Sickle Cell Disease (SCD) is a growing global problem with firm roots in sub-Saharan 
Africa (SSA) representing over 3/4 of the global burden of the disease. The prevalence 
of the sickle mutation (HbS) in SSA has been amplified by the partial resistance to 
Plasmodium falciparum malaria, which is endemic along tropical equatorial Africa. 
Several genetic variants have since been associated with fetal hemoglobin (HbF), the 
disease-ameliorating globin protein, including variants at three principal loci; BCL11A, 
HBS1L-MYB intergenic polymorphisms (HMIP1/2) and the β-globin gene cluster, which 
together account for 10 – 20% HbF variance in SCD patients. Similarly, numerous 
signalling pathways have been implicated in the regulation of γ-globin expression, 
however, a complete understanding of the regulation of HbF remains elusive.  
The overall aims of this project were: 1a) to investigate the known variants in key HbF-
promoting loci such as BCL11A erythroid-specific enhancer, BCL11A, HBS1L-MYB 
intergenic polymorphism (HMIP1/2), the β-globin gene cluster, as well as the influence 
of the co-inheritance of 3.7kb alpha globin gene deletion in a cohort of SCD patients 
from Cameroon; and 1b) to validate novel HbF-promoting loci reported in 2 genome-
wide association studies (GWAS) carried out in a population of Sardinians (Italy) and 
SCD patients from Tanzania and explore the influence of known promoter variants in 
SAR1 associated with HbF in African American patients amongst Cameroonian SCD 
patients; 2) to investigate the molecular mechanisms of hydroxyurea (HU)-induced 
production of HbF using a primary erythroid cell model from hematopoietic stem cells 
(HSCs) derived from umbilical cord blood and lastly, 3) to investigate the prevalence of 
SCD-related polymorphisms; β-globin gene haplotype, HbS mutation and malaria-
resistance variants in 3 SCD-unaffected (HbAA) cohorts from South Africa, Zimbabwe 
and Malawi. 
The studies revealed the following findings:  
Regarding the exploration of HbF-promoting loci: 1) two erythroid-specific enhancer 
polymorphisms in BCL11A (rs1427407 and rs7606173) were shown to account for 8% 
and 6.2% HbF variance in Cameroon SCD patients, respectively; 2)  there is some 
xiii
 
 
 
evidence from the β-globin gene haplotype studies to support a provocative hypothesis 
of a single origin of the HbS mutation in the East Africa/Sudan region, after the original 
study of a Cameroonian cohort, coupled with  a systematic review of the global 
distribution of the β-globin haplotype; 3) no associations among Cameroonian patients 
were observed between the 18 novel and suggestive SNPs and HbF levels from a 
Tanzanian GWAS SCD cohort and the whole genome sequencing of a population in 
Sardinia: 4) Furthermore, no association was found between HbF levels and SAR1a 
promoter variants previously associated with HbF in African American patients.  
Regarding the mechanism of action of HU: 1) A systematic review of the known 
mechanisms of HU-induced HbF revealed 3 main molecular and regulatory pathways; 
(i) epigenetic and transcriptional events regulating response to HU, ii) signalling 
pathways involved in HU-mediated response and iii) post-transcriptional pathways of 
gene expression by microRNAs (miRNAs) regulation. 2) The erythroid model was 
successfully generated and used to show that HU promotes HbF production by down-
regulating negative regulators; BCL11A, KLF-1 and MYB, through miRNA-mediated 
action with miR-26b at the core of MYB silencing.  
Regarding the studies of SCD within the Southern African context: Our data 
confirmed that; 1) the evolutionary dynamics of various African genomes (through 
selective pressure of malaria), with a decreasing frequency of the sickle mutation and 
specific malaria-associated genomic variants, when studying populations from central-
west to southern Africa; 2) the study prompts a debate on the dissociation of the 
assumed congruence between genetics and cultural/linguistic/anthropological heritages 
of various so-called Bantu African populations. It further proposes population 
classification by geographical location evidenced by the presence of the sickle mutation 
in the Malawian and not in the Xhosa study participants, despite several cultural 
similarities. These data indicate that the perspective of using the classical 
ethnolinguistic label of “Bantu” may be irrelevant for pharmacogenetics and drug 
efficacy studies; 3) the findings of the β-globin gene haplotypes in the 3 Southern 
African populations unexposed to malaria, displayed an expected high frequency of the 
Atypical haplotype, a higher prevalence of Benin instead of Bantu haplotype and seeks 
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to contribute to understanding the origin and distribution of the sickle mutation and 
migration path of southern African populations following the Bantu expansion; 4) lastly, 
the clinical and epidemiological study of SCD confirm (i) the increasing burden of adult 
SCD patients at Groote Schuur Hospital in Cape Town, as previously reported in 
paediatric patients at Red Cross War Memorial Hospital, as a result of the recent 
migration of populations from central/eastern African countries where SCD is prevalent 
and (ii) seeks to caution national health and academic institutions to adapt policies, 
health care and professional training, accordingly. 
In conclusion, this multifaceted thesis has reported on: 1) the importance and clinical 
implications of two erythroid-specific enhancer polymorphisms in BCL11A (rs1427407 
and rs7606173), and provided evidence of the necessity and complexity of replicating 
findings of HbF-promoting loci across populations, 2) the post-transcriptional 
mechanism of HU to promote HbF production by down-regulating negative regulators; 
BCL11A, KLF-1 and MYB, through miRNA-mediated action with miR-26b at the core of 
MYB silencing; 3) and the increasing burden of SCD in adult patients in Cape Town and 
the importance of studying Southern African populations to understand the evolutionary 
dynamics of Bantu population genomes under the selective pressure of malaria.  
Collectively, the studies of predisposing polymorphisms to hereditary persistence of 
HbF in adulthood or mechanisms of HbF production in response to HU, particularly 
through miRNAs regulation, reveal some alternative perspectives and routes towards 
identifying new therapeutic targets and approaches for SCD.  
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Chapter 1 – Introduction 
 
Sickle Cell Disease (SCD) is the oldest monogenic disease, first reported in 1910 
(Herrick, 2001), and is concomitant with anaemia, progressive organ damage and 
chronic and acute illness (Weatherall et al., 2005). Sickle Cell Anemia (SCA), the most 
common and severe form of SCD, is caused by a T>A nucleotide substitution in the 
17th position of the β-globin gene on chromosome 11p (Bunn, 1997). The mutation 
causes a change in the 6th amino-acid of the peptide from glutamic acid to valine 
(β6Glu>Val). A hydrophobic motif is then created in the deoxygenated SCA-hemoglobin 
(HbS) resulting in polymerization between the β1 and β2 chains of the HbS molecules 
(Brittenham, Schechter & Noguchi, 1985). The HbS polymers grow and crystalize within 
the erythrocytes, promoting cellular dehydration and disruption of the intracellular 
architecture and oxygen-carrying capacity of the erythrocytes. This manifests in the 
characteristic sickled-shaped erythrocytes (Herrick, 2001). The sickled cells drive 2 
main pathophysiological processes i.e. vaso-occlusion and hemolytic anaemia. The 
aberrant-shaped erythrocytes cause occlusion in micro-vessels via abnormal 
erythrocyte-endothelial interactions resulting in tissue ischemia and inflammation 
(Frenette, 2002). Restoration of blood flow promotes tissue and organ damage through 
the release of free-oxygen radicals that initiate symptoms of acute pain, vasculopathy 
and endothelial dysfunction due to intravascular and extravascular hemolysis 
SCA accounts for nearly 70% of SCD cases in populations of African ethnic origin 
(Serjeant, Hambleton & Thame, 2005) and has the highest disease burden in Sub-
Saharan African with in excess of 300 000 affected new-borns per year, accounting for 
0.74% of all births in the region and 80% of annual global affected child births (Modell & 
Darlison, 2008). The high disease-related mortality is generally ascribed to bacteraemia 
and malaria (Serjeant, 2001; Serjeant, Hambleton & Thame, 2005). SCD is common 
and most severe in Africa but not to the point of exclusion of other continents such as 
North America and Europe with 2 600 and 1 300 affected new-borns annually, 
respectively (Modell & Darlison, 2008). There is strong correlation between the 
frequency of the HbS gene and the historical distribution and incidences of malaria 
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(Williams et al., 2005). This is mainly due to partial carrier-resistance to Plasmodium 
falciparum malaria, albeit the mechanisms of protection are not fully understood. The 
geographical co-occurrence of SCD and malaria and the partial carrier-resistance have 
caused the local amplification and positive selection of the HbS allele (Flint et al., 1998). 
Similarly, genetic mutations that often co-segregate with HbS such as HbC and β-
thalassemia, have also undergone selection within similar populations. Furthermore, it is 
well accepted that the HbS allele exists on diverse genetic haplotype backgrounds 
(Pagnier et al., 1984; Labie et al., 1985), with five, independent and defined region-
specific disease haplotypes based on the combination of five sequence variants across 
the β-globin gene cluster. Four haplotypes are associated with HbS allele in Africa 
(Benin, Bantu/Central African Republic (CAR), Senegal and Cameroon) and the fifth is 
thought to have arisen in India and/or the Arabian Peninsula (Arab/Hindu) (Pagnier et 
al., 1984; Elion et al., 1992). The β-globin haplotypes have been associated with 
disease severity and progression (Steinberg, 2009; Alsultan et al., 2012). 
Approximately, 10% of children with SCA have cerebrovascular accidents (Ohene-
Frempong et al., 1998) and a correlation between silent infarctions and overt strokes in 
young children has been elucidated (Miller et al., 2000; Miller et al., 2001). Pulmonary 
hypertension due to vaso-occlusion is another frequent complication in children with 
SCD (Collins & Orringer, 1982).  Early diagnosis, prophylaxis and penicillin have been 
proven to decrease disease-related mortalities (Gaston et al., 1986; Vichinsky, 1991) 
and drastically improve (Lee et al., 1995)survival rates in the Caribbean (Lee, 1995), 
United States (Quinn, Rogers & Buchanan, 2004), the United Kingdom (Telfer et al., 
2007) as well as in Africa (Fleming, 1989; Rahimy et al., 2009)(Fleming, 1989). Despite, 
SCD being vastly heterogeneous and multi-systemic, fetal hemoglobin (HbF) has 
emerged as has the central disease modifier (Platt et al., 1994), which is amenable to 
therapeutic manipulation (Bauer & Orkin, 2011). HbF is largely regulated by genetic 
variants at three principal loci, BCL11A, HBS1L-MYB and β-globin gene cluster, 
accounting for 10-20% of HbF variation (Menzel et al., 2007; Creary et al., 2009; Thein 
et al., 2009); among SCD patients in USA and Brazil (Lettre et al., 2008), Tanzania 
(Makani et al., 2011) and Cameroon (Wonkam et al., 2014).   
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Currently, hydroxyurea (HU) is the only Food and Drug Administration (FDA-USA)-
approved (Centre of Drug Evaluation and Research App No. 75143, 1998) 
pharmacologic treatment for induction of HbF in patients with SCD. The major HU 
benefit is directly related to its HbF-producing effect (Lebensburger et al., 2010; 
Lebensburger et al., 2011) that leads to significant reduction of pain, acute chest 
episodes, the need for blood transfusions and mortality (Steinberg et al., 2003; 
Steinberg, 2009; Voskaridou et al., 2010; Lobo et al., 2013). The first clinical application 
of HU showed swift and vivid increases in HbF concentration within reticulocytes and 
insignificant toxicity to bone marrow (Platt et al., 1984b) and subsequent trials further 
demonstrated clinical efficacy and increase in survival rates and life expectancy 
(Steinberg et al., 2003; Voskaridou et al., 2010), protection against cerebrovascular 
disease (Zimmerman et al., 2007), long term drug safety, capacity to prevent organ 
damage, reduced morbidity and mortality in school-age children (Kinney et al., 1999), 
toddlers (Hankins et al., 2005; Thornburg et al., 2009) and infants (Wang & Thompson, 
2010). Several studies have demonstrated variability in the response to HU treatment, 
with induced HbF levels ranging from 10% to greater than 30% (Maier-Redelsperger et 
al., 1998; Kinney et al., 1999; Zimmerman et al., 2004). Some of this variance has been 
attributed to variants at principal HbF-promoting loci like BCL11A  (Ware et al., 2011). 
However, despite this, a complete understanding of the molecular mechanisms by 
which HU induces HbF are not fully understood. 
In this thesis, we investigated such critical HbF-promoting loci; BCL11A enhancer, HBB 
globin haplotype, SAR1a and several other variants previously associated with HbF 
(Chapters 3.1.3 and 3.3.2). Secondly, we attempted to elucidate a miRNAs-mediated 
post-transcriptional mechanism of HbF induction through ex-vivo HU treatment of 
human umbilical cord blood-derived erythroid progenitors. Lastly, we reported the 
clinical phenotypes and genomic data of a cohort of SCD patients at Groote Schuur 
Hospital (Cape Town, South Africa) and investigated the prevalence of SCD-related 
polymorphisms; β-globin gene haplotype, HbS mutation and malaria-resistance 
variants; in 3 SCD-unaffected (HbAA) cohorts from South Africa, Zimbabwe and Malawi.  
4 
 
 
Investigation of HbF-promoting loci and the molecular mechanisms of HU carries 
substantial clinical significance as a better understanding of these genomic variants 
could reveal novel genomic drug-targets in SCD; improve population-specific drug 
design, targeting and efficacy, as well as the clinical management of patients based on 
their genetic predispositions. Most importantly, ex-vivo disease modelling will build on 
the knowledge base of drug mechanisms and elucidate potential alternative therapeutic 
approaches and targets, whereas an updated perspective of SCD in southern Africa will 
ensure necessary training to medical personnel, improved patient management and 
counselling and appropriate adaptation of healthcare legislation and policies. 
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Chapter 2 – Aims and Objectives 
 
Aim 1: 
To investigate variants in key HbF-promoting loci such as BCL11A, HBS1L-MYB, 
SAR1, α-thalassemia and the β-globin gene cluster, in a cohort of SCD patients from 
Cameroon and validate novel HbF-promoting loci reported in 2 genome-wide 
association studies (GWAS) carried out in Sardinia and Tanzania and SAR1a promoter 
variants associated with HbF in African American patients. 
Objectives: 
1. Design genotyping assays for HbF-promoting loci (including primer design and 
optimization of PCR, SNaPshot and direct Sanger sequencing assays); 
2. Genotype a total of 28 loci associated with HbF including BCL11A (intragenic 
variants and enhancer elements), SAR1, α-thalassemia 3.7kb gene deletion 
allele and gene polymorphism conferring the β-globin gene haplotypes in 
Cameroon SCD patients. The loci investigated are: rs1427407; rs7606173; 
rs8176703; rs372091; rs2334880; rs2310991; rs4282891; rs76901216; 
rs76901220; X12_123681790; X16_391593; rs10468869; rs10756993; 
rs113267280; rs11754265; rs141494605; rs148706947; rs183437571; 
rs192197462; rs57001381; rs59329875; rs62573842; rs6466533; rs6590706; 
rs67104793; rs7163278; α-thalassemia 3.7 and 4.2kb gene deletions. 
3. Validate (in SCD patients from Cameroon) results observed in genome-wide 
association studies (GWAS) performed in Sardinia and SCD patients from 
Tanzania and SAR1a promoter variants associated with HbF in African American 
patients. 
4. Perform analysis using an additive genetic model, under a generalized linear 
regression framework, to investigate the relationship between these 
polymorphisms and HbF. 
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Aim 2: 
To investigate the molecular mechanisms of hydroxyurea (HU)-induced production of 
HbF using a primary erythroid cell model from hematopoietic stem cells (HSCs) derived 
from umbilical cord blood. 
Objectives: 
1. Recruit and harvest human umbilical cord blood from elective cesarean healthy 
controls (HbAA) from Mowbray Maternity Hospital (Cape Town, South Africa); 
2. Isolate, expand and differentiate human umbilical cord blood-derived HSCs into 
erythroid progenitors; 
3. Treat erythroid and the K562 cells with HU and investigate the molecular 
mechanisms of HbF induction through differential gene, miRNAs and protein 
expression; 
4. Perform miRNA inhibition assays for candidate miRNAs associated with HU; 
protein quantification assays using western blot and flow cytometry.  
Aim 3: 
To investigate the prevalence of SCD-related polymorphisms; β-globin gene haplotype, 
HbS mutation and malaria-resistance variants in 3 SCD-unaffected (HbAA) cohorts from 
South Africa, Zimbabwe and Malawi. 
Objectives: 
1. Perform genotyping assays for select variants associated with SCD; β-globin 
gene haplotype, HbS mutation and malaria-resistance variants on 3 cohorts from 
southern Africa that are unaffected (HbAA) by SCD, from South Africa, 
Zimbabwe and Malawi. 
 
 
 
 
 
7 
 
 
Chapter 3.1 – Results 
 
Study of additional fetal hemoglobin-promoting loci 
 
3.1.1. Bitoungui VL, Pule DG, Hanchard N, Ngogang J and Wonkam A. Beta-Globin 
Gene Haplotypes Among Cameroonians And Review Of The Global Distribution: Is 
There A Case For A Single Sickle Mutation Origin In Africa? OMICS. 2015 19(3): 171-9. 
 
Abstract 
Studies of hemoglobin S haplotypes in African subpopulations have potential 
implications for patient care and our understanding of genetic factors that have shaped 
the prevalence of sickle cell disease (SCD). We evaluated HBB gene cluster haplotypes 
in SCD patients from Cameroon, and reviewed the literature for a global distribution. We 
reviewed medical records to obtain pertinent socio-demographic and clinical features for 
Synopsis of Chapter 3.1 
Fetal hemoglobin (HbF) is the central modifier of Sickle Cell Disease and is inherited 
as a quantitative trait under the regulation of variants at principal HbF-promoting loci. 
Understanding the genetic predispositions to hereditary persistence of HbF in 
adulthood will explain the vast heterogeneity of the disease and improve management. 
The present chapter includes four original publications (reporting on a cohort of 
Cameroon SCD patients) that;  
i) Represent the background of this chapter and describes the global 
distribution of Sickle Cell Disease haplotypes and as a result, puts forward a 
provocative but likely hypothesis of a single origin for the sickle mutation in 
Africa. 
ii) Validates the relationship between HbF and two SNPs (rs1427407 and 
rs7606173) in a BCL11A erythroid-specific enhancer and provides the first 
report on a West African cohort. 
iii) Shows no association between variants previously associated with 
favourable pharmacologic response to HU in African American SCD 
patients. 
iv) Shows no associations between 17 novel SNPs (from a Tanzanian GWAS 
and whole genome sequencing in Sardinia) and HbF levels, other 
hematological indices or clinical events. 
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610 Cameroonian SCD patients, including hemoglobin electrophoresis and full blood 
counts. RFLP-PCR was used to determine the HBB gene haplotype on 1082 
chromosomes. A systematic review of the current literature was undertaken to 
catalogue HBB haplotype frequencies in SCD populations around the world. Benin 
(74%; n = 799) and Cameroon (19%; n = 207) were the most prevalent haplotypes 
observed among Cameroonian patients. There was no significant association between 
HBB haplotypes and clinical life events, anthropometric measures, hematological 
parameters, or fetal hemoglobin (HbF) levels. The literature review of the global 
haplotype distributions was consistent with known historical migrations of the people of 
Africa. Previously reported data from Sudan showed a distinctly unusual pattern; all four 
classical haplotypes were reported, with an exceptionally high proportion of the 
Senegal, Cameroon, and atypical haplotypes. We did not observe any significant 
associations between HBB haplotype and SCD disease course in this cohort. Taken 
together, the data from Cameroon and from the wider literature suggest that a careful 
reassessment of African HBB haplotypes may shed further light on the evolutionary 
dynamics of the sickle allele, which could suggest a single origin of the sickle mutation. 
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and Review of the Global Distribution:
Is There a Case for a Single Sickle Mutation
Origin in Africa?
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Abstract
Studies of hemoglobin S haplotypes in African subpopulations have potential implications for patient care and
our understanding of genetic factors that have shaped the prevalence of sickle cell disease (SCD). We evaluated
HBB gene cluster haplotypes in SCD patients from Cameroon, and reviewed the literature for a global dis-
tribution. We reviewed medical records to obtain pertinent socio-demographic and clinical features for 610
Cameroonian SCD patients, including hemoglobin electrophoresis and full blood counts. RFLP-PCR was used
to determine the HBB gene haplotype on 1082 chromosomes.
A systematic review of the current literature was undertaken to catalogue HBB haplotype frequencies in SCD
populations around the world. Benin (74%; n= 799) and Cameroon (19%; n= 207) were the most prevalent
haplotypes observed among Cameroonian patients. There was no significant association between HBB haplotypes
and clinical life events, anthropometric measures, hematological parameters, or fetal hemoglobin (HbF) levels. The
literature review of the global haplotype distributions was consistent with known historical migrations of the people
of Africa. Previously reported data from Sudan showed a distinctly unusual pattern; all four classical haplotypes
were reported, with an exceptionally high proportion of the Senegal, Cameroon, and atypical haplotypes.
We did not observe any significant associations between HBB haplotype and SCD disease course in this cohort.
Taken together, the data from Cameroon and from the wider literature suggest that a careful reassessment of
African HBB haplotypes may shed further light on the evolutionary dynamics of the sickle allele, which could
suggest a single origin of the sickle mutation.
Introduction
S ickle cell disease (SCD) is caused by a point mutation(A >T) in the sixth codon of the b-globin gene on chro-
mosome 11, resulting in the substitution of the amino acid
valine for glutamic acid.
SCD affects the structure of erythrocytes by altering the
normal biconcave shape to a crescent. During this process the
hemoglobin S (HbS) mutation leads to polymerization and
precipitation of hemoglobin during deoxygenation or de-
hydration, resulting in sickling, abnormal adhesion of
leukocytes and platelets, inflammation, hypercoagulation,
hemolysis, and hypoxia, in addition to microvascular ob-
struction and ultimately organ damage (Bartolucci et al.,
2012). SCD is most prevalent among populations in regions
of the world where malaria has been endemic and it is esti-
mated that 305,800 births with SCD occur annually, nearly
two-third of which take place in Africa (Piel et al., 2013).
It is well accepted that the sicklemutation exists inAfrica on
diverse genetic haplotype backgrounds (Labie al., 1985). Five
typical haplotypes have been described across the b-globin
gene cluster based upon the pattern of specific RFLPs across
the region. Four haplotypes are associated with HbS in Africa
(Benin, Bantu/Central African Republic (CAR), Senegal, and
Cameroon) and the fifth is thought to have arisen in India
and/or the Arabian Peninsula (Arab/Hindu) (Elion et al., 1992;
Pagnier et al., 1984). It has been suggested that these haplo-
types also have an effect on the severity of the disease (Asultan
et al., 2012; Steinberg, 2009) and possibly the clinical response
to hydroxyurea (Friedrisch et al., 2008)—currently the only
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available treatment for SCD. Furthermore, these haplotypes
have a well-defined geographic distribution in Africa, making
it possible to establish the origin of African-descendant pop-
ulations in America (Pagnier et al., 1984; Serjeant, 1989), but
also the origin of SCD among Europeans from Mediterranean
regions. Studies of SCD haplotypes in African subpopulations
therefore have potential implications for the clinical care of
patients and for our understanding of the dynamic population
genetic factors that shape the SCD phenotype.
Cameroon is a sub-Saharan African country with a popu-
lation of about 20 million inhabitants and an annual growth
rate of 3%, with a carrier frequency of SCD ranging from 8%
to 34% (Wheatherall et al., 2001). Universal medical insur-
ance coverage does not exist, and care of SCD patients is
therefore dependent on financial support and care-giving by
family members (Wonkam et al., 2013a). Sadly, poverty in
Cameroon affects more than 50% of the rural population and
up to 30% of the urban population (World Bank, 2010), and
the financial burden of medical care for SCD is often not met
(Wonkam et al., 2013a, 2014a).
SCD patients in Cameroon frequently suffer exceptionally
severe complications such as stroke (Njamnshi et al., 2006)
and executive neurocognitive compromise (Ruffieux et al.,
2013). Consanguinity, ascertained by pedigree analysis, is
observed in 5.7% of the population, most of which is found in
the northern Sahelian regions of Cameroon where the Arabo-
Muslim influence is stronger (Wonkam et al. 2013b). Be-
cause of its central location on the continent, Cameroonians
cultural, linguistic, and genetic diversity mimics that of
various ethno-linguistic groups found in Africa (Tishkoff
et al., 2009). It is therefore anticipated that genetic studies in
this population might reveal important insights to other Af-
rican populations. The aim of this study was to explore the
frequency and influence of HBB haplotypes amongst a group
of Cameroonian SCD patients and to compare our findings to
published data from Africa and worldwide.
Materials And Methods
Ethics statement
Ethical approval was granted by the National Ethical
Committee Ministry of Public Health, Republic of Cameroon
(No 033/CNE/DNM/07), and the University of Cape Town,
Faculty of Health Sciences Human Research Ethics Com-
mittee (HREC RE: 132/2010).
Patients and assessment of clinical events
The study was conducted at the Yaounde´ and Douala,
the two largest cities in Southern Cameroon. Socio-
demographic and clinical data were collected by means of a
structured questionnaire for parents/guardians and patients.
Patients’ medical records were reviewed to delineate their
clinical features over the past 3 years. Specifically, the oc-
currences of vaso-occlusive painful crisis (VOC), hospital
outpatient visits, hospitalizations, overt strokes, blood trans-
fusions, and administration of hydroxyurea were recorded.
Anthropomorphic variables (height, weight, body mass index
(BMI)) and systolic and diastolic blood pressures (SBP and
DBP) were measured in the outpatient setting. Detailed de-
scriptions of sampling methods used in the Cameroonian have
been previously reported (Wonkam et al, 2014c).
Hematological phenotypes
Hemoglobin electrophoresis and routine complete blood
count were conducted on each patient upon arrival at the
hospital. Two methods of fetal hemoglobin (HbF) detection
were employed; the alkali denaturation test (ADT) in 55.5%
(n = 344) of the patients, and subsequent high performance
liquid chromatography (HPLC) in the remainder. HbF levels
measurements done in patients < 5 years old were excluded
from the analysis, because HbF levels are not yet stable at this
age (Wonkam et al, 2014c).
Genotypes
Cameroonian patients. DNA samples were extracted
from peripheral blood, following manufacturer’s instructions
(Puregene blood kit� (Qiagen�, USA) at the molecular di-
agnostic laboratory, Gyneco-Obstetric and Paediatric Hospi-
tal, Yaounde´, Cameroon. Genotype analyses were performed
in the Division of Human Genetics, Faculty of Health Sci-
ences, University of Cape Town.
Molecular diagnostic testing for sickle cell anemia (SCA;
HbSS). SCA diagnosis was carried out using 200 ng of
DNA. A thermocycler (Biorad�, USA) was used to amplify a
770 bp segment of the b-globin gene, followed by Dde I
(Gibco-BRL�, USA) restriction analysis of the PCR product,
as previously reported (Saiki et al., 1985).
Haplotyping of b-globin gene cluster. Five restriction
fragment length polymorphism (RFLP) regions in the b-gene
cluster were amplified using published methods designed to
analyze the XmnI (5’Gc), HindIII (Gc), HindIII (Ac), HincII
(3?’Cb), and HinfI (5’b) restriction sites (Steinberg et al.,
1998). RFLP sites and the fragments were visualized by
agarose gel electrophoresis, and b-globin gene haplotypes
were defined by examining the combination of the restriction
sites. The bS haplotypes were constructed from the absence
( - ) and presence ( + ) of each of the five restriction enzyme
sites in 541 individuals with HbSS. Of the samples studied,
sickle (bS) haplotypes were identified through a specific al-
gorithm (Supplementary Table S1; supplementary material is
available online at www.liebertonline.com/omi)). Haplo-
types were classified as ‘atypical’ if they did not match the
five known typical bS haplotypes.
Literature review
A review of the current literature on SCD haplotypes was
conducted from June 2013 to July 2014 using Pubmed (Na-
tional Library of Medicine), Medline, and Google Scholar.
Key words included a combination of the following: ‘‘Hap-
lotype,’’ ‘‘Sickle Cell,’’ ‘‘Africa,’’ and specific country names
were also used. Prior knowledge of research groups working
on sickle cell disease in Africa and globally further facilitated
the identification and selection of research articles. Only
available full-length articles, in English, with the use of at least
five (5) RFLP to differentiate the five main types of haplotype,
were selected. In cases where multiple studies were reported in
the same population, the most recent with the largest sample
size was included. The main search was conducted by a PhD
student in Human Genetics and the search was reviewed by a
Medical/Human Geneticist with expertise in SCD.
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Statistical analysis
Descriptive statistics were obtained for all quantitative data
using SPSS (IBM, USA version 21.0). Normality was con-
firmed by the Shapiro-Wilk Test followed by the use of
parametric (Chi-squared test and t-test) or nonparametric tests
(Mann-Whitney U test for two samples or the Kruskal-Wallis
one-way ANOVA for more than two samples). To correct for
the skewed HbF distribution, the data were log10-transformed
and normalized to obtain the quantitative trait used in the as-
sociation analysis (after correcting for age, gender, and elec-
trophoresis technique and history of transfusion).
Results
Socio-demographic of Cameroonian SCD patients
The description of the study sample is presented in Table 1.
Among the 610 patients; 50.3% were female with mean age
of 17.3– 10 years (range: 5–54 years) and the majority of
patients were children aged between 5–10 years (32.2%;
n = 196) and adolescents 11–20 years (50%; n = 305). Patients
lived mostly in the urban areas of Yaounde´ and Douala (93%;
n = 567), both located in the southern part of Cameroon. The
median age at diagnosis of SCD, was 3 years (range: 1
month—29 years). Forty two percent (n = 158) of fathers and
23% (n = 108) of mothers were formally employed; and in
75%, the monthly direct incomes were < 300 USD.
Haplotypes in the beta-globin gene cluster,
clinical events, and HbF in Cameroonian patients
Following the full blood count and HbF electrophoresis
and RFLP-PCR, the vast majority of patients were deter-
mined to have SCA (HbSS) (97.4%; n = 594). In addition, 61
randomly selected patients were Sanger sequenced, and SCA
diagnosis was confirmed in all of them. There was no evi-
dence of the deletional form of HbS b-thalassemia.
Based on analysis of 1082 chromosomes, the allele fre-
quencies of various haplotypes showed that Benin (74%;
n = 799) and Cameroon (19%; n = 207) were the most prev-
alent forms. Bantu/CAR (n = 5), Senegal (n = 3), and Indian-
Arab (n = 2) haplotype were very rare. Atypical haplotypes
accounted for 6% (n = 66). Homozygous Benin/Benin hap-
lotypes represented 57% (n= 307), Benin/Cameroon 25%
(n= 137), Benin/atypical 8% (n = 45), and Cameroon/
Cameroon 5% (n= 26) of diploid haplotype frequencies.
There were no significant associations between major hap-
lotype combinations and hematological indices (Table 2),
clinical events (Table 3), or HbF levels (Fig. 1).
Global distribution of haplotypes
As demonstrated in Figure 2 and Table 4, the Benin hap-
lotype was the most prevalent globally with its highest fre-
quency in West Africa, the Mediterranean region, America,
and Europe. The Bantu/CAR haplotype was most prevalent
in central, southern, and East Africa, and in relatively high
proportion in Central and South America and parts of Europe,
as compared to North America. The Senegal haplotype was
restricted to the far west regions of Africa, with the exception
of Sudan and had a relatively low frequency in America; the
Indian-Arab haplotype was almost completely restricted to
part of India and the Middle East.
Exceptional HBB haplotype distribution in Sudan?
When data within Africa was compared, the literature re-
view revealed four major features in Sudanese SCD patients:
1) all four classical SCD haplotypes were reported in sig-
nificant proportions; 2) Cameroon haplotype was reported in
a much higher proportion in Sudan than in Cameroon; 3)
surprisingly, there was a higher proportion of Senegal hap-
lotypes in Sudan when compared to the rest of East Central
and parts of West Africa, and lastly 4) there was a relatively
high proportion of atypical haplotypes (Elderdery et al.,
2012) (Table 4, Fig. 2).
Discussion
To the best of our knowledge, the present study represents
the largest study of HBB haplotypes in a single African
country, and is the most comprehensive review of the global
distribution of HBB SCD haplotypes thus far. The data pre-
sented confirm the origin and flow of people from Africa
through the slave trade and/or migration, and emphasize
differences in settlement on the American coasts dependent
on whether slaves were brought from the Gulf of Guinea or
from Angola (Fong et al., 2013). Similarly, trade and mi-
gration routes to theMediterranean areas and theMiddle East
from West Africa explain the high prevalence of Benin
haplotypes and general pattern of haplotype distribution in
those parts of the world (Fig. 2).
The present study also confirms that the majority of the
chromosomes with the b(S) globin gene are consistent with
one of the five common RFLP haplotypes, designated as
Benin, Bantu/CAR, Senegal, Cameroon, and Arab-Indian
haplotypes. In most settings, 5%–10% of the chromosomes
are less commonly observed haplotypes, usually referred to
as ‘‘atypical’’ haplotypes (Table 4). However, on the African
continent and in two independent studies, atypical haplotypes
Table 1. Description of SCD Cameroonian Patients
Variables N Mean – SD
Minimum–
Maximum
M/F 303/307
Age (Yrs) 610 17.3 – 10 5–58
RBC (1012/L) 610 2.8 – 0.7 1.2–6.5
Hb (g/dL) 610 7.8 – 1.6 3.8–16.5
MCV (fL) 610 84.4 – 9.9 59–117
MCHC (g/dL) 610 34.0 – 3.8 21.5–54.3
WBC (109/L) 610 13.7 – 5.6 2.9–49.8
Monocytes (109/L) 610 1.5 – 1 0.1–11.9
Pl atelets (109/L) 610 374.6 – 123 97–837
HbA2 (%) (HPLC)* 244 3.3 – 1.3 0–9.7
HbF (%) (HPLC)* 244 7.5 – 4.8 0–22.7
N VOC /Yr 572 3 – 3 0–40
N hospital
attendance (per Yr)
608 2.2 – 3.2 0–60
N hospital
admission (per Yr)
606 2.3 – 3 0–30
N patients with at least
one overt stroke
25/608 4.1%
*Hb electrophoresis was also obtained from 344 patients (55.5%)
using alkali denaturation test (ADT), with a mean of 11.4 – 9.4 for
HbF and 4.1– 2.1 for HbA2 levels.
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appear in relatively high frequency in Sudan, in concert with
all the other types of African haplotypes, particularly a rel-
atively high proportion of Senegal and Cameroon haplotypes
(Elderdery et al., 2012; Mohammed et al., 2006). The rela-
tively high frequency of the Cameroon haplotype in Sudan
versus in Cameroon (Elderdery et al., 2012) is not completely
anomalous, but rather the reflection that the geographical
nomenclature of haplotypes (named according to the first
region of observation) does not necessarily reflect their place
of origin. The refinement of the molecular structure (i.e.,
haplotype) in HBB and migration patterns is still urgently
needed, specifically in Africa.
Two decades ago, the observation of a specific RFLP
pattern of the Cameroon haplotype strongly argued for yet
another independent origin of the sickle cell mutation in
Africa (Lapoumeroulie et al., 1992). The Cameroon haplo-
type was then said to be restricted to a single ethnic group, the
Eton of Central Cameroon (Lapoumeroulie et al., 1992),
which is contrary to current data from Sudan (Elderdery et al.,
2012; Mohammed et al., 2006). More recently, a specific
atypical haplotype in Tunisia was considered by authors as
specific to the Tunisian chromosome b(S) (Imen et al., 2011).
In the case of the Cameroon and Tunisia, these specific
haplotypes were likely generated by a variety of genetic
mechanisms including (a) isolated nucleotide changes in one
of the polymorphic restriction sites, (b) simple and double
crossovers between two typical b(S) haplotypes, or much
more frequently between a typical b(S) haplotype and a
different b(A)-associated haplotype that was present in the
population, and (c) gene conversions (Zago et al., 2000)—all
of which have been observed at the beta-globin locus (Borg
et al., 2009; Holloway et al., 2006; Liu et al., 2009; Neumann
et al., 2010; Patrinos et al., 2005; Sankaran et al., 2011).
Thus, a relatively high frequency of what was originally an
atypical b(S) haplotype might subsequently be labeled a
‘‘new’’ haplotype supposedly (albeit unlikely) bearing a new
independent b(S) mutation, as was postulated by the authors
of the original globin haplotype report (Wainscoat et al.,
1983). To date, the existence of at least five different geo-
graphic centers of origin has been postulated on the basis of
the predominance of major haplotypes associated with the
b(S) mutation. The multiple and independent origins of the
b(S) mutation (Chakravarti et al., 1984; Nagel and Fleming,
1992) also fails to account for the absence of b(S) mutation
from malarial regions in Southeast Asia and Oceania (Flint
et al., 1993), although many other hemoglobin gene muta-
tions also confer malaria protection, including a- and
b-thalassemia traits and other structural variants of hemo-
globin that are common in Southeast Asia.
In addition, the hypothesis of multiple independent origins
raises the question of how several identical mutations could
have occurred in a short period of time in Africa after the
appearance of malaria, despite the low mutation rate of nu-
clear DNA (Currat et al., 2002). It is also possible that gene
conversion has played a role in moving the b(S) mutation to
different haplotype backgrounds in sub-Saharan Africa. Re-
solution of RFLP haplotypes with recently described long-
range sickle haplotypes (Ghansah et al., 2012; Hanchard et al.,
Table 2. Median Values of Hematological Indices Among Cameroonian SCD
Patients Conditioned on HBB Haplotypes
Hematological
variables
Benin/Benin
(n = 307)
Benin/Cam
(n = 137)
Benin/Atypical
(n = 45)
Cameroon/Cameroon
(n= 26) P values
RBC (1012/L) 2.7 2.6 2.8 2.6 0.6
Hb (g/dL) 7.7 7.5 7.8 7.6 0.5
MCV (fL) 85 84 86 83.5 0.9
MCHC (g/dL) 33.4 34.1 32.6 34.3 0.5
Platelets (109/L) 395 374 350 382 0.4
WBC (109/L) 12.6 13.6 13.1 14.3 0.5
Lymphocytes (109/L) 5.2 5.6 5.4 6.5 0.1
Monocytes (109/L) 1.3 1.3 1.3 1.3 1
Table 3. Clinical Event Among Cameroonian SCD Patients Conditioned on HBB Haplotypes
Benin/Benin Benin/Cameroon Benin/Atypical Cameroon/Cameroon
N
Median (25th-
75th centiles) N
Median (25th-
75th centiles) N
Median (25th-
75th centiles) N
Median (25th-
75th centiles) P values
BMI (kg/m2) 251 18 (14.9–21) 103 17.2 (15–20.1) 39 17 (14.4–19.7) 23 17.9 (15.1–18.5) 0.12
SBP mmHg 259 108 (100–115) 107 107 (98–115) 40 109 (99–113.5) 21 108 (99–115)
DBP mmHg 259 58 (54–65) 107 58 (52–64) 40 59 (53.5–64.5) 21 56 (53–60) 0.56
No. of VOC/Year
Stroke
Yes 13 – 6 – – – – 0.8
No 294 – 131 – 45 – 25 –
No. of consultation/
Year
301 1 (0–4) 135 2 (0–4) 45 1 (0–3) 26 1 (0–4) 0.66
No. of hospitalization/
Year
301 1 (0–2) 135 1 (0–2) 45 1 (0–2) 26 1 (1–2) 0.54
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FIG. 1. Distribution of fetal hemoglobin levels conditioned on HBB haplotypes. Boxes
have lines at the lower quartile, median, and upper quartile. The plot whiskers extend up
and down from the median a distance 1.5 times the interquartile range of the boxes
(truncated at zero where necessary). Outliers are the points outside the whiskers indicated
as circles. There were not significant differences across various combination of haplotypes
( p = 0.54) and between them.
FIG. 2. Global distribution of haplotypes among various world SCD populations.
Previously reported data allow drawing a global haplotype distribution that was con-
sistent with known historical migrations of the people of Africa. Among Indigenous
African populations, published data from Sudan (arrow) showed a distinctly unusual
pattern; all four classical haplotypes were reported, with an exceptionally high pro-
portion of the Senegal and Cameroon haplotypes.
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2007), together with next-generation sequencing, should pro-
vide definitive answers to this long-standing question.
It is then perhaps provocative and ambitious, but not un-
reasonable, to hypothesize that, there could be a single origin
of the sickle cell mutation, in the region of East Africa/Sudan,
with additional haplotypes generated by diverse structural
mechanisms, and the spread to the rest of the continent
through traditional migratory patterns. Recently, both phy-
logenetic and network analysis indicate that east Africans
possess more ancestral mitochondrial lineages in comparison
to various continental populations placing them at the foot of
the human evolutionary tree. Interestingly, the two most
ancestral mitochondrial sequences in the NJ tree figure refer
to Nubian individuals in Sudan (Elhassan et al., 2014).
Moreover, a compound associated with a lithic Middle Stone
Age industry was discovered in Dhofar Oman and regarded
as evidence of human migration out of Africa through an
Arabian route (Rose et al., 2011).
Therefore, the shared rs7482144 SNP in both the Senegal
and Indian-Arab haplotypes invites the question of whether
Table 4. Global b-S Haplotype Distribution from Previously Reported Data
b-S Haplotypes
Arab-Indian Bantu/Car Benin Cameroon Senegal Atypical
Continents Countries N* (%) N (%) N (%) N (%) N (%) N (%) References
Africa Algeria 0 (0.0) 0 (0.0) 20 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) Pagnier et al., 1984
Angola 0 (0.0) 42 (95.5) 2 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) Lavinha et al,. 1992
Cameroon 3 (0.3) 5 (0.5) 799 (73.8) 207 (19.1) 2 (0.2) 66 (6.1) The present data
Congo 0 (0.0) 211 (91.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 (9.1) Mouele et al., 1999
Egypt 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Guinea 0 (0.0) 9 (22.5) 0 (0.0) 31 (77.5) 0 (0.0) 0 (0.0) Sow et al., 1995
Kenya 0 (0.0) 109 (98.2) 2 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) Ojwang et al., 1987
Madagascar 0 (0.0) 32 (91.4) 0 (0.0) 0 (0.0) 1 (2.9) 2 (5.7) Hewitt et al., 1996
Mauritania 5 (5.6) 4 (4.4) 8 (8.9) 0 (0.0) 70 (77.8) 3 (3.3) Veten et al., 2012
Nigeria 0 (0.0) 6 (1.0) 624 (93.2) 23 (3.4) 0 (0.0) 16 (2.4) Adekile et al., 1992
Senegal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 90 (100.0) 0 (0.0) Currat et al,. 2002
Sudan 0 (0.0) 4 (2.8) 42 (29.4) 50 (35.0) 26 (18.2) 21 (14.6) Elderdery et al., 2012
Tanzania 0 (0.0) 41 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Oner et al., 1992
Tunisia 0 (.0) 9 (2.7) 201 (60.5) 0 (0.0) 0 (0.0) 122 (36.7) Imen et al,. 2011
Uganda 0 (0.0) 207 (99.5) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) Ndugwa et al., 2012
Asia India 128 (91.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 12 (8.6) Mukherjee et al., 2004
Bahrain 33 (89.2) 2 (5.4) 1 (2.7) 0 (0.0) 0 (0.0) 1 (2.7) Al-Arrayed,1995
Iran 87 (53.7) 5 (3.1) 19 (11.7) 4 (2.5) 6 (3.7) 41 (25.3) Rahimi et al., 2003
Iraq 16 (12.5) 10 (7.8) 89 (69.5) 0 (0.0) 0 (0.0) 13 (10.2) Al-Allawi et al., 2012
Jordan 4 (20.0) 0 (0.0) 16 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Kuwait 101 (80.8) 7 (5.6) 14 (11.2) 0 (0.0) 0 (0.0) 3 (2.4) Adekile, 2001
Lebanon 10 (10.0) 15 (15.0) 73 (73.0) 0 (0.0) 0 (0.0) 2 (2.0) Inati et al., 2003
Oman 31 (26.5) 25 (21.4) 61 (52.1) 0 (0.0) 0 (0.0) 0 (0.0) Daar et al,. 2000
Palestine
(wb)#
0 (0.0) 6 (5.1) 104 (88.1) 0 (0.0) 0 (0.0) 8 (6.8) Samarah et al., 2009
Saudi-arabia
(se)^
2 (1.6) 0 (0.0) 122 (98.4) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Syria 6 (33.3) 0 (0.0) 12 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
United
Arab
Emirates
49 (52.0) 24 (26.0) 21 (22.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Kalla & Baysal,
1998
North
America
Canada 0 (0.0) 7 (11.5) 30 (49.2) 8 (13.1) 8 (13.1) 8 (13.1) Oner et al., 1992
Cuba 0 (0.0) 81 (40.9) 101 (51.0) 0 (0.0) 16 (8.1) 0 (0.0) Muniz et al., 1995
Jamaica 0 (0.0) 37 (8.3) 339(76.0) 0 (0.0) 23 (5.2) 47 (10.5) Ndugwa et al., 2012
Mexico 0 (0.0) 26 (78.8) 6 (18.2) 0 (0.0) 0 (0.0) 1 (3.0) Magana et al., 2002
Trinidad 9 (3.2) 49 (17.3) 175 (61.8) 10 (3.5) 24 (8.5) 16 (5.7) Jones-Lecointe et al.,
2008
USA$ 12 (0.8) 129 (21.6) 503 (58.9) 38 (6.1) 76 (8.0) 48 (4.6) Crawford et al., 2002
South
America
Uruguay 0 (0.0) 6 (60.0) 2 (20.0) 0 (0.0) 0 (0.0) 2 (20.0) Luz et al., 2006
Brazil 1 (0.4) 104 (41.6) 138 (55.2) 3 (1.2) 1 (0.4) 3 (1.2) Adorno et al., 2008
Colombia 1 (0.4) 68 (29.7) 76 (33.2) 10 (4.4) 10 (4.4) 64 (27.9) Fong et al., 2013
Suriname 0 (0.0) 23 (29.9) 41 (53.2) 2 (2.6) 2 (2.6) 9 (11.7) Oner et al, 1992
Venezuela 0 (0.0) 57 (32.2) 90 (50.8) 4 (2.3) 25 (14.1) 1 (0.6) Arends et al., 2000
Europe Portugal 0 (0.0) 14 (42.4) 12 (36.4) 0 (0.0) 7 (21.2) 0 (0.0) Lavinha et al., 1992
Italy 0 (0.0) 0 (0.0) 64 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) Schiliro et al., 1992
Turkey 1 (0.5) 0 (0.0) 206 (96.3) 0 (0.0) 0 (0.0) 7 (3.3) Oner et al., 1992
Greece 0 (0.0) 0 (0.0) 13 (92.9) 0 (0.0) 1 (7.1) 0 (0.0) Oner et al., 1992
*N, number of chromosomes; #WB, West Bank; ^SE, South Eastern; $USA, combined African-American and Hispanic data.
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2007), together with next-generation sequencing, should pro-
vide definitive answers to this long-standing question.
It is then perhaps provocative and ambitious, but not un-
reasonable, to hypothesize that, there could be a single origin
of the sickle cell mutation, in the region of East Africa/Sudan,
with additional haplotypes generated by diverse structural
mechanisms, and the spread to the rest of the continent
through traditional migratory patterns. Recently, both phy-
logenetic and network analysis indicate that east Africans
possess more ancestral mitochondrial lineages in comparison
to various continental populations placing them at the foot of
the human evolutionary tree. Interestingly, the two most
ancestral mitochondrial sequences in the NJ tree figure refer
to Nubian individuals in Sudan (Elhassan et al., 2014).
Moreover, a compound associated with a lithic Middle Stone
Age industry was discovered in Dhofar Oman and regarded
as evidence of human migration out of Africa through an
Arabian route (Rose et al., 2011).
Therefore, the shared rs7482144 SNP in both the Senegal
and Indian-Arab haplotypes invites the question of whether
Table 4. Global b-S Haplotype Distribution from Previously Reported Data
b-S Haplotypes
Arab-Indian Bantu/Car Benin Cameroon Senegal Atypical
Continents Countries N* (%) N (%) N (%) N (%) N (%) N (%) References
Africa Algeria 0 (0.0) 0 (0.0) 20 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) Pagnier et al., 1984
Angola 0 (0.0) 42 (95.5) 2 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) Lavinha et al,. 1992
Cameroon 3 (0.3) 5 (0.5) 799 (73.8) 207 (19.1) 2 (0.2) 66 (6.1) The present data
Congo 0 (0.0) 211 (91.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 (9.1) Mouele et al., 1999
Egypt 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Guinea 0 (0.0) 9 (22.5) 0 (0.0) 31 (77.5) 0 (0.0) 0 (0.0) Sow et al., 1995
Kenya 0 (0.0) 109 (98.2) 2 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) Ojwang et al., 1987
Madagascar 0 (0.0) 32 (91.4) 0 (0.0) 0 (0.0) 1 (2.9) 2 (5.7) Hewitt et al., 1996
Mauritania 5 (5.6) 4 (4.4) 8 (8.9) 0 (0.0) 70 (77.8) 3 (3.3) Veten et al., 2012
Nigeria 0 (0.0) 6 (1.0) 624 (93.2) 23 (3.4) 0 (0.0) 16 (2.4) Adekile et al., 1992
Senegal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 90 (100.0) 0 (0.0) Currat et al,. 2002
Sudan 0 (0.0) 4 (2.8) 42 (29.4) 50 (35.0) 26 (18.2) 21 (14.6) Elderdery et al., 2012
Tanzania 0 (0.0) 41 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Oner et al., 1992
Tunisia 0 (.0) 9 (2.7) 201 (60.5) 0 (0.0) 0 (0.0) 122 (36.7) Imen et al,. 2011
Uganda 0 (0.0) 207 (99.5) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) Ndugwa et al., 2012
Asia India 128 (91.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 12 (8.6) Mukherjee et al., 2004
Bahrain 33 (89.2) 2 (5.4) 1 (2.7) 0 (0.0) 0 (0.0) 1 (2.7) Al-Arrayed,1995
Iran 87 (53.7) 5 (3.1) 19 (11.7) 4 (2.5) 6 (3.7) 41 (25.3) Rahimi et al., 2003
Iraq 16 (12.5) 10 (7.8) 89 (69.5) 0 (0.0) 0 (0.0) 13 (10.2) Al-Allawi et al., 2012
Jordan 4 (20.0) 0 (0.0) 16 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Kuwait 101 (80.8) 7 (5.6) 14 (11.2) 0 (0.0) 0 (0.0) 3 (2.4) Adekile, 2001
Lebanon 10 (10.0) 15 (15.0) 73 (73.0) 0 (0.0) 0 (0.0) 2 (2.0) Inati et al., 2003
Oman 31 (26.5) 25 (21.4) 61 (52.1) 0 (0.0) 0 (0.0) 0 (0.0) Daar et al,. 2000
Palestine
(wb)#
0 (0.0) 6 (5.1) 104 (88.1) 0 (0.0) 0 (0.0) 8 (6.8) Samarah et al., 2009
Saudi-arabia
(se)^
2 (1.6) 0 (0.0) 122 (98.4) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
Syria 6 (33.3) 0 (0.0) 12 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) El-Hazemi et al., 1999
United
Arab
Emirates
49 (52.0) 24 (26.0) 21 (22.0) 0 (0.0) 0 (0.0) 0 (0.0) El-Kalla & Baysal,
1998
North
America
Canada 0 (0.0) 7 (11.5) 30 (49.2) 8 (13.1) 8 (13.1) 8 (13.1) Oner et al., 1992
Cuba 0 (0.0) 81 (40.9) 101 (51.0) 0 (0.0) 16 (8.1) 0 (0.0) Muniz et al., 1995
Jamaica 0 (0.0) 37 (8.3) 339(76.0) 0 (0.0) 23 (5.2) 47 (10.5) Ndugwa et al., 2012
Mexico 0 (0.0) 26 (78.8) 6 (18.2) 0 (0.0) 0 (0.0) 1 (3.0) Magana et al., 2002
Trinidad 9 (3.2) 49 (17.3) 175 (61.8) 10 (3.5) 24 (8.5) 16 (5.7) Jones-Lecointe et al.,
2008
USA$ 12 (0.8) 129 (21.6) 503 (58.9) 38 (6.1) 76 (8.0) 48 (4.6) Crawford et al., 2002
South
America
Uruguay 0 (0.0) 6 (60.0) 2 (20.0) 0 (0.0) 0 (0.0) 2 (20.0) Luz et al., 2006
Brazil 1 (0.4) 104 (41.6) 138 (55.2) 3 (1.2) 1 (0.4) 3 (1.2) Adorno et al., 2008
Colombia 1 (0.4) 68 (29.7) 76 (33.2) 10 (4.4) 10 (4.4) 64 (27.9) Fong et al., 2013
Suriname 0 (0.0) 23 (29.9) 41 (53.2) 2 (2.6) 2 (2.6) 9 (11.7) Oner et al, 1992
Venezuela 0 (0.0) 57 (32.2) 90 (50.8) 4 (2.3) 25 (14.1) 1 (0.6) Arends et al., 2000
Europe Portugal 0 (0.0) 14 (42.4) 12 (36.4) 0 (0.0) 7 (21.2) 0 (0.0) Lavinha et al., 1992
Italy 0 (0.0) 0 (0.0) 64 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) Schiliro et al., 1992
Turkey 1 (0.5) 0 (0.0) 206 (96.3) 0 (0.0) 0 (0.0) 7 (3.3) Oner et al., 1992
Greece 0 (0.0) 0 (0.0) 13 (92.9) 0 (0.0) 1 (7.1) 0 (0.0) Oner et al., 1992
*N, number of chromosomes; #WB, West Bank; ^SE, South Eastern; $USA, combined African-American and Hispanic data.
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the Indian-Arab haplotype evolved from an east African
chromosome with Senegal haplotype. In fact, a specific study
of the Senegal haplotype concluded that migration from the
east of Senegal was implicated in the spread of this mutation
across west African populations and the exact geographic
origin of the Senegal b(S) mutation was not located (Currat
et al., 2002). It could well be even further east of Senegal,
perhaps as far east as Sudan/East Africa region. It was
suggested more than 2 decades ago, that although b(S) is
attributed to recent independent mutations occurring ap-
proximately 2000 years ago (Currat et al., 2002), the sepa-
ration and geographical distribution of African populations
allows for the possibility of an ancient origin of b(S) muta-
tion. The authors even suggested that b(S) could have pro-
tected selected populations from malaria in rain forest
refuges during the most recent Ice Age (Stine et al., 2011).
The data reviewed here provides evidence that the detailed
geographic distribution of known sickle haplotypes is still not
well established, as many African countries do not have re-
ported data. Were this available, it is conceivable that a
gradient of haplotype frequencies from East Africa to other
parts of the continent could have emerged differently. Further
genetic studies in well-defined populations from across
Africa are urgently needed, to allow determination of the
exact extent of the spread of various HBB haplotypes, as this
would help to identify the mutation’s geographical origin
precisely, and to explore the recent increase in frequency of
the b(S) mutation, irrespective of its haplotypic background.
The data reported here emphasize the need to re-explore the
origin of sickle cell mutation as well as past and recent
evolutionary dynamics of African human populations, as this
could yield important information about the evolutionary
history of SCD, which of course hold significant clinical
relevance (Adorno et al., 2008).
HbF is the most powerful biological modifier of SCD phe-
notype and influenced by genomic variations. In a recent study,
we confirmed in this group of Cameroonian SCD patients,
robust genetic associations between HbF levels and BCL11A
and HBS1L-MYB intergenic locus (Wonkam et al., 2014c), as
previously reported inAfrican Americans andAfro- Brazilians
(Lettre et al., 2008) and Tanzanians (Makani et al., 2011).
However, due to the virtual absence of the Senegal and Indian-
Arab haplotypes, which contain the XmnI variant (rs7482144),
we lacked power to replicate the association of rs7482144 in
HBG2 with HbF levels in Cameroonian; this SNP explains
2.2% of the variation in HbF levels in African American SCD
patients (Labie et al., 1985; Lettre et al., 2008). Indeed, there
was no significant difference in HbF levels and various hap-
lotypes combinations among this group of Cameroonian SCD
patients (Fig. 1). Contrary to our findings, a recent report ar-
gues that the S haplotype itself (beyond HbF regulation) cor-
relates with disease severity (Bean et al., 2013).
The Cameroon haplotype has previously been associated
with poor clinical outcome and increased stoke episodes in
SCD (Adorno et al., 2008; Steinberg et al., 1998), whereas the
Benin haplotype is thought to confer a relatively favorable
clinical outcome (Steinberg, 2009). In a previous report, we
anticipated that the relatively high prevalence of stroke in
SCD patients in Cameroon could be attributed to the high
proportion of Cameroonian haplotype (Njamnshi et al.,
2006). However, the present data do not confirm this hy-
pothesis, since the most prevalent haplotype in Cameroon is
Benin. The high prevalence of Benin haplotypes rendered the
study underpowered to reveal a significant difference in
phenotypic outcome with specific haplotype combinations.
An alternative explanation could be the influence of envi-
ronmental factors, specifically the limited access to the al-
ready inadequate health care and poverty, illustrated here by
the late age at diagnosis, the low rate of formal employment,
as well as modest direct monthly direct incomes among
parents. In other studies, socioeconomic factors and poor
healthcare infrastructure have been shown to be a major
factor in the high psychosocial burden of SCD among Ca-
meroonian adult SCD patients (Wonkam et al., 2014a,d) and
parents of children with SCD (Wonkam et al., 2013).
Limitations and perspectives
In Cameroon, the data mostly originated from patients liv-
ing in the southern part of the countries and are thus not fully
representative of the general SCD population in Cameroon.
Specifically, data from the northern Sahelian part will be
needed to complete the picture and possibly provide additional
clues of recent population migration from Sudan that brought
the ‘Cameroon’ haplotype to Cameroon. Another limitation of
this study was the self-report nature of some clinical variables
such as VOC episodes, which can lack precision. In addition,
pain tolerance and financial factors could have been limiting
factors for hospital attendance (Wonkam et al., 2014c).
Despite the above limitations, this study represents an
important step toward the understanding of the molecular
structure of SCD in Cameroon, in sub-Saharan African pa-
tients and globally. This study also has a capacity-building
dimension as it was fully performed from design, funding,
molecular analysis, and reporting on the African continent
and could in turn create major collaborative research op-
portunities at the regional and international levels.
Conclusion
This study has 1) confirmed the high frequency of Benin
haplotype and lack of significant association between b(S)
haplotypes and common SCD clinical outcomes in Camer-
oonian SCD patients; 2) highlighted previous data demon-
strating the almost equivalent representation of the four major
HBB haplotypes in Sudan with a much higher frequency of
Cameroon haplotype; 3) provided a comprehensive review of
published data illustrating the distribution of b(S) haplotypes
in world populations, tracking their migration pattern within
and outside of Africa. This preliminary report proposes ex-
tending the studies on HBB haplotype distribution in Africa
and advances the opportunity to re-address the question of the
origin(s) of the Sickle Cell mutation.
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Supplementary Data
Supplementary Table S1. Restriction Endonuclease Cutting Patterns that Represent
Each of the Five HBB Gene Haplotypes
Enzymes XmnI (5’Gc) HindIII (Gc) HindIII (Ac) HincII (3?’Cb) HinfI (5’b)
Haplotypes
Senegal + + - + +
Bantu/Central African Republic - + - - -
Cameroon - + + + +
Benin - - - + -
Arab-Indian + + - + -
( + ) =Cut by a specific restriction endonuclease; (- ) = Is not cut by that specific restriction endonuclease.
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Cape Town, Faculty of Health Sciences Human Research
Ethics Committee (HREC REF: 132/2010). Patients’ re-
cruitment was conducted at the Yaounde´ Central Hospital
and Laquintinie Hospital in Douala, Cameroon. Only clini-
cally stable patients, 5 years or older, with no history of blood
transfusion, hydroxyurea treatment or hospitalisation in the
preceding 6 weeks were included and clinical events were
prospectively collected (Table 1).
Complete routine blood counts of patients and hemoglobin
electrophoresis were conducted upon arrival at the hospital.
Two methods of HbF measurement were employed in this
study for successive groups of patients; initially the alkali
denaturation test (ADT) in 55.5% (n = 347) of the cohort, and
subsequently high performance liquid chromatography
(HPLC), when it became available.
In a previous report, we disaggregated the SCD patients
sample, based on the HbF assessment technique (ADT vs.
HPLC) and found that the significant associations with HbF
levels, examined independently, were present in both sub-
groups in rs11886868 (BCL11A), rs4671393 (BCL11A),
rs28384513 (HMIP 1), and rs9494142 (HMIP 2) (Wonkam
et al., 2014). To further avoid any major influence on the
outcomes of the present study, the association analyses were
also corrected for the electrophoresis techniques.
Genotyping
HbS mutation and HBB haplotypes. DNA samples were
extracted from peripheral blood following the manufac-
turer’s instructions (Puregene Blood Kit, Qiagen�, Ala-
meda, CA, USA). Molecular analysis for the presence of
the sickle mutation was carried out on 200 ng DNA by PCR
to amplify a 770 bp segment of the b-globin gene, followed
by Dde I restriction analysis of the PCR product (Saiki
et al., 1985).
Five restriction fragment length polymorphism (RFLP)
regions in the b-globin gene cluster were amplified using
published primers and methods (Steinberg et al., 1998) to
analyze the XmnI (5’Gc), HindIII (Gc), HindIII (Ac), HincII
(3c’Cb), and HinfI (5’b) for the HBB haplotype background
(Bitoungui et al., 2015).
Detection of 3.7 kb a-globin gene deletions. The 3.7 kb
alpha-globin gene deletions were successfully screened using
the expand-long template PCR (Roche�, UK) following the
instructions reported by Tan et al. (2001) with some modi-
fications previously published (Rumaney et al., 2014).
SNPs. For the 626 samples, multiplex SNaPshot PCR
and capillary electrophoresis were used to genotype both
rs1427407 and rs7606173 at the BCL11A erythroid-specific
enhancer loci. Quality control of the capillary electrophoresis
results was assessed by direct cycle sequencing in a subset of
10% randomly selected samples that confirmed the SNaPshot
results. Details of the methods were previously reported
(Wonkam et al., 2014).
Data analysis
Descriptive statistics were obtained for all quantitative
data using SPSS (IBM, USA version 21.0). A chi-squared
test, with one degree of freedom, was used to perform the
Hardy-Weinberg Equilibrium (HWE) test on the SNPs ge-
notype with the following results: rs7606173 HWE p-value
was 0.534 (X2 = 0.845) and rs1427407 HWE p-value was
0.0042 (X2 = 12.7). To exclude the ascertainment bias due to
Table 1. Cohort Description
Variables Mean – SD Value range
Number
of observations
Age (years) 17.3 – 9.9 5–53 628
RBC (1012/L) 2.3 – 3.1 1.1–2-6.5 626
Hematological indices Hb (g/dl) 7.8 – 1.5 3.5–14.5 626
MCV(fl) 84 – 10.1 59–117 626
MCHC (g/dl) 34 – 3.7 21.5–54.3 626
WBC (109/l) 14 – 5.9 2.9–49.8 626
Lymphocytes (109/l) 5.9 – 2.9 1.9–22.6 626
Monocytes (109/l) 1.5 – 1.0 0.1–11.9 626
Platelets (109/l) 373– 122 97–837 626
HbA2 (%) 3.7 – 1.8 0–9.7 626
HbF (%) 10.1 – 8.6 0–26.8 626
Clinical events Vaso-occlusive crisis (No. /year) 2.9 – 3.4 0–30 593
Consultations (No. /year) 2.8 – 3.5 0–29 591
Hospitalisation (No. /year) 1.4 – 2.1 0–15 591
Stroke 4.2% 25/599
3.7del Alpha-globin gene genotypes aa/aa 59.3% 310/524a
aa/a3.7 29.6% 156/524a
a3.7/a3.7 11.1% 58/524a
HBB haplotypes Benin/Benin 57% 307/541a
Benin/Cameroon 25% 137/541a
Benin/atypical 8% 45/541a
Cameroon/Cameroon 5% 2/541a
aNumber of individuals and not alleles.
PULE ET AL.
Association between Variants at BCL11A Erythroid-Specific
Enhancer and Fetal Hemoglobin Levels
among Sickle Cell Disease Patients in Cameroon:
Implications for Future Therapeutic Interventions
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Abstract
Variants in BCL11A were previously associated with fetal hemoglobin (HbF) levels among Cameroonian sickle
cell disease (SCD) patients, however explaining only *2% of the variance. In the same patients, we have
investigated the relationship between HbF and two SNPs in a BCL11A erythroid-specific enhancer (N = 626).
Minor allele frequencies in rs7606173 and rs1427407 were 0.42 and 0.24, respectively. Both variants were
significantly associated with HbF levels ( p = 3.11e-08 and p= 6.04e-06, respectively) and explained 8% and
6.2% variations, respectively. These data have confirmed a stronger effect on HbF of genomic variations at the
BCL11A erythroid-specific enhancer among patients with SCD in Cameroon, the first report on a West African
population. The relevance of these findings is of prime importance because the disruption of this enhancer
would alter BCL11A expression in erythroid precursors and thus HbF expression, while sparing the induced
functional challenges of any alterations on the expression of this transcription factor in non-erythroid lineages,
thus providing an attractive approach for new treatment strategies of SCD.
Introduction
Adult fetal hemoglobin (HbF) levels alter the mor-bidity of sickle cell disease (SCD) (Platt et al., 1994), by
inhibiting sickle hemoglobin (HbS) polymerization and
therefore reducing hemolytic anemia and tissue injury. The
HbF levels are highly variable and inheritable, primarily
through genetic variants at three principal loci, BCL11A,
HBS1L-MYB, and HBB cluster, accounting for 10%–20% of
HbF variation among SCD patients (Thein and Menzel,
2009). Specifically, variations in BCL11A have been shown
to be amenable to therapeutic manipulation, leading to the
reversal of SCD symptoms in mice models (Xu et al., 2011).
Functional studies have shown that the expression of the
transcriptional repressor BCL11A is regulated by erythroid-
specific enhancers that contain 3¢ DNase hypersensitive sites
(DHS) located +62, + 58, and +55 kb from the transcription
initiation site of BCL11A (Bauer et al., 2013). Two SNPs of
the enhancer element had a stronger association with HbF
levels among African American SCD patients: rs1427407 in
DHS +62 and rs7606173 in DHS +55. This is consistent with
the hypothesis that multiple functional SNPs act in combi-
nation to influence BCL11A regulation (Bauer et al 2013;
Sebastiani et al., 2015).
We previously reported that the minor allele frequencies
(MAFs) of selected variants in BCL11A were similar to those
detected in African Americans (Lettre et al., 2008) and the
relationships with HbF were significant, but explained less of
the variance in expression (*2% vs. 10%) (Wonkam et al.,
2014). Other genomic polymorphisms at this locus could
better tag the relation with HbF level in some West African
SCD patients. In the present study, we have investigated
the relationship between HbF levels and rs1427407 and
rs7606173 in the BCL11A erythroid-specific enhancer among
626 patients with SCD (HbSS) from Cameroon.
Methods
Study population and HbF measurement
The study was performed with the approval of the National
Ethical Committee Ministry of Public Health, Republic of
Cameroon (No 033/CNE/DNM/07), and the University of
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HBB haplotypes Benin/Benin 57% 307/541a
Benin/Cameroon 25% 137/541a
Benin/atypical 8% 45/541a
Cameroon/Cameroon 5% 2/541a
aNumber of individuals and not alleles.
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Association between Variants at BCL11A Erythroid-Specific
Enhancer and Fetal Hemoglobin Levels
among Sickle Cell Disease Patients in Cameroon:
Implications for Future Therapeutic Interventions
Gift Dineo Pule,1 Valentina Josiane Ngo Bitoungui,2 Bernard Chetcha Chemegni,2
Andre Pascal Kengne,3 Stylianos Antonarakis,4 and Ambroise Wonkam1
Abstract
Variants in BCL11A were previously associated with fetal hemoglobin (HbF) levels among Cameroonian sickle
cell disease (SCD) patients, however explaining only *2% of the variance. In the same patients, we have
investigated the relationship between HbF and two SNPs in a BCL11A erythroid-specific enhancer (N = 626).
Minor allele frequencies in rs7606173 and rs1427407 were 0.42 and 0.24, respectively. Both variants were
significantly associated with HbF levels ( p = 3.11e-08 and p= 6.04e-06, respectively) and explained 8% and
6.2% variations, respectively. These data have confirmed a stronger effect on HbF of genomic variations at the
BCL11A erythroid-specific enhancer among patients with SCD in Cameroon, the first report on a West African
population. The relevance of these findings is of prime importance because the disruption of this enhancer
would alter BCL11A expression in erythroid precursors and thus HbF expression, while sparing the induced
functional challenges of any alterations on the expression of this transcription factor in non-erythroid lineages,
thus providing an attractive approach for new treatment strategies of SCD.
Introduction
Adult fetal hemoglobin (HbF) levels alter the mor-bidity of sickle cell disease (SCD) (Platt et al., 1994), by
inhibiting sickle hemoglobin (HbS) polymerization and
therefore reducing hemolytic anemia and tissue injury. The
HbF levels are highly variable and inheritable, primarily
through genetic variants at three principal loci, BCL11A,
HBS1L-MYB, and HBB cluster, accounting for 10%–20% of
HbF variation among SCD patients (Thein and Menzel,
2009). Specifically, variations in BCL11A have been shown
to be amenable to therapeutic manipulation, leading to the
reversal of SCD symptoms in mice models (Xu et al., 2011).
Functional studies have shown that the expression of the
transcriptional repressor BCL11A is regulated by erythroid-
specific enhancers that contain 3¢ DNase hypersensitive sites
(DHS) located +62, + 58, and +55 kb from the transcription
initiation site of BCL11A (Bauer et al., 2013). Two SNPs of
the enhancer element had a stronger association with HbF
levels among African American SCD patients: rs1427407 in
DHS +62 and rs7606173 in DHS +55. This is consistent with
the hypothesis that multiple functional SNPs act in combi-
nation to influence BCL11A regulation (Bauer et al 2013;
Sebastiani et al., 2015).
We previously reported that the minor allele frequencies
(MAFs) of selected variants in BCL11A were similar to those
detected in African Americans (Lettre et al., 2008) and the
relationships with HbF were significant, but explained less of
the variance in expression (*2% vs. 10%) (Wonkam et al.,
2014). Other genomic polymorphisms at this locus could
better tag the relation with HbF level in some West African
SCD patients. In the present study, we have investigated
the relationship between HbF levels and rs1427407 and
rs7606173 in the BCL11A erythroid-specific enhancer among
626 patients with SCD (HbSS) from Cameroon.
Methods
Study population and HbF measurement
The study was performed with the approval of the National
Ethical Committee Ministry of Public Health, Republic of
Cameroon (No 033/CNE/DNM/07), and the University of
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SCD scientific communities for the following reasons. First,
nearly two-thirds of SCD patients globally are born and re-
side in Africa (Piel et al., 2013) and any potentially important
SCD research performed on other populations should be
replicated in African populations to assess and confirm their
relevance for future care and therapeutic interventions.
Second, it well known that Africans have the highest ge-
netic variations and diversities (Gurdasani et al., 2015), im-
plying some regional genetic specificities. For instance, we
have previously shown that rs9399137, which acts as a tag-
ging HbF-promoting SNP for the HMIP-2 sub-locus in Eu-
ropean populations (Thein et al., 2007), occurs at a low
frequency in this Cameroonian cohort (Wonkam et al., 2014).
In addition, a 3 bp deletion in perfect linkage disequilibrium
(LD) with rs9399137 in Chinese, European, and some Afri-
can American populations was reported to be the candidate
functional motif for the HMIP-2 region (Farell et al., 2011).
However, in these Cameroonian patients, rs9389269was not
linked to rs9399137 (r2= 0; D’= 0.138) (Wonkamet al., 2014).
Moreover, we reported, in the HMIP-2 sub-locus, a much
higher frequency of rs9389269 (0.18) in Cameroonians as
compared to Tanzanian SCD patients (0.03), an observation
that could indicate a high degree of variation in theMAF of this
SNP amongst SCD patients from various African population
groups (Wonkam et al., 2014). These results emphasize the
need to report on multiple African populations to fully capture
the importance of various disease-modifying SNPs.
Lastly, Sebastiani et al. (2015) have reported on the as-
sociation between variants at BCL11A erythroid-specific
enhancer and HbF levels in African American SCD patients.
However, among self-identified African Americans, analysis
of genomic admixture indicates that the median proportion of
European ancestry is 18.5% with very large variation, rang-
ing from an estimate of over 99%West African ancestry less
than 1% (Bryc et al., 2010). Therefore, any results of genomic
studies performed on African Americans are not always ap-
propriate proxies of what could be expected among sub-
Saharan Africans. The importance of replicating findings of
HbF-promoting SNPs at BCL11A in various populations is
thus crucial to identifying possible targets for therapeutic
intervention to increase HbF levels in patients with SCD.
Nevertheless, a major clinical caution of exploring the
decreased expression of BCL11A, in order to promote HbF
expression, rests on the other deleterious functional impli-
cations of this transcription factor, whose reduced expres-
sion could have serious developmental and neurological
consequences. Indeed, patients described with microdele-
tions encompassing BCL11A display neurodevelopmental
abnormalities including intellectual disability and brain
malformation (Balci et al., 2015; Funnell et al., 2015; Peter
et al., 2014). This emphasises the importance of theBCL11A
erythroid-specific enhancer being subject to genetic varia-
tions that influence HbF levels as reported in the present
study.
Bioinformatics analysis suggests that rs7606173 in DHS
+55 changes a binding site for MZF1, a gene actively tran-
scribed in hematopoietic cells (Sebastiani et al., 2015) and
most importantly, functional analysis have shown that the
disruption of this enhancer would impair BCL11A expression
in erythroid precursors and thus HbF expression, while
conserving the ‘‘undruggable’’ nature of this transcription
factor in non-erythroid lineages (Bauer et al., 2013).
It is also possible that, in the future, genome editing could
allow the introduction of beneficial SNPs at the BCL11A
erythroid-specific enhancer locus to improve the clinical
course of SCD patients. Preliminary proof of concept was
shown by experiments that introduced the -175> point mu-
tation and successfully elevated HbF into erythroid cell lines
(Wienert et al., 2015). In addition, using a specific guide,
RNA and Cas9, authors recently corrected one allele of the
SCDHBB gene in human erythroid cells (Huang et al., 2015).
A limitation of the present research is the number of SNPs
that were studied. Additional genotyping of SNPs will allow
the definition of various haplotypes that will best capture the
combinatorial importance of BCL11A elements (Bae et al.,
2012).
Conclusion and Perspectives
The present study validates the relationship between HbF
levels and SNPs in a BCL11A erythroid-specific enhancer
among SCD patients in Cameroon, the first report on a West
African cohort. The relevance of this finding is of prime
importance because the disruption of this enhancer would
impair BCL11A expression in erythroid precursors and thus
HbF expression, while sparing the induced various functional
challenges of any alterations of this transcription factor ex-
pression in non-erythroid lineages, thus providing an attrac-
tive approach for future treatment of SCD.
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technical genotyping reasons, about 10% (N= 60) of the sam-
ples were Sanger-sequenced by an independent laboratory
(Central Analytical Facilities, University of Stellenbosch) and
confirmed all the SNP genotyping results.
The observed frequencies of the rs1427407 variant could
be biased by the presence of a third T allele (MAF = 0.048) in
92 samples, suggesting the presence of copy number varia-
tions (CNVs) that could be involved in the regulation of
BCL11A in some individuals. Alternatively, the violation of
HWE for rs1427407 could possibly be due to a selective
effect of this HbF-promoting SNP that could potentially in-
fluence the course of SCD and ultimately the survival of some
patients. These various observations and hypotheses deserve
further investigations.
Owing to the skewed distribution of HbF level, we log10-
transformed HbF values to approximate normal distribution,
and then used these transformed values in the association
analysis after correcting for age; gender, electrophoresis tech-
nique, history of transfusion, HBB haplotypes, and the 3.7 kb
alpha-globin gene deletion genotypes. Using an additive ge-
netic model, under a generalized linear regression framework,
we investigated the relationship between the SNPs (rs1427407
and rs7606173) and HbF levels, using the R statistical package
version 3.0.3 (The R Foundation for statistical computing,
Vienna, Austria). Significance was set at 5%.
Results
Patients
Table 1 summarizes the description of the cohort. All
patients were homozygous for the HbS mutation. Among
them, 50.3% (n= 316) were female. After the analysis of 1082
chromosomes, Benin (74%; n= 799) and Cameroon haplo-
types (19%; n= 207) were the most prevalent. In combination,
the Benin/Benin haplotype represented 57% (n= 307) and the
Benin/Cameroon 25% (n= 137) of the cohort (Table 1).
Among 524 patients successfully genotyped for the 3.7 kb
alpha-globin gene deletion, 40.7% (n= 214) had co-inherited
alpha-thalassaemia (Table 1).
SNPs in BCL11A hypersensitivity sites and HbF levels
In the present study, MAFs in both rs7606173 and
rs1427407 variants were 0.42 and 0.24, respectively (Table
2). Both genetic variants were significantly associated with
HbF levels ( p = 3.11e-08 and p = 6.04e-06) (Fig. 1A) and
explained 8% and 6.2% variations in HbF levels, respectively
(Table 2). The relationship of both SNPs with HbF was not
influenced by the electrophoresis techniques, alpha-thalassaemia
genotypes, or HBB haplotypes. There were no significant asso-
ciations between the two SNPs and other various hematological
indices or clinical events, but rs7606173 that was associatedwith
hemoglobin levels (p=0.02) and consultation rates (p=0.04).
Discussion
The present article is the first report on the importance of
the SNPs rs1427407 and rs7606173 among West African
SCD patients. The results are consistent with those reported
among African Americans (Bauer et al., 2013) and patients
from Saudi Arabia and India (Sebastiani et al., 2015) and
Tanzania for rs1427407 (Ntatiro et al., 2015). The results of
this study are of particular importance for the local and global
Table 2. Differential HbF Association Results for Selected SNPs at the BCL11A
Specific Erythroid Enhancer in Cameroonian SCD HbSS Patients (N = 626)
Locus Chr. 2 SNP Position&
Allele
change MAF$
Effect Size#
(SE)
Variance
explained (%) P values
BCL11A enhancer rs1427407 (DHS +62) 60718043 C>A 0.26 0.119 (0.024) 6.2 6.04e-06
BCL11A enhancer rs7606173 (DHS +55) 60725451 C>G 0.42 0.1 (0.025) 8 3.11e-08
&Chr, chromosome; Position on NCBI Build 36.1; $MAF, minor allele frequency; #Effect sizes and standard errors are given in standard
deviation units for the minor allele.
FIG. 1. Box-plots showing the distribution of foetal haemoglobin levels conditioned on
SNP genotypes. (A) Fetal hemoglobin levels, conditioned on the rs7606173 SNP geno-
types, and (B) conditioned on the rs1427407 SNP genotypes. Boxes have lines at the lower
quartile, median, and upper quartile. The plot whiskers extend up and down from the
median a distance 1.5 times the interquartile range of the boxes (truncated at zero where
necessary). Outliers are the points outside the whiskers indicated as circles.
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SCD scientific communities for the following reasons. First,
nearly two-thirds of SCD patients globally are born and re-
side in Africa (Piel et al., 2013) and any potentially important
SCD research performed on other populations should be
replicated in African populations to assess and confirm their
relevance for future care and therapeutic interventions.
Second, it well known that Africans have the highest ge-
netic variations and diversities (Gurdasani et al., 2015), im-
plying some regional genetic specificities. For instance, we
have previously shown that rs9399137, which acts as a tag-
ging HbF-promoting SNP for the HMIP-2 sub-locus in Eu-
ropean populations (Thein et al., 2007), occurs at a low
frequency in this Cameroonian cohort (Wonkam et al., 2014).
In addition, a 3 bp deletion in perfect linkage disequilibrium
(LD) with rs9399137 in Chinese, European, and some Afri-
can American populations was reported to be the candidate
functional motif for the HMIP-2 region (Farell et al., 2011).
However, in these Cameroonian patients, rs9389269was not
linked to rs9399137 (r2= 0; D’= 0.138) (Wonkamet al., 2014).
Moreover, we reported, in the HMIP-2 sub-locus, a much
higher frequency of rs9389269 (0.18) in Cameroonians as
compared to Tanzanian SCD patients (0.03), an observation
that could indicate a high degree of variation in theMAF of this
SNP amongst SCD patients from various African population
groups (Wonkam et al., 2014). These results emphasize the
need to report on multiple African populations to fully capture
the importance of various disease-modifying SNPs.
Lastly, Sebastiani et al. (2015) have reported on the as-
sociation between variants at BCL11A erythroid-specific
enhancer and HbF levels in African American SCD patients.
However, among self-identified African Americans, analysis
of genomic admixture indicates that the median proportion of
European ancestry is 18.5% with very large variation, rang-
ing from an estimate of over 99%West African ancestry less
than 1% (Bryc et al., 2010). Therefore, any results of genomic
studies performed on African Americans are not always ap-
propriate proxies of what could be expected among sub-
Saharan Africans. The importance of replicating findings of
HbF-promoting SNPs at BCL11A in various populations is
thus crucial to identifying possible targets for therapeutic
intervention to increase HbF levels in patients with SCD.
Nevertheless, a major clinical caution of exploring the
decreased expression of BCL11A, in order to promote HbF
expression, rests on the other deleterious functional impli-
cations of this transcription factor, whose reduced expres-
sion could have serious developmental and neurological
consequences. Indeed, patients described with microdele-
tions encompassing BCL11A display neurodevelopmental
abnormalities including intellectual disability and brain
malformation (Balci et al., 2015; Funnell et al., 2015; Peter
et al., 2014). This emphasises the importance of theBCL11A
erythroid-specific enhancer being subject to genetic varia-
tions that influence HbF levels as reported in the present
study.
Bioinformatics analysis suggests that rs7606173 in DHS
+55 changes a binding site for MZF1, a gene actively tran-
scribed in hematopoietic cells (Sebastiani et al., 2015) and
most importantly, functional analysis have shown that the
disruption of this enhancer would impair BCL11A expression
in erythroid precursors and thus HbF expression, while
conserving the ‘‘undruggable’’ nature of this transcription
factor in non-erythroid lineages (Bauer et al., 2013).
It is also possible that, in the future, genome editing could
allow the introduction of beneficial SNPs at the BCL11A
erythroid-specific enhancer locus to improve the clinical
course of SCD patients. Preliminary proof of concept was
shown by experiments that introduced the -175> point mu-
tation and successfully elevated HbF into erythroid cell lines
(Wienert et al., 2015). In addition, using a specific guide,
RNA and Cas9, authors recently corrected one allele of the
SCDHBB gene in human erythroid cells (Huang et al., 2015).
A limitation of the present research is the number of SNPs
that were studied. Additional genotyping of SNPs will allow
the definition of various haplotypes that will best capture the
combinatorial importance of BCL11A elements (Bae et al.,
2012).
Conclusion and Perspectives
The present study validates the relationship between HbF
levels and SNPs in a BCL11A erythroid-specific enhancer
among SCD patients in Cameroon, the first report on a West
African cohort. The relevance of this finding is of prime
importance because the disruption of this enhancer would
impair BCL11A expression in erythroid precursors and thus
HbF expression, while sparing the induced various functional
challenges of any alterations of this transcription factor ex-
pression in non-erythroid lineages, thus providing an attrac-
tive approach for future treatment of SCD.
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technical genotyping reasons, about 10% (N= 60) of the sam-
ples were Sanger-sequenced by an independent laboratory
(Central Analytical Facilities, University of Stellenbosch) and
confirmed all the SNP genotyping results.
The observed frequencies of the rs1427407 variant could
be biased by the presence of a third T allele (MAF = 0.048) in
92 samples, suggesting the presence of copy number varia-
tions (CNVs) that could be involved in the regulation of
BCL11A in some individuals. Alternatively, the violation of
HWE for rs1427407 could possibly be due to a selective
effect of this HbF-promoting SNP that could potentially in-
fluence the course of SCD and ultimately the survival of some
patients. These various observations and hypotheses deserve
further investigations.
Owing to the skewed distribution of HbF level, we log10-
transformed HbF values to approximate normal distribution,
and then used these transformed values in the association
analysis after correcting for age; gender, electrophoresis tech-
nique, history of transfusion, HBB haplotypes, and the 3.7 kb
alpha-globin gene deletion genotypes. Using an additive ge-
netic model, under a generalized linear regression framework,
we investigated the relationship between the SNPs (rs1427407
and rs7606173) and HbF levels, using the R statistical package
version 3.0.3 (The R Foundation for statistical computing,
Vienna, Austria). Significance was set at 5%.
Results
Patients
Table 1 summarizes the description of the cohort. All
patients were homozygous for the HbS mutation. Among
them, 50.3% (n= 316) were female. After the analysis of 1082
chromosomes, Benin (74%; n= 799) and Cameroon haplo-
types (19%; n= 207) were the most prevalent. In combination,
the Benin/Benin haplotype represented 57% (n= 307) and the
Benin/Cameroon 25% (n= 137) of the cohort (Table 1).
Among 524 patients successfully genotyped for the 3.7 kb
alpha-globin gene deletion, 40.7% (n= 214) had co-inherited
alpha-thalassaemia (Table 1).
SNPs in BCL11A hypersensitivity sites and HbF levels
In the present study, MAFs in both rs7606173 and
rs1427407 variants were 0.42 and 0.24, respectively (Table
2). Both genetic variants were significantly associated with
HbF levels ( p = 3.11e-08 and p = 6.04e-06) (Fig. 1A) and
explained 8% and 6.2% variations in HbF levels, respectively
(Table 2). The relationship of both SNPs with HbF was not
influenced by the electrophoresis techniques, alpha-thalassaemia
genotypes, or HBB haplotypes. There were no significant asso-
ciations between the two SNPs and other various hematological
indices or clinical events, but rs7606173 that was associatedwith
hemoglobin levels (p=0.02) and consultation rates (p=0.04).
Discussion
The present article is the first report on the importance of
the SNPs rs1427407 and rs7606173 among West African
SCD patients. The results are consistent with those reported
among African Americans (Bauer et al., 2013) and patients
from Saudi Arabia and India (Sebastiani et al., 2015) and
Tanzania for rs1427407 (Ntatiro et al., 2015). The results of
this study are of particular importance for the local and global
Table 2. Differential HbF Association Results for Selected SNPs at the BCL11A
Specific Erythroid Enhancer in Cameroonian SCD HbSS Patients (N = 626)
Locus Chr. 2 SNP Position&
Allele
change MAF$
Effect Size#
(SE)
Variance
explained (%) P values
BCL11A enhancer rs1427407 (DHS +62) 60718043 C>A 0.26 0.119 (0.024) 6.2 6.04e-06
BCL11A enhancer rs7606173 (DHS +55) 60725451 C>G 0.42 0.1 (0.025) 8 3.11e-08
&Chr, chromosome; Position on NCBI Build 36.1; $MAF, minor allele frequency; #Effect sizes and standard errors are given in standard
deviation units for the minor allele.
FIG. 1. Box-plots showing the distribution of foetal haemoglobin levels conditioned on
SNP genotypes. (A) Fetal hemoglobin levels, conditioned on the rs7606173 SNP geno-
types, and (B) conditioned on the rs1427407 SNP genotypes. Boxes have lines at the lower
quartile, median, and upper quartile. The plot whiskers extend up and down from the
median a distance 1.5 times the interquartile range of the boxes (truncated at zero where
necessary). Outliers are the points outside the whiskers indicated as circles.
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Adult fetal hemoglobin (HbF) has been shown to ameliorate symptoms of Sickle Cell 
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Using the expand-long template PCR (Roche Diagnostics,
Basel, Switzerland), the 3.7 kb a-globin gene deletion was
successfully screened following a previously reported proto-
col.(10)
All variants were analyzed using the iPLEX Gold
Sequenom Mass Genotyping Array (Inqaba Biotec, Pretoria,
South Africa). The results were validated by direct cycle
sequencing of a subset of the sample (n¼ 45; 10.0%) using
previously reported methods.(4)
Statistical analyses
Descriptive statistics were obtained for all quantitative data
using the Statistical Package for the Social Sciences (version
21.0; SPSS Inc., IBM, Chicago, IL). A v2 with one degree of
freedom, was used to perform the Hardy–Weinberg equilib-
rium (HWE) test on the SNP genotype with five SNPs
(rs11754265, rs62573842, rs7163278, rs10468869 and
rs10756993) out of HWE (p< .05). To correct for the skew-
ness of the Hb distribution, we log10-transformed and nor-
malized the data to obtain the quantitative trait used in the
association analysis (after correcting for age, gender, and
electrophoresis technique, transfusion history, a-thalassemia
(a-thal) genotypes and haplotypes in the b-globin-like gene
clusters). Statistical models to investigate the relationship
between Hb F-associated SNPs and sickle cell disease com-
plications were conducted using an additive genetic model,
under a generalized linear regression framework, in the R
statistical package version 3.0.3 (The R Foundation for
Statistical Computing, Vienna, Austria). Significance was set
at 5.0%.
A total of 453 patients were included; Table 1 summarizes
their description. All participants had carried homozygous
Hb S; 50.7% (n¼ 230) were female; the mean age was
17.9 ± 10.5 years. Overt stroke was reported in 4.9% (n¼ 22)
of the patients and the mean Hb F level was 10.4 ± 8.7%.
The most prevalent b-globin gene cluster haplotype was
Benin [� � �þ �] (Supplementary Table 1) (73.0%,
n¼ 661 chromosomes); 28.6 and 8.4% of patients had coin-
herited a single or double 3.7 kb a-globin gene deletion,
respectively.
The minor allele frequencies of all the variants investi-
gated are shown in Table 2. The majority of variants (7/10)
reported from the Sardinian population were either mono-
morphic (n¼ 4) or very rare (n¼ 3) in the Cameroonian
sickle cell disease patients. One out of eight variants from
the Tanzanian cohort was monomorphic. No associations
were observed between the SNPs and Hb F levels in
Cameroonian affected by sickle cell disease (Table 2) nor
were there any associations between these variants and any
other hematological indices or clinical events.
This study did not replicate, among sickle cell disease
patients from Cameroon, the suggestive novel variants asso-
ciated with Hb F in populations from Tanzania (6) and
novel variants identified in a population from Sardinia.(7)
Similarly, the suggestive novel variants reported in the
Tanzanians were not replicated in a British cohort of largely
Caribbean/West African descent, which the authors attrib-
uted to the small sample size or different ancestry;(6) the lat-
ter reason further supports the considerable heterogeneity of
genetic variants within African populations.(11) This differ-
ence was also emphasized by the fact that rs192197462 was
present as a monomorphic polymorphism in this study,
although significantly associated with Hb F levels in sickle
cell disease patients from Tanzania. We also previously
reported, in the HMIP-2 sublocus, a much higher frequency
of rs9389269 (0.18) in Cameroonian as compared to the
Tanzanian sickle cell disease patients (0.03).(4) Furthermore,
Table 1. Description of the studied cohort.
Variables Parameters Mean ± SD
Value
ranges
Numbers
observed
Hematological indices Age (years) 17.9 ± 10.5 5.0–58.0 453
RBC (1012/L) 2.7 ± 0.7 12.0–5.5 453
Hb (g/dL) 7.8 ± 1.6 4.0–14.5 453
MCV (fL) 84.9 ± 10.0 61.0–112.0 453
MCHC (g/dL) 34.1 ± 3.8 23.3–54.0 453
WBC (109/L) 14.2 ± 6.1 3.5–49.8 453
Lymphocytes (109/L) 6.0 ± 3.1 0.87–20.4 453
Monocytes (109/L) 1.6 ± 1.2 0.1–11.9 453
Platelets (109/L) 370.4 ± 130.6 108.0–837.0 453
Hb A2 (%) 3.8 ± 1.9 0.1–18.2 453
Hb F (%) 10.4 ± 8.7 0.0–37.4 453
Clinical events VOC crises (n/year) 2.9 ± 3.5 0–40 453
Consultations (n/year) 3.1 ± 3.8 0–40 453
Hospitalization (n/year) 1.5 ± 2.6 0–30 453
Overt strokes (%) 4.9 22/453a
a Genotypes (%) aa/aa 63.0 285/453a
aa/–a3.7 28.6 130/453a
–a3.7/–a3.7 8.4 38/453a
b Haplotypes (%) Benin/Benin 50.5 229/453a
Benin/Cameroon 22.5 103/453a
Benin/Atypical 4.2 19/453a
Cameroon/Cameroon 4.2 19/453a
Atypical: the restriction endonuclease cutting patterns were variable and did not fit with the five classical haplotypes; Benin: [– – –þ –];
Cameroon: [–þþþþ]; Hb: hemoglobin; MCV: mean corpuscular volume; MCHC: mean corpuscular Hb concentration; RBC: red blood cell
counts; VOC: vasoocclusive crises; WBC: white blood cell counts. (See haplotype classification in Supplementary Table 1).
aNumber of individuals not alleles.
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Adult Hb F has been shown to be a highly variable quantita-
tive trait that can alter the morbidity of sickle cell disease by
reducing hemolytic anemia and organ damage, through the
inhibition of Hb S (HBB: c.20A>T) polymerization.(1) Hb
F level is an inheritable trait associated with genetic poly-
morphisms at three principal loci, BCL11A, HBS1L-MYB
and the b-globin gene cluster, which accounts for
10.0–20.0% variance in Hb F in sickle cell disease
patients.(2–5) Additional loci that account for more variation
in Hb F levels are still to be found. Recently, a genomewide
association study (GWAS) of Hb F in sickle cell disease
patients in Tanzania revealed eight additional loci suggestive
of being novel, with associations that reached a genome-
wide significance of p< 10�6.(6) In addition, 10 other Hb
F-associated novel loci were recently identified though
whole-genome sequencing studies of a population in
Sardinia.(7) In order to possibly replicate these findings in
sickle cell disease patients from Cameroon, we investigated
in the present study the association with Hb F level with 18
select single-nucleotide polymorphisms (SNPs), from the Hb
F-promoting novel loci found in Tanzanians and Sardinians.
The study was approved by the University of Cape Town,
Faculty of Health Sciences Human Research Ethics
Committee (HREC REF: 132/2010), Cape Town, South
Africa and the National Ethics Committee Ministry of Public
Health, Yaounde, Republic of Cameroon (No. 033/CNE/
DNM/07). Patients were recruited at the Yaounde Central
Hospital and Laquintinie Hospital in Douala, Cameroon.
Only clinically stable patients, aged 5 years or older, with no
history of hydroxyurea treatment, blood transfusion or hos-
pitalization in the preceding 6 weeks were included, and
clinical events were prospectively collected (Table 1).
Routine blood counts of patients and hemoglobin (Hb) elec-
trophoresis were conducted on arrival at the hospital, ini-
tially using the alkali denaturation test (ADT) in 55.5%
(n¼ 249) of the cohort and subsequently high-performance
liquid chromatography (HPLC), when it became available.(4)
In a previous report, we disaggregated the Cameroonian
sickle cell disease patients’ sample, based on the Hb F assess-
ment technique (ADT vs. HPLC) and found that the signifi-
cant associations with Hb F levels, examined independently,
were present in both subgroups in rs11886868 (BCL11A),
rs4671393 (BCL11A), rs28384513 (HMIP-1) and rs9494142
(HMIP-2).(4) In the present study, the association analyses
were also corrected for the electrophoresis techniques, as
stated later.
DNA was extracted from peripheral blood following the
manufacturer’s instructions (Puregene Blood Kit; Qiagen
GmbH, Hilden, Germany). Molecular analysis to determine
the presence of the sickle mutation was carried out on
200 ng DNA by polymerase chain reaction (PCR) to amplify
a 770 bp segment of the b-globin gene, followed by DdeI
restriction analysis of the PCR product.(8)
Using published primers and methods, five restriction
fragment length polymorphism (RFLP) sites in the b-globin
gene cluster were amplified to analyze the XmnI (50Gc),
HindIII (Gc), HindIII (Ac), HincII (30wb) and HinfI (50b) for
the HBB haplotype background (Supplementary Table 1).(9)
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Using the expand-long template PCR (Roche Diagnostics,
Basel, Switzerland), the 3.7 kb a-globin gene deletion was
successfully screened following a previously reported proto-
col.(10)
All variants were analyzed using the iPLEX Gold
Sequenom Mass Genotyping Array (Inqaba Biotec, Pretoria,
South Africa). The results were validated by direct cycle
sequencing of a subset of the sample (n¼ 45; 10.0%) using
previously reported methods.(4)
Statistical analyses
Descriptive statistics were obtained for all quantitative data
using the Statistical Package for the Social Sciences (version
21.0; SPSS Inc., IBM, Chicago, IL). A v2 with one degree of
freedom, was used to perform the Hardy–Weinberg equilib-
rium (HWE) test on the SNP genotype with five SNPs
(rs11754265, rs62573842, rs7163278, rs10468869 and
rs10756993) out of HWE (p< .05). To correct for the skew-
ness of the Hb distribution, we log10-transformed and nor-
malized the data to obtain the quantitative trait used in the
association analysis (after correcting for age, gender, and
electrophoresis technique, transfusion history, a-thalassemia
(a-thal) genotypes and haplotypes in the b-globin-like gene
clusters). Statistical models to investigate the relationship
between Hb F-associated SNPs and sickle cell disease com-
plications were conducted using an additive genetic model,
under a generalized linear regression framework, in the R
statistical package version 3.0.3 (The R Foundation for
Statistical Computing, Vienna, Austria). Significance was set
at 5.0%.
A total of 453 patients were included; Table 1 summarizes
their description. All participants had carried homozygous
Hb S; 50.7% (n¼ 230) were female; the mean age was
17.9 ± 10.5 years. Overt stroke was reported in 4.9% (n¼ 22)
of the patients and the mean Hb F level was 10.4 ± 8.7%.
The most prevalent b-globin gene cluster haplotype was
Benin [� � �þ �] (Supplementary Table 1) (73.0%,
n¼ 661 chromosomes); 28.6 and 8.4% of patients had coin-
herited a single or double 3.7 kb a-globin gene deletion,
respectively.
The minor allele frequencies of all the variants investi-
gated are shown in Table 2. The majority of variants (7/10)
reported from the Sardinian population were either mono-
morphic (n¼ 4) or very rare (n¼ 3) in the Cameroonian
sickle cell disease patients. One out of eight variants from
the Tanzanian cohort was monomorphic. No associations
were observed between the SNPs and Hb F levels in
Cameroonian affected by sickle cell disease (Table 2) nor
were there any associations between these variants and any
other hematological indices or clinical events.
This study did not replicate, among sickle cell disease
patients from Cameroon, the suggestive novel variants asso-
ciated with Hb F in populations from Tanzania (6) and
novel variants identified in a population from Sardinia.(7)
Similarly, the suggestive novel variants reported in the
Tanzanians were not replicated in a British cohort of largely
Caribbean/West African descent, which the authors attrib-
uted to the small sample size or different ancestry;(6) the lat-
ter reason further supports the considerable heterogeneity of
genetic variants within African populations.(11) This differ-
ence was also emphasized by the fact that rs192197462 was
present as a monomorphic polymorphism in this study,
although significantly associated with Hb F levels in sickle
cell disease patients from Tanzania. We also previously
reported, in the HMIP-2 sublocus, a much higher frequency
of rs9389269 (0.18) in Cameroonian as compared to the
Tanzanian sickle cell disease patients (0.03).(4) Furthermore,
Table 1. Description of the studied cohort.
Variables Parameters Mean ± SD
Value
ranges
Numbers
observed
Hematological indices Age (years) 17.9 ± 10.5 5.0–58.0 453
RBC (1012/L) 2.7 ± 0.7 12.0–5.5 453
Hb (g/dL) 7.8 ± 1.6 4.0–14.5 453
MCV (fL) 84.9 ± 10.0 61.0–112.0 453
MCHC (g/dL) 34.1 ± 3.8 23.3–54.0 453
WBC (109/L) 14.2 ± 6.1 3.5–49.8 453
Lymphocytes (109/L) 6.0 ± 3.1 0.87–20.4 453
Monocytes (109/L) 1.6 ± 1.2 0.1–11.9 453
Platelets (109/L) 370.4 ± 130.6 108.0–837.0 453
Hb A2 (%) 3.8 ± 1.9 0.1–18.2 453
Hb F (%) 10.4 ± 8.7 0.0–37.4 453
Clinical events VOC crises (n/year) 2.9 ± 3.5 0–40 453
Consultations (n/year) 3.1 ± 3.8 0–40 453
Hospitalization (n/year) 1.5 ± 2.6 0–30 453
Overt strokes (%) 4.9 22/453a
a Genotypes (%) aa/aa 63.0 285/453a
aa/–a3.7 28.6 130/453a
–a3.7/–a3.7 8.4 38/453a
b Haplotypes (%) Benin/Benin 50.5 229/453a
Benin/Cameroon 22.5 103/453a
Benin/Atypical 4.2 19/453a
Cameroon/Cameroon 4.2 19/453a
Atypical: the restriction endonuclease cutting patterns were variable and did not fit with the five classical haplotypes; Benin: [– – –þ –];
Cameroon: [–þþþþ]; Hb: hemoglobin; MCV: mean corpuscular volume; MCHC: mean corpuscular Hb concentration; RBC: red blood cell
counts; VOC: vasoocclusive crises; WBC: white blood cell counts. (See haplotype classification in Supplementary Table 1).
aNumber of individuals not alleles.
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Adult Hb F has been shown to be a highly variable quantita-
tive trait that can alter the morbidity of sickle cell disease by
reducing hemolytic anemia and organ damage, through the
inhibition of Hb S (HBB: c.20A>T) polymerization.(1) Hb
F level is an inheritable trait associated with genetic poly-
morphisms at three principal loci, BCL11A, HBS1L-MYB
and the b-globin gene cluster, which accounts for
10.0–20.0% variance in Hb F in sickle cell disease
patients.(2–5) Additional loci that account for more variation
in Hb F levels are still to be found. Recently, a genomewide
association study (GWAS) of Hb F in sickle cell disease
patients in Tanzania revealed eight additional loci suggestive
of being novel, with associations that reached a genome-
wide significance of p< 10�6.(6) In addition, 10 other Hb
F-associated novel loci were recently identified though
whole-genome sequencing studies of a population in
Sardinia.(7) In order to possibly replicate these findings in
sickle cell disease patients from Cameroon, we investigated
in the present study the association with Hb F level with 18
select single-nucleotide polymorphisms (SNPs), from the Hb
F-promoting novel loci found in Tanzanians and Sardinians.
The study was approved by the University of Cape Town,
Faculty of Health Sciences Human Research Ethics
Committee (HREC REF: 132/2010), Cape Town, South
Africa and the National Ethics Committee Ministry of Public
Health, Yaounde, Republic of Cameroon (No. 033/CNE/
DNM/07). Patients were recruited at the Yaounde Central
Hospital and Laquintinie Hospital in Douala, Cameroon.
Only clinically stable patients, aged 5 years or older, with no
history of hydroxyurea treatment, blood transfusion or hos-
pitalization in the preceding 6 weeks were included, and
clinical events were prospectively collected (Table 1).
Routine blood counts of patients and hemoglobin (Hb) elec-
trophoresis were conducted on arrival at the hospital, ini-
tially using the alkali denaturation test (ADT) in 55.5%
(n¼ 249) of the cohort and subsequently high-performance
liquid chromatography (HPLC), when it became available.(4)
In a previous report, we disaggregated the Cameroonian
sickle cell disease patients’ sample, based on the Hb F assess-
ment technique (ADT vs. HPLC) and found that the signifi-
cant associations with Hb F levels, examined independently,
were present in both subgroups in rs11886868 (BCL11A),
rs4671393 (BCL11A), rs28384513 (HMIP-1) and rs9494142
(HMIP-2).(4) In the present study, the association analyses
were also corrected for the electrophoresis techniques, as
stated later.
DNA was extracted from peripheral blood following the
manufacturer’s instructions (Puregene Blood Kit; Qiagen
GmbH, Hilden, Germany). Molecular analysis to determine
the presence of the sickle mutation was carried out on
200 ng DNA by polymerase chain reaction (PCR) to amplify
a 770 bp segment of the b-globin gene, followed by DdeI
restriction analysis of the PCR product.(8)
Using published primers and methods, five restriction
fragment length polymorphism (RFLP) sites in the b-globin
gene cluster were amplified to analyze the XmnI (50Gc),
HindIII (Gc), HindIII (Ac), HincII (30wb) and HinfI (50b) for
the HBB haplotype background (Supplementary Table 1).(9)
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Hb F regulation is a highly heterogeneous system and sub-
ject to regulatory and signaling pathways that develop differ-
ently across different populations.(12)
Indeed, the majority of variants described in Sardinians
(7/10) were either monomorphic or very rare in
Cameroonians with sickle cell disease (Table 2) and could be
attributed to the founder nature of the Sardinian population
used. This founder effect could account for some variants
that are extremely rare in the rest of the world; in some
cases, reaching high enough frequencies to provide unex-
pected biological insights.(7) For instance, X12_123681790,
monomorphic in Cameroonians, was associated with HBA1
levels in Sardinians. Similarly, rs113267280 located in the
CCND3 gene, a regulator of erythropoiesis particularly cell
division during terminal erythroid differentiation,(13) was
also associated with HBA1 levels in Sardinians. Furthermore,
rs183437571 was also imputed as monomorphic in the
TwinsUK cohort,(14) suggesting that significant variations
also exist within European populations. The data further
highlight the complexity of Hb F genomic regulation and
illustrate the difficulties that will be encountered when
attempting to replicate some variant association results.
Taken together, the data suggest that the discovery of
new Hb F-promoting loci that are relevant in most popula-
tions will require integrated large-scale genome-wide studies
across many populations. Specifically, future studies should
include multiple African populations, from where the disease
burden is highest and also because of the highest genetic
diversity among Africans.(11) Moreover, the use in future
research of appropriate GWAS panels that capture the full
genomic diversity in African populations, one of which is in
development within the H3Africa Consortium (www.
h3Africa.com), could provide more insight into the missing
heritability of the persistence of Hb F production. Indeed, in
a recent GWAS study among African–Americans, using the
Illumina Omni1-Quad System (San Diego, CA) that contains
high density of SNP coverage of the human genome (1,140,
419 SNPs) with 76.0% coverage of polymorphisms validated
in people of African ancestry, novel candidate SNPs associ-
ated with Hb F levels were reported in the SPARC, GJC1,
EFTUD2 and JAZF1 genes.(15) Further exploration of
known genetic modifiers of Hb F expression such as
BCL11A, HBS1L-MYB, b-globin gene cluster,(2–5) Kr€uppel-
like factor 1 (KLF-1), (haplo-insufficiency),(16,17) SAR1 (18)
and SALL2,(19) could serve as central nodes for gene net-
work analyses to identify other pathways, genes and variants
critical for Hb F production. Possible targets for novel thera-
peutic agents could be potent Hb F regulators such as KLF-
1, known activator of BCL11A, via transcriptional and post-
transcriptional mechanisms.(20)
The present study was a replication, in Cameroonian
sickle cell disease patients, of putative novel Hb F-promoting
loci identified in Tanzanian sickle cell disease patients and
the general Sardinian population: no significant associations
with Hb F were observed at these loci. The lack of associ-
ation further demonstrates the complexity of finding add-
itional Hb F-promoting loci that have multipopulation
relevance. These and other similar observations call for more
multicenter GWAS with SNPs panels that are representative
of interpopulations genetic diversity, particularly that within
sub-Saharan Africa, where the disease burden is highest.
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Table 2. Association between selected single nucleotide polymorphisms and Hb F in sickle cell disease patients in Cameroon.
SNPs Gene Chromosome loci Alleles MAF Effect size (SE) p Value
Variants reported in the general population in Sardinia (7)
X12_123681790 MPHOSPH9 intron X12_123681790 Aa NA NA NA
X16_391593 a-globin gene cluster X16_391593 T/C 0.001 0.27 (–1.59–2.14) .774
rs113267280 CCND3 6:41952511 T/G 0.001 0.34 (–1.54–2.21) .725
rs117544265 HBS1L 6:135356216 C/G 0.256 0.058 (–0.11–0.23) .501
rs141494605 HBM 16:216593 Ta NA NA NA
rs148706947 AXIN1 16:342218 C/T 0.002 0.82 (–0.50–2.15) .220
rs183437571 NFIX 19:13121899 Ca NA NA NA
rs570013781 a-globin gene cluster 16:149539 Ga NA NA NA
rs67104793 XRN1 3:142444839 A/delA 0.243 –0.05 (–0.21–0.10) .504
rs59329875 CTSA 20:44547672 C/T 0.244 –0.09 (–0.21–0.06) .257
Variants reported in sickle cell disease patients in Tanzania (6)
rs62573842 intergenic 9:32264314 A/G 0.216 0.13 (–0.02–0.27 .089
rs6466533 LOC105375366 7:79163576 T/C 0.237 0.12 (–0.03–0.28) .112
rs6590706 OPCML 11:133465011 A/G 0.314 0.02 (–0.11–0.15) .749
rs7163278 LOC105370983 15:93345162 T/C 0.052 –0.06 (–0.30–0.19) .656
rs10468869 intergenic 18:51795403 A/G 0.360 –0.01 (–0.14–0.12) .867
rs10756993 ADAMTSL1 9:18839726 C/A 0.174 –0.11 (–0.30–0.08) .243
rs192197462 intergenic 14:57116065 Aa NA NA NA
rs28567737 CCDC61/MIR769 19:46531219 C/T 0.471 –0.14 (–0.29–0.10) 1.000
Alleles: major/minor; MAF: minor allele frequency; NA: not applicable. SE: effect size and range; SNPs: single nucleotide polymorphisms.
aMonomorphic.
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Hb F regulation is a highly heterogeneous system and sub-
ject to regulatory and signaling pathways that develop differ-
ently across different populations.(12)
Indeed, the majority of variants described in Sardinians
(7/10) were either monomorphic or very rare in
Cameroonians with sickle cell disease (Table 2) and could be
attributed to the founder nature of the Sardinian population
used. This founder effect could account for some variants
that are extremely rare in the rest of the world; in some
cases, reaching high enough frequencies to provide unex-
pected biological insights.(7) For instance, X12_123681790,
monomorphic in Cameroonians, was associated with HBA1
levels in Sardinians. Similarly, rs113267280 located in the
CCND3 gene, a regulator of erythropoiesis particularly cell
division during terminal erythroid differentiation,(13) was
also associated with HBA1 levels in Sardinians. Furthermore,
rs183437571 was also imputed as monomorphic in the
TwinsUK cohort,(14) suggesting that significant variations
also exist within European populations. The data further
highlight the complexity of Hb F genomic regulation and
illustrate the difficulties that will be encountered when
attempting to replicate some variant association results.
Taken together, the data suggest that the discovery of
new Hb F-promoting loci that are relevant in most popula-
tions will require integrated large-scale genome-wide studies
across many populations. Specifically, future studies should
include multiple African populations, from where the disease
burden is highest and also because of the highest genetic
diversity among Africans.(11) Moreover, the use in future
research of appropriate GWAS panels that capture the full
genomic diversity in African populations, one of which is in
development within the H3Africa Consortium (www.
h3Africa.com), could provide more insight into the missing
heritability of the persistence of Hb F production. Indeed, in
a recent GWAS study among African–Americans, using the
Illumina Omni1-Quad System (San Diego, CA) that contains
high density of SNP coverage of the human genome (1,140,
419 SNPs) with 76.0% coverage of polymorphisms validated
in people of African ancestry, novel candidate SNPs associ-
ated with Hb F levels were reported in the SPARC, GJC1,
EFTUD2 and JAZF1 genes.(15) Further exploration of
known genetic modifiers of Hb F expression such as
BCL11A, HBS1L-MYB, b-globin gene cluster,(2–5) Kr€uppel-
like factor 1 (KLF-1), (haplo-insufficiency),(16,17) SAR1 (18)
and SALL2,(19) could serve as central nodes for gene net-
work analyses to identify other pathways, genes and variants
critical for Hb F production. Possible targets for novel thera-
peutic agents could be potent Hb F regulators such as KLF-
1, known activator of BCL11A, via transcriptional and post-
transcriptional mechanisms.(20)
The present study was a replication, in Cameroonian
sickle cell disease patients, of putative novel Hb F-promoting
loci identified in Tanzanian sickle cell disease patients and
the general Sardinian population: no significant associations
with Hb F were observed at these loci. The lack of associ-
ation further demonstrates the complexity of finding add-
itional Hb F-promoting loci that have multipopulation
relevance. These and other similar observations call for more
multicenter GWAS with SNPs panels that are representative
of interpopulations genetic diversity, particularly that within
sub-Saharan Africa, where the disease burden is highest.
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guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related 
(SAR1a) protein that were previously associated with HbF after HU treatment in African 
American patients, were investigated in 484 SCD patients from Cameroon. No 
associations were observed between any of the promoter variants and baseline HbF, 
clinical events or other hematological indices. The results of this study demonstrate the 
population-specificity of the heterogeneous mechanisms regulating HbF production. 
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Abstract 
Background: Reactivation of adult hemoglobin (HbF) is currently a dominant therapeutic 
approach to Sickle Cell Disease (SCD). In this study, we have investigated among SCD 
patients from Cameroon, the association of HbF level and variants in the HU-inducible small 
guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related 
(SAR1a) protein, previously shown to be associated with HbF after HU treatment in African 
American SCD patients.  
Findings: Only patients >5 years old were included; hemoglobin electrophoresis and a full 
blood count were conducted upon arrival at the hospital. RFLP-PCR was used to describe the 
HBB gene haplotypes and Gap PCR to investigate the 3.7 kb α-globin gene deletion. The 
iPLEX Gold Sequenom Mass Genotyping Array and cycle sequencing were used for the 
genotyping of four selected SNPs in SAR1a (rs2310991; rs4282891; rs76901216 and 
rs76901220). Genetic analysis was performed using an additive genetic model, under a 
generalized linear regression framework. 484 patients were studied. No associations were 
observed between any of the promoter variants and baseline HbF, clinical events or other 
hematological indices.  
Conclusion: The results of this study could be explained by possible population-specificity 
of some tagging genomic variants associated with HbF production and illustrated the 
complexity of replicating HbF-promoting variants association results across African 
populations. 
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Background 
Reactivation of adult fetal hemoglobin (HbF) is currently the dominant approach for the 
treatment of Sickle Cell Disease (SCD). The expression of adult HbF is a quantitative trait 
that is subject to several predisposing loci affecting the persistence of HbF in adulthood, 
particularly three principal loci; BCL11A, HBS1L-MYB intergenic variants and the five 
sequence polymorphisms along the β-globin gene cluster that confer the SCD haplotype (1-
3). Taken in sum, these loci have been associated with the disease-ameliorating HbF and 
account for 10-20% of the variance (4-7). Furthermore, the BCL11A erythroid-specific 
enhancer variants have been shown to account for significant variance in HbF in African 
American (8,9), Tanzanian (10) and Cameroonian SCD patient cohorts (11).  
HbF response to hydroxyurea (HU), has been shown to be subject to a myriad of genetic 
variations (SNPs, signalling pathways and pharmacogenomics interactions) and 
environmental factors (socio-economic factors, quality of care, exposure to malaria and 
infections) (12). Furthermore, some of these variants have been associated with favourable 
pharmacologic response to HU treatment like the small guanosine triphosphate (GTP)-
binding protein, secretion-associated and RAS-related (SAR) protein (13). SAR proteins have 
been shown to be critical to γ-globin expression (14) via the Giα/JNK/Jun pathway (15) in 
response to HU. Four variants (rs2310991; rs4282891; rs76901216 and rs76901220) in the 
SAR1a promoter were associated with significant increases in HbF levels in African 
American SCD patients on HU for 2 years (13). In this present study, we have investigated 
the relationship between the four SAR1a promoter variants and baseline HbF in SCD patients 
from Cameroon, without any HU treatment.  
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Findings 
Research hypothesis 
In this study, we hypothesize that selected variants in SAR1a promoter associated with 
significant increases in HbF levels in African American SCD patients on HU, are also 
associated with baseline HbF in SCD patients from Cameroon, without any HU treatment.  
Methods 
Study population and HbF measurement 
Patients’ recruitment occurred at the Yaoundé Central Hospital and Laquintinie Hospital in 
Douala, Cameroon. Only clinically stable patients, 5 years and older, with no history of blood 
transfusion, HU treatment, or hospitalisation in the preceding 6 weeks were included and 
clinical events were prospectively collected (Table 1). Whole blood counts of patients and Hb 
electrophoresis were conducted on arrival at the hospital, initially using the alkali 
denaturation test (ADT) in 55.5% (n = 266) of the cohort, and when it became available, high 
performance liquid chromatography (HPLC). In a previous study of this cohort, the SCD 
patient cohort was disaggregated based on the technique used for HbF assessment (HPLC vs 
ADT) and found similar but independently examined associations between HbF levels and 
BCL11A and HBS1L-MYB intergenic variants (5). 
Genotyping 
HbS mutation and HBB haplotypes 
DNA was extracted from peripheral blood following the manufacturer’s instructions 
(Puregene Blood Kit, Qiagen®, USA). Molecular analysis to determine the presence of the 
sickle mutation was carried out on 200 ng DNA by PCR to amplify a 770 bp segment of the 
β-globin gene, followed by Dde I restriction analysis of the PCR product (16). 
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Using published primers and methods, five restriction fragment length polymorphism (RFLP) 
sites in the β-globin gene cluster were amplified (17) to analyse the XmnI (5'Gγ), HindIII 
(Gγ), HindIII (Aγ), HincII (3˙'Ψβ) and HinfI (5'β) for the HBB haplotype background (18).  
Detection of 3.7 kb α-globin gene deletions  
Using the expand-long template PCR (Roche®, UK), the 3.7 kb α-globin gene deletion was 
successfully screened following the instructions reported (19) with some modifications 
previously published (20). 
SNPs 
A total of 484 samples were analysed initially using SNaPshot sequencing and capillary 
electrophoresis (n = 234), then the rest analysed using the iPLEX Gold Sequenom Mass 
Genotyping Array (Inqaba Biotec, South Africa). The results were validated by direct cycle 
sequencing of a subset (n = 48; 10%) of the samples using previously reported methods (5).  
Data analysis 
Descriptive statistics were obtained for all quantitative data using SPSS (IBM, USA version 
21.0). A chi-squared test, with 1 degree of freedom, was used to perform the Hardy-Weinberg 
Equilibrium (HWE) test on the SNPs genotype with three SNPs (rs4282891; rs2310991 and 
rs76901216) out of HWE (p < 0.05). Using an additive genetic model, under a generalized 
linear regression framework, we investigated the relationship between the SNPs and HbF 
levels, using the R statistical package version 3.0.3 (The R Foundation for statistical 
computing, Vienna, Austria). Significance was set at 5%.  
Results 
Patient cohort 
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Table 1 summarises the main characteristics of the cohort. All patients had confirmed SCA 
diagnosis (HbSS) among whom 50.2% (n = 243) were female and the mean age of the cohort 
was 17.9 years (±10.6). After genotyping β-globin gene haplotypes for 968 chromosomes, the 
most prevalent were Benin (72.5%, n = 702) and Cameroon (19.2%, n = 186). Haplotypes 
given in combinations, the Benin/Benin haplotype was 50.2% (n = 243) and the 
Benin/Cameroon haplotype 21.7% (n = 105) of the patient cohort (Table 1). The frequency of 
the 3.7kb α-globin gene deletion (α3.7) was 22.5% (n = 222) of 968 chromosomes, where 
28.5% and 8.6% of patients had co-inherited a single (αα/α3.7) and double (α3.7/α3.7) 
deletions, respectively (Table 1). The average number of annual reported vaso-occlusive 
crises was 2.8 (±3.3) with a similar yearly rate of hospital consultation (3.0 ± 3.9) and mean 
1.4 (±2.5) hospitalization per year. Overt stroke was reported in 4.5% (n = 22) of the patients. 
No association between SNPs and HbF 
The minor allele frequency (MAF) of the SAR1a promoter SNPs is shown in Table 2. There 
was no association between the four selected promoter SNPs and HbF levels in the patient 
cohort neither was there an association with clinical events or hematological indices. The 
influence of the electrophoretic technique, α-globin genotypes and β-globin haplotypes on the 
relationship between the SNPs and HbF levels was tested and no significant effect was 
observed. 
Discussion 
Four variants (rs2310991; rs4282891; rs76901220 and rs76901216) have previously been 
associated with higher percent HbF and significant change in HbF levels after HU treatment 
for two years in African American SCA patients enrolled in the National Institutes of Health 
(NIH)’s Sickle Cell Pulmonary Hypertension Screening Study (ClinicalTrials.org; 
NCT00011648). It has been reported that SAR1 is induced by HU towards the production of 
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HbF in erythroid cells (14,15) via activation of the Giα/JNK/Jun pathway. This and other 
critical signalling pathways in HU-induced HbF as well as genomic variants associated with 
HbS mutation and the disease course have been reviewed (12). Given the responsiveness of 
SAR1 to HU treatment and prior associations with HU-induced HbF, four promoter 
polymorphisms were investigated in a cohort of SCA patients not treated with HU to 
determine possible associations between the SNPs and baseline HbF. If these variants result 
in differential expression of SAR1 and thus HbF, this loci could become a candidate for 
therapeutic manipulation for ameliorating SCA and other hemoglobinopathies. However, 
none of the selected SNPs were associated with HbF, other hematological indices or clinical 
events. Furthermore, the difference between the minor allele frequencies (MAF) in African 
American SCA patients (13) and results from the present study may be attributed to the well 
reported high diversity among African population (21,22) and more specifically to admixture 
among African Americans, with African ancestry that could vary from 1 to 99 % (23,24). 
Replication of association studies across different populations, particularly of varied genetic 
backgrounds and environmental settings, is imperative to understanding the complex 
processes of HbF production and genetic polymorphisms predisposing to persistence of adult 
HbF, more so in sub-Saharan Africa where the burden of disease is highest.  
Conclusion 
The present study did not find any association between selected SNPs in the HU-inducible 
SAR1a protein, and HbF among SCD patients from Cameroon. Although SAR1a is a known 
regulator of HbF expression under HU therapy, it is interesting to know, however, that the 
SAR1a protein does not participate in HbF regulation at steady state in SCD patients. These 
findings emphasize the genetic heterogeneity of African populations affected by SCD with 
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regard to HbF-promoting loci and the need to perform replication studies of key association 
findings in several SCD populations to fully capture their significance. 
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Table 1: Cohort description 
 
Table 2. No association between SAR1a promoter polymorphisms and baseline HbF in 
Cameroon SCD patients 
SNP SNP 
position 
Chromosome loci Alleles# MAF$ Effect Size& 
(SE) 
P-value 
rs2310991 -1377 10:70171890 A/C 0.334 -0.05  
(-0.14 to 0.05) 
0.335 
rs4282891 Intron 1  
+100 
10:70170313 A/C 0.336 0.03  
(-0.08 to 0.13) 
0.645 
rs76901216 -809 71601084 C/G 0.295 -0.07  
(-0.20 to 0.05) 
0.265 
rs76901220 -385 10: 71600660 G* - - - 
#Alleles: major/minor, $MAF: minor allele frequency,*monomorphic, &Effect size and range. 
Variables  Mean ± SD Value range Number of 
observations 
Age (years)  17.9 ± 10.6 5 – 57 484 
 
Haematological indices 
RBC (1012/L) 2.8 ± 0.7 1.2 - 5.5 484 
Hb (g/dl) 7.8 ± 1.6 4.0 - 13.5 484 
MCV(fl) 84.6 ± 10.0 61 - 112 484 
MCHC (g/dl) 34.2 ± 3.8 22.3 - 54.0 484 
WBC (109/l) 14.7 ± 6.4 3.5 - 48.8 484 
Lymphocytes (109/l) 6.1 ± 3.3 0.87 - 20.4 484 
Monocytes (109/l) 1.7 ± 1.4 0.1 - 10.9 484 
Platelets (109/l) 371.5 ± 131.6 108 - 827 484 
HbA2 (%) 3.6 ± 2.1 0.1 - 18.2 484 
HbF (%) 10.1 ± 8.5 0 – 37.4 484 
Clinical events Vaso-Occlusive 
crisis (No. /year) 
2.8 ± 3.3 0 - 40 484 
Consultations  
(No. /year) 
3.0 ± 3.9 0 - 24 484 
Hospitalisation 
(No. /year) 
1.4 ± 2.5 0 - 30 484 
Overt stroke 4.5%  22 / 484 
3.7del α-globin gene 
genotypes 
αα/αα 62.9%  304 / 484¢ 
αα/α3.7 28.5%  138 / 484¢ 
α3.7/α3.7 8.6%  42 / 484¢ 
β-globin gene haplotypes Benin/Benin 50.2%  243 / 484¢ 
Benin/Cameroon 21.7%  105 / 484¢ 
Benin/Atypical 4.1%  20 / 484¢ 
Cameroon/Cameroon 4.1%  20 / 484¢ 
¢ Number of individuals and not alleles; RBC: red blood cells; Hb: hemoglobin; MCV: mean 
corpuscular volume; MCHC: mean corpuscular haemoglobin concentration; WBC: white 
blood cells; HbA2: hemoglobin α2; HbF: hemoglobin F. 
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Chapter 3.2 – Results 
 
Mechanisms of hydroxyurea-induced γ-globin expression in Sickle Cell Disease 
 
3.2.1. Pule GD, Mowla S, Novitzky N, Wiysonge C and Wonkam A. Systematic review 
of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of Sickle 
Cell Disease. Expert Review of Hematology. 2015 8(5): 669-79. 
Abstract 
To report on molecular mechanisms of fetal hemoglobin (HbF) induction by hydroxyurea 
(HU) for the treatment of sickle cell disease. Study Design: Systematic review. Results: 
Studies have provided consistent associations between genomic variations in HbF-
promoting loci and variable HbF level in response to HU. Numerous signal transduction 
pathways have been implicated, through the identification of key genomic variants in 
BCL11A, HBS1L-MYB, SAR1 or XmnI polymorphism that predispose the response to 
the treatment, and signal transduction pathways that modulate γ-globin expression 
(cAMP/cGMP; Giα/c-Jun N-terminal kinase/Jun; methylation and miRNA). Three main 
molecular pathways have been reported: i) Epigenetic modifications, transcriptional 
Synopsis of Chapter 3.2 
Hydroxyurea (HU) is the only available, FDA approved, drug treatment for Sickle Cell 
Disease and has demonstrated clinical efficacy and amelioration of disease 
symptoms, mostly through increasing fetal hemoglobin (HbF). A comprehensive 
understanding of the mechanisms of HbF-induction by HU treatment is the main focus 
of this chapter, which includes three publications that; 
i) Represent the background of this chapter and thorough systematic review of 
all currently known mechanisms by which HU promotes expression of HbF 
towards treatment and amelioration of SCD. 
ii) Investigates the transcriptional and post-transcriptional pathways involved in 
the production of HbF in response to HU in primary erythroid cells derived 
from umbilical cord blood hematopoietic stem cells. 
iii) Comment on the availability of various treatment approaches for SCD in 
Africa compared to the West and argues for a cross-continent effort from 
government, private sector and research institutes towards improving 
access to good medical care for patients. 
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events and signaling pathways involved in HU-mediated response, ii) Signaling 
pathways involving HU-mediated response and iii) Post-transcriptional pathways 
(regulation by miRNAs). Conclusions: The complete picture of HU-mediated 
mechanisms of HbF production in Sickle Cell Disease remains elusive. Research on 
post-transcriptional mechanisms could lead to therapeutic targets that may minimize 
alterations to the cellular transcriptome. 
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(HU) for the treatment of sickle cell disease. Study Design: Systematic review. Results: Studies
have provided consistent associations between genomic variations in HbF-promoting loci and
variable HbF level in response to HU. Numerous signal transduction pathways have been
implicated, through the identification of key genomic variants in BCL11A, HBS1L-MYB, SAR1
or XmnI polymorphism that predispose the response to the treatment, and signal transduction
pathways that modulate g-globin expression (cAMP/cGMP; Gia/c-Jun N-terminal kinase/Jun;
methylation and miRNA). Three main molecular pathways have been reported: i) Epigenetic
modifications, transcriptional events and signaling pathways involved in HU-mediated
response, ii) Signaling pathways involving HU-mediated response and iii) Post-transcriptional
pathways (regulation by miRNAs). Conclusions: The complete picture of HU-mediated
mechanisms of HbF production in Sickle Cell Disease remains elusive. Research on post-
transcriptional mechanisms could lead to therapeutic targets that may minimize alterations to
the cellular transcriptome.
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Sickle cell disease (SCD) is a monogenic,
hematological and multi-organ disorder associ-
ated with progressive organ damage and
chronic and acute illness (Wheatherall et al.,
2005). SCD is caused by a point mutation
(A > T) in the sixth codon of the b-globin
gene on chromosome 11, resulting in the sub-
stitution of the amino acid glutamic acid to
valine. The resulting hemoglobin S (HbS)
leads to polymerization and precipitation of
hemoglobin during deoxygenation or dehydra-
tion resulting in sickling, abnormal adhesion
of leukocytes and platelets, inflammation,
hypercoagulation, hemolysis and hypoxia, in
addition to microvascular obstruction and
ultimately organ damage [1].
There is strong correlation between the
frequency of the HbS gene and the historical
distribution and incidences of malaria [2]. It is
estimated that > 300,000 births with SCD
occur annually, nearly two-third of which take
place in Africa [3]. SCD is relatively common
in other continents such as North America
and Europe with 2600 and 1300 affected new-
borns annually, respectively [4]. It is well
accepted that the sickle mutation exists in
Africa on diverse genetic haplotype back-
grounds [5]. Five typical haplotypes have been
described across the b-globin gene cluster
based upon the pattern of specific restriction
fragment-length polymorphisms across the
region. Four haplotypes are associated with
HbS in Africa (Benin, Bantu/Central African
Republic, Senegal and Cameroon) and the
fifth is thought to have arisen in India
and/or the Arabian Peninsula (Arab/Hindu)
[6,7]. It has been suggested that these haplo-
types also have an effect on the severity of the
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disease through their genetically determined effect on HbF
level [8,9].
Indeed, despite the fact that there are several key phenotypes
of SCD (anemia, stroke, infections), fetal hemoglobin (HbF)
has emerged as a central disease modifier [10], that is amenable
to therapeutic manipulation [11]. Genetic variants at three prin-
cipal loci, BCL11A, HBS1L-MYB and HBB cluster, account for
10–20% of HbF variation [12–14]; among SCD patients in the
US and Brazil [15], Tanzania [16] and Cameroon [17]. Currently,
hydroxyurea (HU) is the only US FDA-approved pharmaco-
logic treatment for induction of HbF in patients with SCD.
The major HU benefit is directly related to its HbF-producing
effect [18,19] that leads to significant reduction of pain, acute
chest episodes, the need for blood transfusions and
mortality [8,20–22].
A few studies have shown that individual responses to HU
treatment are highly variable, with induced HbF levels ranging
from 10% to > 30% HbF [23–25]; and sibling pairs analysis has
shown that strong genetic component could influence this vari-
able response to HU [20]. Some authors have hypothesized that
the effect of HU on HbF level could act through HbF-
promoting loci like BCL11A [26]. Recent GWAS studies have
revealed further sequence variants that could influence the
response to HU [27]. However, the precise molecular mode of
action of HU, though these genetic variants, remained to be
comprehensively determined.
In this paper, it is our aim to provide a comprehensive and
systematic review of the current literature on HU’s mode of
action at the molecular levels and postulate on future work in
this field. It is anticipated that adequate knowledge of the
mode of action of HU will result in the exploration of alterna-
tive therapeutic agents that may minimize alterations to the
cellular transcriptome.
Methods
A review of the current literature on reported mechanisms of
HbF induction by HU treatment was conducted from October
2014 to December 2014 using Pubmed (National Library of
Medicine), Medline and Google scholar. Key words included
individual use or a combination of the following: ‘Hydroxyurea
or HU or hydroxycarbamide’, ‘Foetal hemoglobin or HbF or
gamma globin’, ‘hemoglobin-induction’, ‘Sickle Cell treatment’
and ‘erythroid treatment’, and specific author names were also
used. Prior knowledge of research groups working on HU and
SCD Africa and globally further facilitated the identification
and selection of research articles. Only available full-length
articles, in English, with the use of HU on erythroid cells (cell
lines and/or primary cells) were selected. In cases where multi-
ple studies reported a similar pathway, the most recent with
the most detailed mechanisms of HbF induction was included.
The main search was conducted by a PhD student in Human
Genetics and reviewed by a Medical/Human Geneticist with
expertise in SCD and a Hematologist/Cell biologist with exper-
tise in signal transduction pathways. A total of 563 articles
were consulted after the search, eliminating on the basis of the
article title and its relevance to the scope of the review. Subse-
quently, 361 papers were retrieved and their abstracts and
results sections perused for further elimination, of which a final
total of 129 papers were selected for inclusion in the review.
Results
SCD is highly heterogeneous in clinical manifestation and dis-
ease severity even though patients may be diagnosed with the
same genetic mutation resulting in the disease. HbF is a major
modifier of the SCD disease phenotype that has been associ-
ated with reduced risk for vaso-occlusive complications, organ
damages and increased life expectancy [10,21,28–30]. During gesta-
tion, the g-globin genes are the predominantly transcribed
genes from the b-cluster. After birth the expression of the
g-globin genes is replaced by the adult b-globin genes; this pro-
cess is known as the ‘Fetal Switch’ [31]. However, some HbF
remains to be heterogeneously transcribed with variable expres-
sion levels across HbF red blood cells (F cells) [32]. Initial
observations suggested that HBB haplotypes also have an effect
on the severity of SCD [8,9]. The Bantu haplotype being the
less favorable and the Indian-Arab haplotype associated with
the least severity; as the latter is associated with higher HbF
levels [33], due to a single nucleotide polymorphism (SNP)
upstream of the b-globin gene (rs7482144 or Xmn-Gg), charac-
teristically present in Indian Arab and Senegal haplotypes [34].
The degree of HbF expression and the blood percentage of F
cells at adulthood are heritable quantitative trait loci [35]. Nor-
mal individuals have <0.6% HbF distributed among 1–7% F
cells in their peripheral blood. However, approximately 2% of
the population produce up to 5% HbF and 25% F cells, a trait
known as heterocellular Hereditary Persistence of HbF [36].
Heterocellular Hereditary Persistence of HbF is characterized
by a persistent high level of HbF in adults [32] and a genome-
wide SNP scan of 10 members of a Maltese family with heter-
ocellular Hereditary Persistence of HbF revealed a nonsense
mutation in the KLF-1 gene, a critical activator of BCL11A
[32]. This mutation was characterized and shown to cause an
ablation of the DNA binding domain of this erythroid tran-
scription factor and thus provided a rationale for the effect of
KLF-1 haploinsufficiency on HbF levels. In total, genetic var-
iants at three principal loci, BCL11A, HBS1L-MYB and HBB
cluster, account for 10–20% of HbF variation [13,14,37].
BCL11A loci have been shown to be amenable to therapeutic
manipulation with the aim to increase HbF level [38,39] that
have major implications for research on new treatments of
SCD.
HU treatment & Hbf induction in SCD
Currently, HU is the only pharmacologic treatment for induc-
tion of HbF in patients with SCD both approved by the FDA
in 1998 and by the European Medicines Agency in 2007. In
addition, the National Institutes of Health Officer of Medical
Applications of Research and the Agency of Healthcare
Research and Quality both declared HU as an effective drug
treatment for adults and children with SCD [40–42]. HU is an
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oral, S-phase specific cytotoxic,
anti-metabolic and anti-neoplastic drug
treatment; it is a potent inhibitor of a
ubiquitous enzyme called ribonucleotide
reductase [43]. In 1984, the first clinical
application of HU in hemoglobinopathies
demonstrated swift and vivid increases in
HbF concentration within reticulocytes
and insignificant toxicity to bone mar-
row [44]. Initial trial showed that HU was
associated with decreases in the frequen-
cies of painful episodes, acute chest syn-
drome, hospitalization and transfusions
[28]. Subsequent trials in SCD have dem-
onstrated clinical efficacy and increase in
survival rates and life expectancy [20,21],
protection against cerebrovascular dis-
ease [45], long-term drug safety, capacity
to prevent organ damage and reduced
morbidity and mortality in school-age
children [24], toddlers [46,47] and
infants [48]. HU has also been associated with clinical drift,
where physicians use the drug for related complications of
SCD such as stroke prevention, priapism and pulmonary
hypertension [49].
However, potential short and long-term potential adverse
effects such as male impotence [49–51], susceptibility to infec-
tions [52–55], potential teratogenic effect [28,56] and cutaneous
adverse reactions [57] have also been associated with HU.
Although sparse and in the majority unsupported, some studies
have demonstrated recovery of spermatogenesis, normal counts
and motility after the cessation of HU treatment [58]. The fear
of such side effects has been a subject of concern to some pro-
fessionals [59,60], parents as well as patients [40,61–64] and a poten-
tial barrier to compliance in some settings [65,66]. As a
consequence, HU is still underutilized [40,61], despite the studies
that have reported on the overall drug safety [67] and limited
evidence regarding potential HU-induced leukemogenic [68] or
teratogenic effects [69]. It is however noteworthy that there are
no present data validating fertility and teratogenic effects of
HU nor on the incidence of abnormal pregnancies as a result
of HU treated father. The decision for continuation (or other-
wise) of HU in instances of pregnant SCD mothers on HU
should thus be taken on a case-to-case basis where the risk of
cessation is carefully weighed against potential effects of termi-
nating an effective treatment [21,70]. Furthermore, less evidence
is currently available on the persistence over time of responses
to HU. Long-term studies such as the HU Study of Long-
Term Effects, HU Safety and Organ Toxicity together with
BABY HUG follow-up studies continue to reveal more phar-
macogenetics data to help define long-term risk of early initia-
tion of HU, potential adverse effects and persistence of
response.
It is evident that concomitant to more HU clinical trials,
predictive drug-responder indexes, efficacy and toxicity studies,
educating physicians and/or care providers as well as the global
healthcare system is necessary to overcome other barriers such
as access to specialty care, insurance coverage as well as further
provider-level aspects such as care giver ambivalence. It is also
urgent to fully understand HU molecular mode of action, in
order to explore alternative and potential less toxic and more
acceptable agent that could equally increase the level of HbF.
Genomic variants associated with HU-induced HbF level
Patients’ response to HU is highly variable, with induced HbF
levels ranging from as low as 2% to > 30% HbF [23–25], poten-
tially due to the pharmacogenomic interactions [67]; but our
understanding of the reasons for the wide spectrum of clinical
responses to HU treatment is incomplete [71]. It has been ini-
tially suggested that haplotypes in the HBB gene cluster possi-
bly affect possibly the clinical response to HU, likely mediated
by their genetically determined effect on HbF level (TABLE 1)
[34,72,73]. There is a positive association between the XmnI poly-
morphism (rs7482144) in the g-globin promoter and HbF lev-
els in numerous populations [15,16,74–76], as well as accounting
for > 2% in HbF variation in patients and 13–32% in F cell
variation in non-anemic European population [77]. This poly-
morphism has also been associated with the less severe disease
course of patients with Senegal and/or Indian-Arab haplotype
backgrounds as well as improved response to HU treat-
ment [74,75,77–81]. Subsequent research provides some evidence
that the effect of HU on HbF level could act on other HbF-
promoting loci like BCL11A [26]. Indeed, BCL11A is central to
the ‘fetal switch’, BCL11A is co-expressed, directly interacts
and co-occupies the b-globin loci with SOX-6 in association
with the Mi-2/nucleosome remodeling and deacetylase complex
for long-range re-conformation of the b-globin cluster for the
transcriptional silencing of g-globin [38]. Besides BCL11A, from
DNA structural alteration to sequence modification, the
Table 1. Genomic variants associated with hydroxyurea-induced HbF
level.
Gene SNPs Chromosome:
locus
Ref.
HBB gene cluster haplotype rs7482144 11:5254939 [5,34,72–81,131]
BCL11A
ARG1/2
HBS1L-MYB
rs1427407
rs4671393
rs7606173
rs7557939
rs1186868
rs2295644
rs17599586
rs28384513
rs9399137
2:60490908
2:60491212
3:60493111
2:60494212
2:61764103
14:67599842
6:131583579
6:135055071
6:135097880
[132]
SAR1 rs2310991
rs4282891
rs76901216
3:142444839
10:70171890
10:70170313
[82,83]
SALL2 rs61743453 14:21523209 [27]
HbF: Fetal hemoglobin; SNP: Single nucleotide polymorphism.
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secretion-associated and ras-related protein (SAR-1) has been
shown to play a significant role in g-globin regulation [82] and
three SNPs in the SAR-1a in its promoter sequence have been
associated with level of HbF in peripheral blood of SCD
patients on HU [83]. Variants in regulatory sequences of SAR-1
were shown in vitro to be associated with HU induced HbF
production, underlying SAR-1 as an alternative therapeutic tar-
get for b-globin disorders [82]. Recent GWAS studies have also
shown that a coding variant in Spalt-like transcription factor,
or SALL2, was associated with higher final HbF in response to
HU treatment, a new insight into the pharmacological HbF
upregulation by HU in patients with SCD [27] that deserves
further functional studies.
Molecular pathway of action of HU
Various molecular pathways have been reported to explain the
mode of action of HU (TABLE 2 & FIGURE 1): i) Epigenetic modifica-
tions, transcriptional events and signaling pathways involved in
HU-mediated response, ii) Signaling pathways involving
HU-mediated response and iii) Post-transcriptional pathways
(regulation by miRNAs).
Epigenetic & transcriptional events regulating HU
response
BCL11A, SOX-6 and the Mi-2/nucleosome remodeling and
deacetylase complex co-occupy the b-globin loci for long-range
re-conformation of the b-globin cluster for the transcriptional
silencing of g-globin [38]. Chromosomal looping mediates the
long range interaction between methylation-sensitive regulatory
sites in the locus control region and the b-globin gene cluster.
It has also been shown that BCL11A occupies the LCR
HS3 and the intergenic region between GgA and d-globin
genes [31]. Acetylation-based transcriptional activity has been
observed in the LCR, d- and b-globin genes as well as the
intergenic region between Ag and d-globin genes, whereas
methylation was most observed in the CpG islands of the
g-globin proximal promoter [38,84]. Furthermore, HU-induced
HbF has previously been inversely correlated with Gg-globin
methylation in SCD patients [84]. Albeit, the changes in meth-
ylation did not reach statistical significance, decreases in meth-
ylated CpG islands in the Gg-globin promoter were identified
and associated with increased g-globin expression. Such epige-
netic modifications have proven to play a significant role in the
transcriptional regulation of the b-globin gene cluster and thus
may require further investigation to find target-specific chroma-
tin remodeling agents for the re-activation of g-globin expres-
sion to ameliorate SCD symptoms.
Signaling pathways involved in HU-mediated response
Cyclic AMP & GMP pathways
The cGMP pathway has been implicated as a role player in the
induction of HbF in vitro, in K562 cells and human erythro-
blasts, as well as in vivo, in SCD patients [85–87]. The pivotal
role of the cGMP-dependent pathway in g-globin expression
regulation has previously been described [85] with sGC-PKG
being involved in g-globin induction in response to HU [86].
A humanized SCD mouse model of TNF-a-induced acute
vaso-occlusion has been used to delineate an HU-induced nitric
oxide (NO)-cGMP pathway, where HU-induced NO stimulates
intracellular sGC thus increasing cGMP and thus PKG [88]. The
observed effects of increased PKG included induction of
g-globin expression in erythroid cells and decreased leukocyte
recruitment and adhesion. Although still a mouse model, this
pathway is considered true also in humans and provides numer-
ous therapeutic targets for HbF production.
There is cross-talk between the cGMP- and cAMP-
dependent pathways and it has been demonstrated in several
cell types [89]. Central to the cross-talk is the cAMP-specific
Table 2. Summary of mechanisms of HbF production in response to hydroxyurea.
Signal level Pathway Mechanism of g-globin induction Ref.
Epigenetic and transcriptional events DNA remodeling
DNA methylation
Mi-2/NuRD; Acetylation and methylation
DNMT-1
[31,38,84,133,134]
[131,132]
Signaling pathways Gia/JNK/Jun NFkB induction of SAR1 [82]
cGMP sGC-PKG and NO-induced sGC-PKG [86,88,90,91]
cAMP MYB transcriptional control [90,124,135]
MAPKs Erk1-2/p38/JNK/CREB1 [91,97–100,136]
Nitric oxide eNOS, flow-induced ATP and anti-sickling [85,123]
Phosphorylation ElF2a [128]
Transcription factors GATA-1/2; p21; EPO; KLF1 [32,101,137]
Stress signals ROS (superoxide and hydroxyl radicals) [104]
Post-transcription Translational
Regulation
miR-494; 15a; 16–1; 151–3p; 148b [84,124–126,138–141]
elF2a: Eukaryotic initiation factor 2a; eNOS: Endothelial nitric oxide synthase; NFkB: Nuclear factor k B; NuRD: Nucleosome remodeling and deacetylase; ROS: Reactive
oxygen species; SAR1: Secretion-associated and ras-related protein.
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phosphodiesterase 3 that is inhibited by cGMP and results in
the activation of cAMP-dependent PKA through the increase
of intracellular cAMP levels [85]. The role of the cAMP path-
way and the mechanisms of HbF regulation have been
described previously with c-Myb identified as a key role player
in the cAMP-mediated inhibition of g-globin expression, par-
ticularly in K562 cells that significantly express c-Myb when
compared to adult erythroblasts [90], possibly suggesting the
absence of c-Myb/cAMP regulation of HbF in adult erythro-
blasts. Although c-Myb reduces the transcriptional activity in
the g-globin promoter, which is concomitant with the low
expression of c-Myb in g-globin expressing-adult erythroblasts,
induction of the cAMP pathway is central to erythroid differen-
tiation in K562 cells [90]. The role of the cAMP pathway in
g-globin regulation in erythroblasts appears to be transient and
developmental stage-specific, with significantly higher intracel-
lular cAMP levels in fetal liver erythroblasts when compared to
the low-to-undetectable levels in adult erythroblasts. These data
advocate for further investigation of the cAMP pathway and
identification of the ‘cAMP-switch’ during erythropoiesis as a
potential therapeutic target for cAMP-mediated HbF induction
in erythroblasts. Furthermore, the polar role of the cAMP path-
way in K562, where it inhibits g-globin expression, and adult
erythroblasts, where it induces HbF production, suggests that
the role of the cAMP pathway in the regulation of HbF may
depend on the global cellular context of erythroid cells.
MAP kinases
MAPKs such as ERK, p38 and c-Jun N-terminal kinase (JNK)
appear to be independent of cAMP-dependent pathways regu-
lating HbF [91], even though cross-talk between cAMP-
dependent and MAPK pathways has been described in non-
erythroid cells [92–96]. Several studies have investigated the role
of MAPKs in HbF production using erythroid cells [97–100].
HU has been shown to increase phosphorylation of MAPK
p38, while simultaneously causing dephosphorylation of ERK
and JNK [97], effects which are known to affect erythroid dif-
ferentiation and induce g-globin expression. Furthermore, spe-
cific inhibition of p38 in K562 cells without affecting ERK
and JNK resulted in decreased expression of g-globin, contrary
to inhibition of ERK.
JNK/Jun pathway
Recently, the role of SAR1, a small guanosine triphosphate-
binding protein in adult erythroid cells [101], in HU-induced HbF
has been shown in bone marrow CD34+ and K562 cells [82].
Nuclear factor k B was shown to be central to the expression of
SAR1 through direct binding to the promoter sequence after
induction by HU. Furthermore, the involvement of JNK/Jun
phosphorylation and Gia pathways in g-globin expression was
demonstrated through inhibition and silencing experiments in
both CD34+ and K562 cells, resulting in the reduction of HbF
and thus demonstrating that activation of the Gia/JNK/Jun path-
way proteins is necessary for nuclear factor k B dependent
SAR1 expression in the production of HU-mediated HbF.
Other molecular pathways
GATA erythroid transcription factors are widely considered key
modulators of g-globin expression [101]. Both GATA-1 and
GATA-2 proteins have been associated with HU treatment in
K562 cells prompting the possibility of a HU-induced GATA-1
and/or -2/p21-dependent signal transduction pathway toward
g-globin expression [101]. Reactive oxygen species such as super-
oxide, hydrogen peroxide (H2O2) and NO have been shown to
mediate the phosphorylation of p38 MAPK [102,103], whose asso-
ciation with HbF production was discussed above. Inducers of
g-globin such as sodium butyrate and trichostatin A have dem-
onstrated an H2O2-dependent activation of p38 through phos-
phorylation and subsequent HbF production in erythroid
progenitors and K562 cells [104]. However, HU-induced g-glo-
bin expression is independent of H2O2 formation, albeit other
reactive oxygen species such as NO, superoxide and hydroxyl
radicals are known to activate MAPKs and cGMP [105,106].
Nitric oxide
HU treatment is known to improve blood flow through reper-
fusion and decreased sickling; however, the reasons for the
improved circulation are not completely understood. NO
release has had a long-standing association with HU-induced
improved blood flow through vasodilation [107–113]. Recently, a
rabbit erythrocyte model was used to demonstrate that HU reg-
ulates the production of NO by the enzyme endothelial NO
synthase [114], and further showing that the released NO indu-
ces blood flow-induced ATP, which is a known mediator of
vasodilation through endothelial cell purinergic receptor bind-
ing [115–118] and subsequent release of endothelial NO [119–121].
The improved blood flow results from the NO-induced
increase in oxygen affinity of sickle erythrocytes in SCD
patients because NO exhibits anti-sickling properties and inhib-
its HbS polymerization [85,122]. NO may be released by
HU
SARsGC
GTP
cAMP
PKG
PKA
MYB
miRNAs
GATA-2
p-(JNK/Jun) MAPKs
p-p38 Pl3/ERK/JNK
γ-globin
PDE3 cGMP
Figure 1. Various HU-activated signal transduction
pathways for g-globin expression.
Summarized pathways previously associated and/or induced by HU
treatment in primary erythroid and K562 cells.
HU: Hydroxyurea.
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endothelial cells and/or erythrocytes, establishing a feedback
loop with flow-derived ATP release from erythrocytes and pro-
vide rationale for some of the immediate reported benefits of
HU treatment (improved blood flow and attenuated sickling
events in SCD patients) [123].
Post-transcriptional pathways: regulation by miRNAs
Transcriptional regulation through short non-coding RNA oli-
gonucleotides (miRNAs) holds significant promise in explaining
variances in HbF induction in SCD patients of similar genomic
background and environmental influence. Recently, a study
demonstrated significant HU-induced miRNAs expression in
SCD patients and associated with HbF at both baseline
(miR-494) and maximum dose tolerated (miR-26b and
miR-151-3p). Furthermore, HU has also been shown to upre-
gulate miR-15a and miR-16-1, whose direct target is MYB, a
critical regulator of g-globin expression [124]. Downregulation
of miR-148b has also exhibited tumor suppressor properties
through inhibition of cell proliferation in gastric cancer [125].
Reticulocytes have also been shown to contain miRNAs,
although enucleated and previously thought not to contain any
nucleic acids [126]. Furthermore, it was shown that the miRNA
profile of terminally differentiated erythrocytes from SCD
patients was significantly different from unaffected individuals,
thereby prompting an association with disease physiology.
Defective terminal differentiation during sickle cell erythropoie-
sis was supported by an association with poor expression of
miR-320 [126]. The role of miRNAs in hematopoiesis, specifi-
cally erythropoiesis and erythrocyte physiology has also been
previously reviewed [127].
The field of post-transcriptional regulation of HbF has made
a recent surge to scientific interest as a potential level along the
pathway to g-globin expression for therapeutic targets. In a
recent study, inhibition of dephosphorylation of the eukaryotic
initiation factor 2a, a critical regulator of protein translation,
enhanced production of HbF and was devoid of any changes at
the levels of gene transcription, cellular proliferation and differ-
entiation [128]. The use of salubrinal, a known inhibitor of
eukaryotic initiation factor 2a phosphorylation, improved g-
globin mRNA turnover to HbF without a globin preference
shift (the ratio of g/[g+b] remained unchanged), and thereby
elucidating another level for potential therapeutic targets. In
support of these findings, salubrinal was further shown to
increase translation efficiency during the recovery phase of cel-
lular stress response through an increase in the number of selec-
tive translating ribosomes on the g-globin mRNA [129]. Further
investigation of translation-altering agents and the global
disease-specific miRNA profile in understudied and highly het-
erogeneous populations such as in Africa promises to yield
mechanistic insight into the disease phenotype and differential
response to HU treatment.
Discussion & conclusion
HU treatment has demonstrated success in several settings,
both in children and adults with SCD. The current dilemma
stems from various clinical responses to the treatment and often
the lack thereof. There has been great progress made towards
understanding various mechanisms by which HU induces HbF
production through identifying key genomic variants that pre-
dispose the response to the treatment, various environmental
contributors as well as specific signal transduction pathways
that modulate g-globin expression. However, the complete pic-
ture of HU-mediated HbF production remains elusive. While
the majority of HU benefit on SCD is directly related to the
amount of HbF produced, it is also suspected that HU has
some disease modulating effects outside of HbF induction,
such as stress hematopoiesis, endothelial NO release or the
reduction of leukocyte counts, that the present paper has not
fully addressed.
In recent times, there has been a shift in the search for thera-
peutic targets toward the post-transcriptional and post-
translational mechanisms that regulate HbF production as a
way of minimizing alterations to the global transcriptional sys-
tem through stress. There is an urgent need to investigate the
role of miRNAs in HU-induced HbF production in SCD
patients and further explore other potent negative regulators of
g-globin expression and target of miRNAs, with the aim of elu-
cidating a miRNA-mediated signaling transduction pathway
induced by HU treatment. The outcomes of such studies
would firstly yield post-transcriptional population-specific var-
iants and provide potential explanations for the vast inter-
patient variation in response to HU treatment. And, secondly,
delineate another regulatory level of gene expression to known
pathways and therefore possibly reveal therapeutic targets that
may minimize alterations to the cellular transcriptome.
Expert commentary
HU treatment has demonstrated success in several settings,
both in children and adults with SCD. Negating the sparse evi-
dence on the potential treatment-related adverse effect and the
barriers to use, as the only available drug treatment for SCD,
HU has a potential role in ameliorating the global problem of
SCD, particularly in high disease burden locales such as Africa.
The current dilemma stems from various clinical responses to
the treatment and often the lack thereof. This challenge could
be overcome in the future with three clinical trials underway in
Africa, spanning Angola, Congo, Kenya and Nigeria, as well as
North America and Europe, with 21 and 3 open trials, respec-
tively [130]. Furthermore, there has been great progress made
towards understanding various mechanisms by which HU
induces HbF production through identifying key genomic var-
iants that predispose the response to the treatment, various
environmental contributors as well as specific signal transduc-
tion pathways that modulate g-globin expression. However, the
complete picture of HU-mediated HbF production remains
elusive. The present study represents, to our knowledge, the
first systematic review on known molecular mechanism of
action of HU-induced HbF in SCD, the only medication avail-
able for this condition of global importance. It is anticipated
that adequate knowledge of the mode of action of HU will
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result in the exploration of alternative therapeutic agents with
possibly less toxicity.
Five-year view
The study has provided some specific perspectives in future
research, specifically on post-transcriptional regulations by miR-
NAs that could lead to possible therapeutic targets that minimize
alterations to the cellular transcriptome. There is an urgent need
to investigate the role of miRNAs in HU-induced HbF produc-
tion in SCD patients and further explore other potent negative
regulators of g-globin expression and target of miRNAs, with
the aim of elucidating a miRNA-mediated signaling transduc-
tion pathway induced by HU treatment. The outcomes of such
studies would firstly yield post-transcriptional population-
specific variants and provide potential explanations for the vast
inter-patient variation in response to HU treatment. And, sec-
ondly, delineate another regulatory level of gene expression to
known pathways and therefore possibly reveal therapeutic targets
that may minimize alterations to the cellular transcriptome.
While the majority of HU benefit on SCD is directly
related to the amount of HbF produced, it is also suspected
that HU has some disease modulating effects outside of HbF
induction, such as stress hematopoiesis, endothelial NO
release or the reduction of leukocyte counts; this paper did
not explore those mechanisms. It is anticipated that more
research on other HU-modulating effects on SCD outside of
HbF induction will evolve from these areas to complete a
comprehensive profile of the mechanism of action of HU
in SCD.
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Key issues
. The study has summarized various molecular pathways that have been reported to explain the mode of action of hydroxyurea (HU).
. Numerous signal transduction pathways have been implicated, through the identification of key genomic variants in BCL11A, HBS1L-
MYB or SAR1 that predispose the response to the HU treatment in Sickle Cell Disease.
. Additional signal transduction pathways modulate g-globin expression (cAMP/cGMP; Gia/c-Jun N-terminal kinase/Jun; methylation and
miRNA).
. Three main molecular pathways have been reported:
– Epigenetic modifications, transcriptional events and signaling pathways involved in HU-mediated response
– Signaling pathways involving HU-mediated responsePost-transcriptional pathways (regulation by miRNAs)
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Abstract 
Background: The major therapeutic benefit of hydroxyurea, the only FDA-approved 
pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal 
hemoglobin (HbF) production that leads to significant reduction of morbidity and 
mortality. However, potential adverse effects such as infertility, susceptibility to 
infections, or teratogenic effect have been subject of concerns. Therefore, 
understanding HU molecular mechanisms of action, could lead to alternative therapeutic 
agents to increase HbF with less toxicity. This paper investigated whether HU-induced 
HbF could operate through post-transcriptional miRNAs regulation of BCL11A, KLF-1 
and MYB, potent negative regulators of HbF. Both ex vivo differentiated primary 
erythroid cells from seven unrelated individuals, and K562 cells were treated with 
hydroxyurea (100 μM) and changes in BCL11A, KLF-1, GATA-1, MYB, β- and γ-globin 
gene expression were investigated. To explore potential mechanisms of post-
transcriptional regulation, changes in expression of seven targeted miRNAs, previously 
associated with basal γ-globin expression were examined using miScript primer assays. 
In addition, K562 cells were transfected with miScript miRNA inhibitors/anti-miRNAs 
followed by Western Blot analysis to assess the effect on HbF protein levels. Direct 
interaction between miRNAs and the MYB 3′-untranslated region (UTR) was also 
investigated by a dual-luciferase reporter assays.  
Results: Down-regulation of BCL11A and MYB was associated with a sevenfold 
increase in γ-globin expression in both primary and K562 cells (p < 0.003). Similarly, 
KLF-1 was down-regulated in both cell models, corresponding to the repressed 
expression of BCL11A and β-globin gene (p < 0.04). HU induced differential expression 
of all miRNAs in both cell models, particularly miR-15a, miR-16, miR-26b and miR-151-
3p. An HU-induced miRNAs-mediated mechanism of HbF regulation was illustrated with 
59
 
 
 
the inhibition of miR-26b and -151-3p resulting in reduced HbF protein levels. There 
was direct interaction between miR-26b with the MYB 3′-untranslated region (UTR).  
Conclusions: These experiments have shown the association between critical regulators 
of γ-globin expression (MYB, BCL11A and KLF-1) and specific miRNAs; in response to 
HU, and demonstrated a mechanism of HbF production through HU-induced miRNAs 
inhibition of MYB. The role of miRNAs-mediated post-transcriptional regulation of HbF 
provides potential targets for new treatments of SCD that may minimize alterations to 
the cellular transcriptome 
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geted miRNAs, previously associated with basal γ-globin expression were examined using miScript primer assays. In 
addition, K562 cells were transfected with miScript miRNA inhibitors/anti-miRNAs followed by Western Blot analysis to 
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Results: Down-regulation of BCL11A and MYB was associated with a sevenfold increase in γ-globin expression in 
both primary and K562 cells (p < 0.003). Similarly, KLF-1 was down-regulated in both cell models, corresponding to 
the repressed expression of BCL11A and β-globin gene (p < 0.04). HU induced differential expression of all miRNAs in 
both cell models, particularly miR-15a, miR-16, miR-26b and miR-151-3p. An HU-induced miRNAs-mediated mecha-
nism of HbF regulation was illustrated with the inhibition of miR-26b and -151-3p resulting in reduced HbF protein 
levels. There was direct interaction between miR-26b with the MYB 3′-untranslated region (UTR).
Conclusions: These experiments have shown the association between critical regulators of γ-globin expression 
(MYB, BCL11A and KLF-1) and specific miRNAs; in response to HU, and demonstrated a mechanism of HbF production 
through HU-induced miRNAs inhibition of MYB. The role of miRNAs-mediated post-transcriptional regulation of HbF 
provides potential targets for new treatments of SCD that may minimize alterations to the cellular transcriptome.
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Background
Sickle cell disease (SCD) occupies a prominent place in 
human genetics, as the paradigmatic example of a mono-
genic disorder, that was described over 100  years ago, 
and in 1949, it became the first human disease to be deci-
phered at the molecular level [1]. SCD is a monogenic, 
hematological and multi-organ disorder associated acute 
and chronic illness, and progressive organ damage [2]. 
The disease is due to a single point mutation (Glu6Val) 
that causes polymerization of the mutant hemoglobin 
(Hb) S, resulting in sickling of erythrocytes. Inflamma-
tion, hemolysis, microvascular obstruction and organ 
damage characterize the clinical expression of SCD, 
which is highly variable in individual patients [3]. Sub-
Saharan Africa (SSA) has the highest disease burden 
with approximately 305,800 affected new-borns per year, 
accounting for 0.74 % of all births in the region (Modell 
et al. 2008) and 80 % of annual global affected child births 
[4]. Despite this high incidence, the life-saving public 
health programs have not been implemented in most 
SSA countries often associated with limited medical 
resources and infrastructures. As a consequence, neona-
tal and childhood mortality due to SCD remains high and 
estimates suggest that without intervention, up to 90 % of 
affected children in SSA die by age five from SCD [4, 5]. 
Nevertheless, SCD patients manifest with wide varying 
degrees of severity. In combination with environmental 
factors, several genomic loci, influence the clinical course 
of SCD. Indeed, despite the fact that there are several 
key phenotypes of SCD (anemia, stroke, infections), fetal 
hemoglobin (HbF) has emerged as a central disease mod-
ifier [3], that is amenable to therapeutic manipulation [6]. 
Genetic variants at three principal loci, BCL11A, HBS1L-
MYB and HBB cluster account for 10–20 % of HbF vari-
ation [7–9]; among SCD patients in USA and Brazil [10], 
Tanzania [5] and Cameroon [11]. Currently, hydroxyurea 
(HU) is the only FDA-approved pharmacologic treatment 
for the induction of HbF in patients with SCD. The major 
HU benefit is directly related to its HbF-producing effect 
[12, 13] that leads to significant reduction of pain, acute 
chest episodes, mortality and the need for blood transfu-
sions [14–17]. HU has also been associated with clinical 
drift, where physicians use the drug for related compli-
cations of SCD such as stroke prevention, priapism and 
pulmonary hypertension [18]. However potential short 
and long term adverse effects such as infertility [18–20], 
susceptibility to infections [21–24], potential terato-
genic effect [25, 26], have also been associated with HU. 
The fear of such side-effects has been a subject of con-
cern to some professionals [27, 28], parents as well as 
patients [29–33] and a potential barrier to compliance 
in some settings [34, 35]. As a consequence, HU is still 
underutilized [29, 30]. It is then urgent to fully under-
stand HU molecular mechanisms of action, in order 
to explore alternative and potential less toxic and more 
acceptable agents that could equally increase the level of 
HbF.
Several other HU-mediated mechanisms of disease 
amelioration have been reported including production of 
nitric oxide, regulation of soluble guanylyl cyclase, cyclic 
adenosine and guanosine monophosphate [36, 37] as 
well as erythropoietic stress response [38]. Furthermore, 
various signalling pathways have been implicated in HU-
mediated fetal hemoglobin (HbF) induction such as the 
Giα/JNK/Jun [39]; p38/MAPK/CREB1 [40]; cAMP-medi-
ated response [41, 42]; erythropoietin (EPO)-induced 
activation of the ERK-1/ERK-2 MAPK [43]; histone dea-
cetylase (HDAC) and DNA methyl-transferase (DNMT) 
inhibitor-mediated epigenetic modification of γ-globin 
expression. Despite this, a complete understanding of 
HU-mediated HbF production remains incomplete.
Post-transcriptional regulation of γ-globin expression 
through micro RNAs (miRNAs) has been shown to play 
an important role in HU-mediated HbF induction as HU 
causes differential expression of a suite of miRNAs associ-
ated with basal and γ-globin expression at maximum toler-
ated dose (MTD) in SCD patients [44, 45]. Likewise, DNA 
methylation has been significantly associated with baseline 
HbF [38, 46, 47] but provided no substantial explanation 
for HbF induction in response to HU. Small non-coding 
RNAs, particularly miRNAs, however, have emerged as 
powerful regulators and modifiers of gene expression 
through inhibition of mRNA translation [48], which has 
implications for hematopoiesis and erythropoiesis [49, 50], 
particularly in the distinct miRNA expression patterns in 
SCD patients [51] and the severity of anaemia [52]. More-
over, a few reports have specifically implicated the miR-
NAs in the regulation of HbF [44, 53, 54].
This study has further investigated whether the induc-
tion of HbF by HU treatment could operate through 
post-transcriptional regulation of BCL11A, KLF-1 and 
MYB, by analysing changes in expression of select miR-
NAs in erythroid cells derived from umbilical cord blood 
CD34+ hematopoietic stem cells and the K562 cell line.
Results
CD34+ hematopoietic cells
The average volume of umbilical cord blood collected was 
108 ml (±25 ml) with a 1.3 % (±0.5 %) yield of CD34+
cells at an average 87 % (±6 %) percentage purity of the
cell population after Dynabead magnetic separation tech-
nology (Fig. 1a). The CFU-GEMMs also produced several 
burst-forming unit-erythroid cells (BFU-E) and erythroid 
clusters typically formed during expansion (Fig. 1b).
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Background
Sickle cell disease (SCD) occupies a prominent place in 
human genetics, as the paradigmatic example of a mono-
genic disorder, that was described over 100  years ago, 
and in 1949, it became the first human disease to be deci-
phered at the molecular level [1]. SCD is a monogenic, 
hematological and multi-organ disorder associated acute 
and chronic illness, and progressive organ damage [2]. 
The disease is due to a single point mutation (Glu6Val) 
that causes polymerization of the mutant hemoglobin 
(Hb) S, resulting in sickling of erythrocytes. Inflamma-
tion, hemolysis, microvascular obstruction and organ 
damage characterize the clinical expression of SCD, 
which is highly variable in individual patients [3]. Sub-
Saharan Africa (SSA) has the highest disease burden 
with approximately 305,800 affected new-borns per year, 
accounting for 0.74 % of all births in the region (Modell 
et al. 2008) and 80 % of annual global affected child births 
[4]. Despite this high incidence, the life-saving public 
health programs have not been implemented in most 
SSA countries often associated with limited medical 
resources and infrastructures. As a consequence, neona-
tal and childhood mortality due to SCD remains high and 
estimates suggest that without intervention, up to 90 % of 
affected children in SSA die by age five from SCD [4, 5]. 
Nevertheless, SCD patients manifest with wide varying 
degrees of severity. In combination with environmental 
factors, several genomic loci, influence the clinical course 
of SCD. Indeed, despite the fact that there are several 
key phenotypes of SCD (anemia, stroke, infections), fetal 
hemoglobin (HbF) has emerged as a central disease mod-
ifier [3], that is amenable to therapeutic manipulation [6]. 
Genetic variants at three principal loci, BCL11A, HBS1L-
MYB and HBB cluster account for 10–20 % of HbF vari-
ation [7–9]; among SCD patients in USA and Brazil [10], 
Tanzania [5] and Cameroon [11]. Currently, hydroxyurea 
(HU) is the only FDA-approved pharmacologic treatment 
for the induction of HbF in patients with SCD. The major 
HU benefit is directly related to its HbF-producing effect 
[12, 13] that leads to significant reduction of pain, acute 
chest episodes, mortality and the need for blood transfu-
sions [14–17]. HU has also been associated with clinical 
drift, where physicians use the drug for related compli-
cations of SCD such as stroke prevention, priapism and 
pulmonary hypertension [18]. However potential short 
and long term adverse effects such as infertility [18–20], 
susceptibility to infections [21–24], potential terato-
genic effect [25, 26], have also been associated with HU. 
The fear of such side-effects has been a subject of con-
cern to some professionals [27, 28], parents as well as 
patients [29–33] and a potential barrier to compliance 
in some settings [34, 35]. As a consequence, HU is still 
underutilized [29, 30]. It is then urgent to fully under-
stand HU molecular mechanisms of action, in order 
to explore alternative and potential less toxic and more 
acceptable agents that could equally increase the level of 
HbF.
Several other HU-mediated mechanisms of disease 
amelioration have been reported including production of 
nitric oxide, regulation of soluble guanylyl cyclase, cyclic 
adenosine and guanosine monophosphate [36, 37] as 
well as erythropoietic stress response [38]. Furthermore, 
various signalling pathways have been implicated in HU-
mediated fetal hemoglobin (HbF) induction such as the 
Giα/JNK/Jun [39]; p38/MAPK/CREB1 [40]; cAMP-medi-
ated response [41, 42]; erythropoietin (EPO)-induced 
activation of the ERK-1/ERK-2 MAPK [43]; histone dea-
cetylase (HDAC) and DNA methyl-transferase (DNMT) 
inhibitor-mediated epigenetic modification of γ-globin 
expression. Despite this, a complete understanding of 
HU-mediated HbF production remains incomplete.
Post-transcriptional regulation of γ-globin expression 
through micro RNAs (miRNAs) has been shown to play 
an important role in HU-mediated HbF induction as HU 
causes differential expression of a suite of miRNAs associ-
ated with basal and γ-globin expression at maximum toler-
ated dose (MTD) in SCD patients [44, 45]. Likewise, DNA 
methylation has been significantly associated with baseline 
HbF [38, 46, 47] but provided no substantial explanation 
for HbF induction in response to HU. Small non-coding 
RNAs, particularly miRNAs, however, have emerged as 
powerful regulators and modifiers of gene expression 
through inhibition of mRNA translation [48], which has 
implications for hematopoiesis and erythropoiesis [49, 50], 
particularly in the distinct miRNA expression patterns in 
SCD patients [51] and the severity of anaemia [52]. More-
over, a few reports have specifically implicated the miR-
NAs in the regulation of HbF [44, 53, 54].
This study has further investigated whether the induc-
tion of HbF by HU treatment could operate through 
post-transcriptional regulation of BCL11A, KLF-1 and 
MYB, by analysing changes in expression of select miR-
NAs in erythroid cells derived from umbilical cord blood 
CD34+ hematopoietic stem cells and the K562 cell line.
Results
CD34+ hematopoietic cells
The average volume of umbilical cord blood collected was 
108 ml (±25 ml) with a 1.3 % (±0.5 %) yield of CD34+
cells at an average 87 % (±6 %) percentage purity of the
cell population after Dynabead magnetic separation tech-
nology (Fig. 1a). The CFU-GEMMs also produced several 
burst-forming unit-erythroid cells (BFU-E) and erythroid 
clusters typically formed during expansion (Fig. 1b).
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Ex‑vivo differentiation of CD34+ cells
CD34+ cells were cultured using an ex vivo single-phase 
expansion and differentiation protocol and all pri-
mary CD34+ primary lines were successfully expanded 
(mean fold expansion 4.2; ±  2.7) and differentiated into
erythroid progenitors with average expression of 84  % 
(±3 %) and 83 % (±8 %) for CD235a and CD71, respec-
tively (Fig.  1a). The first half of the expansion and dif-
ferentiation was characterized by cluster-like colonies 
of erythroid cells and sparse loose-lying cells (Fig. 1b, c). 
During early differentiation (days 1–3) large blasts were 
observed in culture followed by proerythroblast mor-
phology around day 5. The morphology typical of baso-
philic erythroblasts was observed on days 7–8 (Fig.  1b) 
and on day 15, the majority of the cells had ortho/poly-
chromatophilic morphology, which was confirmed by 
the expression of cell-surface markers CD71 and CD235a 
(Additional file  1: Figure S1), at which point differen-
tiation was halted and cells treated with HU for various 
analyses.
WST‑1 cell proliferation assay
To determine the optimal concentration and exposure 
time to HU, K562 cells (8 × 104 cells) were treated with
varying doses of HU and for 2, 4, 6, 12 and 24 h. Six hour 
(6) exposure time and 100  µM were determined to be
optimal as there was minimal initial cytotoxic effect and
sufficient cellular metabolic activity to alter gene expres-
sion in response to HU (Additional file 2: Figure S2).
Hydroxyurea induces γ‑globin expression in both erythroid 
and K562 cells
Erythroid progenitors from seven unrelated individu-
als and the K562 cell line were successfully analysed for 
Fig. 1 Flow cytometry showing differentiation of CD34+ cells to erythroid progenitors (a) and the cluster-like basophilic erythroblast morphology 
of erythroid cells on day 7 of differentiation (b) and the colony-forming hematopoietic cell units (CFU-E) (c). CD34+ hematopoietic stem cells were 
purified from umbilical cord blood mononuclear cells using Dynabead magnetic separation to a purity of 87.6 %. After the 15 day single-phase 
ex vivo expansion and differentiation, the cell population was 92.7 and 78.2 % CD235a+ and CD71+, respectively with minimal CD34 positivity. This 
confirmed our differentiation and provided erythroid cells for down-stream experiments (a). During the expansion and differentiation of HSCs to 
erythroid cells, the cells formed cluster-like colonies before separating into single cells in suspension, which was typical of terminal differentiation 
(b). The hematopoietic colony formation assay was performed to confirm the stem-like behaviour of the Dyna-bead selected CD34+ HSCs prior to 
expansion and differentiation. The colony-forming unit- granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM) semi-solid cultures were 
grown for 14 days and stained for colony counting (c)
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differential gene expression in response to HU treatment, 
with three technical and independent qPCR experimen-
tal repeats for K562 cells and one experimental repeat for 
ex vivo derived erythroid cells due to the limited number 
of cells. Subsequently, four of the ex  vivo derived lines 
were analysed for corresponding miRNA expression. 
HU treatment of K562 cells showed a sigmoidal pattern 
of expression in BCL11A transcription with an apparent 
down-regulation at 6  h, an expression pattern inverse 
to the γ-globin that showed a sevenfold upregulation 
at the same HU exposure time (Fig. 2). KLF-1, a critical 
activator of BCL11A [55], and MYB, a potent activator 
of KLF-1 [56, 57] and negative regulator of γ-globin [58] 
had similar expression patterns and were significantly 
down-regulated at 12 h (p < 0.03). β-Globin and GATA-1 
expression remained largely unaffected by HU treatment 
with the exception of a slight down-regulation also after 
12 h treatment.
The gene expression pattern in the primary erythroid 
lines was largely similar to that in K562 cells with an 
inverse relationship between γ-globin expression and its 
critical regulators; BCL11A, KLF-1 and MYB. Some pri-
mary lines had a sevenfold (p <  0.003) up-regulation of 
γ-globin expression  6  h after HU treatment associated 
with the down-regulation of MYB (p < 0.04) and BCL11A 
expression (Fig.  3). Gene expression analysis was done 
after successful ex vivo differentiation of primary eryth-
roid cells and HU treatment for 24 h.
Hydroxyurea up‑regulates miRNAs associated 
with inhibition of BCL11A and MYB
In the primary lines analysed for miRNAs expression 6 h 
post treatment, there was inter-individual variation in 
expression however, miR-26b was significantly down-reg-
ulated in all but one primary line (Fig. 4). HU treatment 
also caused sigmoidal time-dependent changes in miR-
NAs expression in K562 cells (Additional file  3: Figure 
S3), with significant up-regulation of miR-15a and miR-
16-1 at 6 h (p value 0.027 and 0.002, respectively), which
are known inhibitors of MYB [54]. MiR-151-3p and miR-
451 were also significantly up-regulated at 6 h post treat-
ment (0.041 and 0.042, respectively) and although not
statistically significant, miR-494 had a twofold increase.
All miRNAs were down-regulated 12  h after treatment
and returned to baseline after 24 h.
MicroRNA inhibition
The inhibition of miR-26b and miR-151-3p resulted in a 
significant decrease in γ-globin expression (Fig. 5), which 
could be partially rescued when cells were treated with 
HU. This suggests that most miRNAs target negative reg-
ulators of HbF as their inhibition causes up-regulation of 
γ-globin expression. At a higher concentration (25 nM), 
all miRNAs down-regulated HbF (Additional file 4: Fig-
ure S4). Cells were co-transfected with select pairing of 
miRNAs in order to investigate the combinatorial effect 
of anti-miRNAs. The effect of miR-26b/miR-151-3p and 
miR-151-3p/miR-494 were comparable in the decrease of 
HbF. Although the inhibition of miR-494 had no appar-
ent effect on HbF, co-transfection with miR-26b resulted 
in near-complete transient knock-down of HbF.
MiR‑26b directly targets MYB 3′‑UTR
Given the clear association between (i) HU and MYB 
expression; (ii) HU and our candidate miRNAs and 
(iii) the miRNAs and MYB expression patterns, dual-
luciferase reporter assays were conducted using the
pGL3-MYB-3′UTR to investigate the potential direct
interactions between our candidate miRNAs and the
MYB-3′-UTR (1191 base pairs). The amount of lucif-
erase activity from the vector is directly proportional
to the miRNAs occupancy of the UTR, which is known
to induce mRNA transcript degradation via the RNA-
induced silencing complex (RISC) [59]. There was a
2.2-fold increase in luciferase activity when cells were co-
transfected with anti-miR-26b (Fig.  6a) and similarly, a
time-dependent change in luciferase activity in response
to HU treatment, with the highest luciferase activity
observed after 12  h of HU treatment. Similarly, how-
ever less apparent, luciferase activity was observed with
the transfection of anti-miR-151-3p, anti-miR-451 and
anti-miR-494 (Additional file  5: Figure S5). To confirm
that miR-26b directly interacts with the MYB 3′-UTR
and initiates RISC-mediated mRNA degradation, there
was gradual recovery of the luciferase activity with the
decrease in concentration of the transfected anti-miR-
26b (Fig. 6b). Therefore, at low anti-miR-26b concentra-
tion (2.5 nM), endogenous miR-26b is permitted to bind
the MYB 3′-UTR, which would result in MYB mRNA
degradation and therefore up-regulation of γ-globin
expression.
Discussion
Although HU has demonstrated significant clinical 
improvements in SCD patients, a complete understand-
ing of the myriad of molecular mechanisms by which 
HU induces the disease-ameliorating HbF remain elusive 
[60]. This paper demonstrates the post-transcriptional 
effect of HU on critical regulators of γ-globin expres-
sion and associated miRNAs using two models; erythroid 
cells derived from umbilical cord blood CD34+ HSCs and 
K562 cells. Cord blood-derived CD34+ cells are an abun-
dant, non-invasive and largely unutilised source of HSCs 
and a good model to investigate erythropoiesis [61, 62] 
and elucidate the molecular mechanisms of HbF produc-
tion in response to therapeutic agents [63]. The volume 
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Ex‑vivo differentiation of CD34+ cells
CD34+ cells were cultured using an ex vivo single-phase 
expansion and differentiation protocol and all pri-
mary CD34+ primary lines were successfully expanded 
(mean fold expansion 4.2; ±  2.7) and differentiated into
erythroid progenitors with average expression of 84  % 
(±3 %) and 83 % (±8 %) for CD235a and CD71, respec-
tively (Fig.  1a). The first half of the expansion and dif-
ferentiation was characterized by cluster-like colonies 
of erythroid cells and sparse loose-lying cells (Fig. 1b, c). 
During early differentiation (days 1–3) large blasts were 
observed in culture followed by proerythroblast mor-
phology around day 5. The morphology typical of baso-
philic erythroblasts was observed on days 7–8 (Fig.  1b) 
and on day 15, the majority of the cells had ortho/poly-
chromatophilic morphology, which was confirmed by 
the expression of cell-surface markers CD71 and CD235a 
(Additional file  1: Figure S1), at which point differen-
tiation was halted and cells treated with HU for various 
analyses.
WST‑1 cell proliferation assay
To determine the optimal concentration and exposure 
time to HU, K562 cells (8 × 104 cells) were treated with
varying doses of HU and for 2, 4, 6, 12 and 24 h. Six hour 
(6) exposure time and 100  µM were determined to be
optimal as there was minimal initial cytotoxic effect and
sufficient cellular metabolic activity to alter gene expres-
sion in response to HU (Additional file 2: Figure S2).
Hydroxyurea induces γ‑globin expression in both erythroid 
and K562 cells
Erythroid progenitors from seven unrelated individu-
als and the K562 cell line were successfully analysed for 
Fig. 1 Flow cytometry showing differentiation of CD34+ cells to erythroid progenitors (a) and the cluster-like basophilic erythroblast morphology 
of erythroid cells on day 7 of differentiation (b) and the colony-forming hematopoietic cell units (CFU-E) (c). CD34+ hematopoietic stem cells were 
purified from umbilical cord blood mononuclear cells using Dynabead magnetic separation to a purity of 87.6 %. After the 15 day single-phase 
ex vivo expansion and differentiation, the cell population was 92.7 and 78.2 % CD235a+ and CD71+, respectively with minimal CD34 positivity. This 
confirmed our differentiation and provided erythroid cells for down-stream experiments (a). During the expansion and differentiation of HSCs to 
erythroid cells, the cells formed cluster-like colonies before separating into single cells in suspension, which was typical of terminal differentiation 
(b). The hematopoietic colony formation assay was performed to confirm the stem-like behaviour of the Dyna-bead selected CD34+ HSCs prior to 
expansion and differentiation. The colony-forming unit- granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM) semi-solid cultures were 
grown for 14 days and stained for colony counting (c)
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differential gene expression in response to HU treatment, 
with three technical and independent qPCR experimen-
tal repeats for K562 cells and one experimental repeat for 
ex vivo derived erythroid cells due to the limited number 
of cells. Subsequently, four of the ex  vivo derived lines 
were analysed for corresponding miRNA expression. 
HU treatment of K562 cells showed a sigmoidal pattern 
of expression in BCL11A transcription with an apparent 
down-regulation at 6  h, an expression pattern inverse 
to the γ-globin that showed a sevenfold upregulation 
at the same HU exposure time (Fig. 2). KLF-1, a critical 
activator of BCL11A [55], and MYB, a potent activator 
of KLF-1 [56, 57] and negative regulator of γ-globin [58] 
had similar expression patterns and were significantly 
down-regulated at 12 h (p < 0.03). β-Globin and GATA-1 
expression remained largely unaffected by HU treatment 
with the exception of a slight down-regulation also after 
12 h treatment.
The gene expression pattern in the primary erythroid 
lines was largely similar to that in K562 cells with an 
inverse relationship between γ-globin expression and its 
critical regulators; BCL11A, KLF-1 and MYB. Some pri-
mary lines had a sevenfold (p <  0.003) up-regulation of 
γ-globin expression  6  h after HU treatment associated 
with the down-regulation of MYB (p < 0.04) and BCL11A 
expression (Fig.  3). Gene expression analysis was done 
after successful ex vivo differentiation of primary eryth-
roid cells and HU treatment for 24 h.
Hydroxyurea up‑regulates miRNAs associated 
with inhibition of BCL11A and MYB
In the primary lines analysed for miRNAs expression 6 h 
post treatment, there was inter-individual variation in 
expression however, miR-26b was significantly down-reg-
ulated in all but one primary line (Fig. 4). HU treatment 
also caused sigmoidal time-dependent changes in miR-
NAs expression in K562 cells (Additional file  3: Figure 
S3), with significant up-regulation of miR-15a and miR-
16-1 at 6 h (p value 0.027 and 0.002, respectively), which
are known inhibitors of MYB [54]. MiR-151-3p and miR-
451 were also significantly up-regulated at 6 h post treat-
ment (0.041 and 0.042, respectively) and although not
statistically significant, miR-494 had a twofold increase.
All miRNAs were down-regulated 12  h after treatment
and returned to baseline after 24 h.
MicroRNA inhibition
The inhibition of miR-26b and miR-151-3p resulted in a 
significant decrease in γ-globin expression (Fig. 5), which 
could be partially rescued when cells were treated with 
HU. This suggests that most miRNAs target negative reg-
ulators of HbF as their inhibition causes up-regulation of 
γ-globin expression. At a higher concentration (25 nM), 
all miRNAs down-regulated HbF (Additional file 4: Fig-
ure S4). Cells were co-transfected with select pairing of 
miRNAs in order to investigate the combinatorial effect 
of anti-miRNAs. The effect of miR-26b/miR-151-3p and 
miR-151-3p/miR-494 were comparable in the decrease of 
HbF. Although the inhibition of miR-494 had no appar-
ent effect on HbF, co-transfection with miR-26b resulted 
in near-complete transient knock-down of HbF.
MiR‑26b directly targets MYB 3′‑UTR
Given the clear association between (i) HU and MYB 
expression; (ii) HU and our candidate miRNAs and 
(iii) the miRNAs and MYB expression patterns, dual-
luciferase reporter assays were conducted using the
pGL3-MYB-3′UTR to investigate the potential direct
interactions between our candidate miRNAs and the
MYB-3′-UTR (1191 base pairs). The amount of lucif-
erase activity from the vector is directly proportional
to the miRNAs occupancy of the UTR, which is known
to induce mRNA transcript degradation via the RNA-
induced silencing complex (RISC) [59]. There was a
2.2-fold increase in luciferase activity when cells were co-
transfected with anti-miR-26b (Fig.  6a) and similarly, a
time-dependent change in luciferase activity in response
to HU treatment, with the highest luciferase activity
observed after 12  h of HU treatment. Similarly, how-
ever less apparent, luciferase activity was observed with
the transfection of anti-miR-151-3p, anti-miR-451 and
anti-miR-494 (Additional file  5: Figure S5). To confirm
that miR-26b directly interacts with the MYB 3′-UTR
and initiates RISC-mediated mRNA degradation, there
was gradual recovery of the luciferase activity with the
decrease in concentration of the transfected anti-miR-
26b (Fig. 6b). Therefore, at low anti-miR-26b concentra-
tion (2.5 nM), endogenous miR-26b is permitted to bind
the MYB 3′-UTR, which would result in MYB mRNA
degradation and therefore up-regulation of γ-globin
expression.
Discussion
Although HU has demonstrated significant clinical 
improvements in SCD patients, a complete understand-
ing of the myriad of molecular mechanisms by which 
HU induces the disease-ameliorating HbF remain elusive 
[60]. This paper demonstrates the post-transcriptional 
effect of HU on critical regulators of γ-globin expres-
sion and associated miRNAs using two models; erythroid 
cells derived from umbilical cord blood CD34+ HSCs and 
K562 cells. Cord blood-derived CD34+ cells are an abun-
dant, non-invasive and largely unutilised source of HSCs 
and a good model to investigate erythropoiesis [61, 62] 
and elucidate the molecular mechanisms of HbF produc-
tion in response to therapeutic agents [63]. The volume 
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of cord blood collected in this study was consistent with 
expected norms [64] although the average CD34+ cell 
yield was slightly lower, possibly due to our stringent cell 
separation method. Erythroid cells were successfully dif-
ferentiated using an ex vivo single-phase expansion and 
differentiation protocol [65] with minor alterations to 
achieve optimal ex vivo expansion [66]. Given that HU is 
thought to induce γ-globin via perturbation of erythroid 
cell maturation [36, 67], in this study HSCs were differen-
tiated to orthochromatophilic erythroblasts for 15 days. 
It has been previously demonstrated that cells treated 
with HU around day 6 and harvested at day 10 of differ-
entiation consist mostly of basophilic and polychromat-
ophilic normoblasts, comparable to untreated cultures 
at a similar stage [68]. In another study, investigating 
the effect of HU on BCL11A, KLF-1 and TAL-1 in bone 
marrow-derived basophilic erythroblasts, post terminal 
differentiation, there was no significant difference in the 
expression of the markers of late erythroid differentiation, 
CD235a and CD71, between HU treated and untreated 
cells [54]. Likewise in this study, the comparable levels of 
CD235a and CD71 between pairwise samples (HU+ and
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expression of BCL11A and HBG-1 (HbF) with the highest fold increase in HbF corresponding to the lowest BCL11A expression between 6 and 12 h 
after HU treatment. KLF-1, an activator of BCL11A, also followed a similar trend, lowest after 12 h of HU treatment. GATA-1 was also down-regulated 
at the same time point as well as the negative regulator, MYB. * Significant difference, p < 0.05
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HU−) confirms that at the point of expression analyses,
the paired samples were at a similar maturation stage 
(Additional file 1: Figure S1), and thus the erythroid cell 
maturation cannot account for the observed changes in 
expression. It is thus more likely that the observed induc-
tion of γ-globin is a result of the repression of BCL11A, 
KLF-1 and MYB. Therefore, with further development of 
expansion and differentiation protocols, the use of cord 
blood stem cells can be extended to routine laboratory 
disease modelling and testing of therapeutic agents above 
and beyond the curative transplantation value of this bio-
logical material.
The WST-1 assay, a non-radioactive spectrophoto-
metric quantification of cellular metabolic activity and 
proliferation was used to determine the optimal HU 
concentration and cellular incubation periods within 
a 24 h period given that HU is commonly prescribed to 
SCD patients as a daily oral drug [69]. The most apparent 
effects of HU on γ-globin, its critical regulators (BCL11A, 
MYB, KLF-1) and erythroid transcription factor, GATA-
1, was between 6 and 12  h after 100  µM treatment, at 
which time cellular metabolic activity was sufficient to 
assess changes in gene expression.
Using paired analysis, we demonstrated a sevenfold 
(p < 0.003) up-regulation of γ-globin expression and cor-
responding down-regulation of BCL11A in both eryth-
roid and K562 cells (Figs. 2, 3). BCL11A has been shown 
to be a critical negative regulator of γ-globin and funda-
mental to the ‘fetal switch’ from γ- to β-globin expression 
[58]. Furthermore, it has been successfully shown to be 
responsive to therapeutic manipulation for potential SCD 
treatment [65]. The time-dependent patterns of BCL11A 
and γ-globin gene expression are inversely related, with 
the most apparent effect at 6  h in both erythroid and 
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of cord blood collected in this study was consistent with 
expected norms [64] although the average CD34+ cell 
yield was slightly lower, possibly due to our stringent cell 
separation method. Erythroid cells were successfully dif-
ferentiated using an ex vivo single-phase expansion and 
differentiation protocol [65] with minor alterations to 
achieve optimal ex vivo expansion [66]. Given that HU is 
thought to induce γ-globin via perturbation of erythroid 
cell maturation [36, 67], in this study HSCs were differen-
tiated to orthochromatophilic erythroblasts for 15 days. 
It has been previously demonstrated that cells treated 
with HU around day 6 and harvested at day 10 of differ-
entiation consist mostly of basophilic and polychromat-
ophilic normoblasts, comparable to untreated cultures 
at a similar stage [68]. In another study, investigating 
the effect of HU on BCL11A, KLF-1 and TAL-1 in bone 
marrow-derived basophilic erythroblasts, post terminal 
differentiation, there was no significant difference in the 
expression of the markers of late erythroid differentiation, 
CD235a and CD71, between HU treated and untreated 
cells [54]. Likewise in this study, the comparable levels of 
CD235a and CD71 between pairwise samples (HU+ and
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HU−) confirms that at the point of expression analyses,
the paired samples were at a similar maturation stage 
(Additional file 1: Figure S1), and thus the erythroid cell 
maturation cannot account for the observed changes in 
expression. It is thus more likely that the observed induc-
tion of γ-globin is a result of the repression of BCL11A, 
KLF-1 and MYB. Therefore, with further development of 
expansion and differentiation protocols, the use of cord 
blood stem cells can be extended to routine laboratory 
disease modelling and testing of therapeutic agents above 
and beyond the curative transplantation value of this bio-
logical material.
The WST-1 assay, a non-radioactive spectrophoto-
metric quantification of cellular metabolic activity and 
proliferation was used to determine the optimal HU 
concentration and cellular incubation periods within 
a 24 h period given that HU is commonly prescribed to 
SCD patients as a daily oral drug [69]. The most apparent 
effects of HU on γ-globin, its critical regulators (BCL11A, 
MYB, KLF-1) and erythroid transcription factor, GATA-
1, was between 6 and 12  h after 100  µM treatment, at 
which time cellular metabolic activity was sufficient to 
assess changes in gene expression.
Using paired analysis, we demonstrated a sevenfold 
(p < 0.003) up-regulation of γ-globin expression and cor-
responding down-regulation of BCL11A in both eryth-
roid and K562 cells (Figs. 2, 3). BCL11A has been shown 
to be a critical negative regulator of γ-globin and funda-
mental to the ‘fetal switch’ from γ- to β-globin expression 
[58]. Furthermore, it has been successfully shown to be 
responsive to therapeutic manipulation for potential SCD 
treatment [65]. The time-dependent patterns of BCL11A 
and γ-globin gene expression are inversely related, with 
the most apparent effect at 6  h in both erythroid and 
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K562 cells. Similarly, KLF-1 was down-regulated in both 
cell models, corresponding to the repressed expression 
of BCL11A and β-globin gene (p  <  0.04). This result is 
consistent with the function of KLF-1 as an activator of 
BCL11A and its association with haplo-insufficiency-
induced hereditary persistence of fetal hemoglobin [55]. 
GATA-1 expression was similar to KLF-1, which is con-
sistent with evidence that this principal erythroid tran-
scription factor co-occupies the 5′ locus control regions 
and 3′ DNase I-hypersensitivity site of the β-globin gene 
cluster and associates with BCL11A in the Mi-2/nucleo-
some remodelling and deacetylases (NuRD) complex and 
therefore possibly critical in the repression of HbF pro-
duction [58, 65, 70]. Down-regulation of MYB in both 
erythroid and K562 cells corresponded with induction of 
γ-globin expression and was inversely related to miR-26b 
as well as miR-15a and miR-16-1, which have been impli-
cated in the elevation of HbF production via directly tar-
geting the MYB transcription factor [45]. Although HU 
induced down-regulation of BCL11A; KLF-1 and MYB, 
the effect on γ-globin expression was variable, which sug-
gests that HU may interact with many genes upstream 
of γ-globin induction and also induce other post-tran-
scriptional changes of gene expression through miRNAs. 
Recently similar effects of HU on BCL11A and KLF-1 
were demonstrated in late differentiation erythroblasts 
derived from bone marrow progenitors, also implicating 
TAL-1 in the regulation of BCL11A; KLF-1 via promoter-
binding and MYB repression [54]. Furthermore, K562 
cells were previously used to demonstrate the crucial role 
of TAL-1 as the DNA-binding component of the LDB-1 
complex regulating the long-range looping of the globin 
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gene cluster to allow interaction between the 5′-LCR and 
the β-globin gene [71]. Taken in sum with the results of 
the present study, HU induces γ-globin through numer-
ous networks comprising BCL11A, KLF-1, TAL-1 and 
MYB. The data of this study also demonstrated an asso-
ciation between miR-26b and γ-globin expression, which 
has previously been shown both at basal and MTD in 
HU-treated SCD patients [44]. There was a 4.5-fold up-
regulation of miR-16-1 and miR-151-3p in K562 cells 
(Additional file  3: Figure S3), which was related to the 
most apparent induction of HbF at 6  h after HU treat-
ment. A direct target of DNMT-1, miR-148a [72], was 
also up-regulated 6 h after HU treatment, which corre-
lated to γ-globin induction. These findings suggest that 
the observed HbF production may also be through other 
post-transcriptional regulatory modalities such as meth-
ylation inhibition in the β-globin gene cluster.
The inhibition of the miRNAs, particularly miR-26b, 
unequivocally demonstrates a causative effect by HU on 
the induction of HbF through miRNA-mediated mech-
anisms. This is further supported by the near-complete 
transient knock-down of HbF when miR-26b and miR-
494 are co-inhibited. The inhibition of miR-26b, miR-
151-3p and miR-451 results in apparent decreases in
HbF in comparison to all controls (inhibitor negative
control; untransfected and HU treated cells). This effect
is likely because miR-26b inhibits MYB translation,
causing reduced KLF-1 activation and thus lowering
BCL11A expression, thereby increasing HbF produc-
tion (Figs.  5, 6, 7). Therefore these data highlight the
critical role played by potent negative regulators of HbF
such as MYB, KLF-1 and BCL11A and demonstrate
that miRNAs provide a viable therapeutically respon-
sive tier of HbF production for SCD treatment (Fig. 7),
importantly while sparring the undruggable nature
these transcription factors in non-erythroid cells
[73]. Overall, the K562 cell experimental repeats were
similar and although there was expected inter-indi-
vidual variation in the degree and timing of up- and/
or down-regulation of γ-globin and its key regulators
in the erythroid model, the trends remained true and
largely comparable. Despite the fact that several studies
have and continue to utilise K562 as a model to inves-
tigate various components of γ-globin expression [39,
53, 74–77], it could be argued that K562 cells are not
an ideal model for studying globin switching because
of their bias expression of γ-globin. We however, saw
this as an advantage in a number of ways: (1) the aim
of this study was not to demonstrate the switching in
expression of the globin genes (β to γ) but rather to
use a stable cell line model in conjunction with cord
blood-derived erythroid cells to demonstrate increases
in γ-globin and decreases its regulators (BCL11A, KLF-
1 and MYB) in response to HU, and for this purpose,
K562 cells would suffice as a model; (2) in choosing the
whether to use miRNA mimics or anti-miRNAs (miR-
inhibitors), the high expression of γ-globin in K562 was
considered; if our hypothesis of HU-induced miRNA-
mediated repression of MYB was correct, the use of
mimics would not only introduce unnaturally high lev-
els of miRNAs into this model (which we felt may in
fact result in some artefactual results merely because of
this unnatural state of aberrant concentration of miR-
NAs in the cells) but it would also be compounded by
any co-treatments with HU in causing γ-globin expres-
sion. This rationale led to the choice of anti-miRNAs,
which would go toward decreasing the already high lev-
els of γ-globin in K562 (via MYB) and also provide an
obvious opportunity of the rescue of miR-26b inhibi-
tion with HU co-treatment.
a
b
Fig. 5 Inhibition of candidate miRNAs down-regulates HbF in K562 
cells. The effect of anti-miRNAs (5 mM) on HbF protein levels in K562 
cells (western blot analysis—a; western blot densitometric illustra-
tion—b). Inhibition of miR-26b and miR-151-3p results in decreased 
HbF levels in comparison to the control anti-miRNA. HbF expression 
is partially recovered with HU treatment. All anti-miRNAs co-trans-
fections result in reduced HbF levels, particularly co-transfection of 
anti-miR-26b and anti-miR-494 resulting in near-complete transient 
knock-down of HbF
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K562 cells. Similarly, KLF-1 was down-regulated in both 
cell models, corresponding to the repressed expression 
of BCL11A and β-globin gene (p  <  0.04). This result is 
consistent with the function of KLF-1 as an activator of 
BCL11A and its association with haplo-insufficiency-
induced hereditary persistence of fetal hemoglobin [55]. 
GATA-1 expression was similar to KLF-1, which is con-
sistent with evidence that this principal erythroid tran-
scription factor co-occupies the 5′ locus control regions 
and 3′ DNase I-hypersensitivity site of the β-globin gene 
cluster and associates with BCL11A in the Mi-2/nucleo-
some remodelling and deacetylases (NuRD) complex and 
therefore possibly critical in the repression of HbF pro-
duction [58, 65, 70]. Down-regulation of MYB in both 
erythroid and K562 cells corresponded with induction of 
γ-globin expression and was inversely related to miR-26b 
as well as miR-15a and miR-16-1, which have been impli-
cated in the elevation of HbF production via directly tar-
geting the MYB transcription factor [45]. Although HU 
induced down-regulation of BCL11A; KLF-1 and MYB, 
the effect on γ-globin expression was variable, which sug-
gests that HU may interact with many genes upstream 
of γ-globin induction and also induce other post-tran-
scriptional changes of gene expression through miRNAs. 
Recently similar effects of HU on BCL11A and KLF-1 
were demonstrated in late differentiation erythroblasts 
derived from bone marrow progenitors, also implicating 
TAL-1 in the regulation of BCL11A; KLF-1 via promoter-
binding and MYB repression [54]. Furthermore, K562 
cells were previously used to demonstrate the crucial role 
of TAL-1 as the DNA-binding component of the LDB-1 
complex regulating the long-range looping of the globin 
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Fig. 4 Hydroxyurea induces differential expression of miRNAs associated with BCL11A and MYB repression in erythroid cells. Treatment of primary 
cells with HU causes differential regulation of miRNAs as early as 6 h post treatment. There is inter-individual variation in expression however, miR-
26b was significantly down-regulated in all but one primary lines. And conversely, miR-451 is down-regulated in all but 1 of the erythroid lines. HU 
induces variation in the expression of miRNAs associated with key regulators of HbF. * Significant difference, p < 0.05
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gene cluster to allow interaction between the 5′-LCR and 
the β-globin gene [71]. Taken in sum with the results of 
the present study, HU induces γ-globin through numer-
ous networks comprising BCL11A, KLF-1, TAL-1 and 
MYB. The data of this study also demonstrated an asso-
ciation between miR-26b and γ-globin expression, which 
has previously been shown both at basal and MTD in 
HU-treated SCD patients [44]. There was a 4.5-fold up-
regulation of miR-16-1 and miR-151-3p in K562 cells 
(Additional file  3: Figure S3), which was related to the 
most apparent induction of HbF at 6  h after HU treat-
ment. A direct target of DNMT-1, miR-148a [72], was 
also up-regulated 6 h after HU treatment, which corre-
lated to γ-globin induction. These findings suggest that 
the observed HbF production may also be through other 
post-transcriptional regulatory modalities such as meth-
ylation inhibition in the β-globin gene cluster.
The inhibition of the miRNAs, particularly miR-26b, 
unequivocally demonstrates a causative effect by HU on 
the induction of HbF through miRNA-mediated mech-
anisms. This is further supported by the near-complete 
transient knock-down of HbF when miR-26b and miR-
494 are co-inhibited. The inhibition of miR-26b, miR-
151-3p and miR-451 results in apparent decreases in
HbF in comparison to all controls (inhibitor negative
control; untransfected and HU treated cells). This effect
is likely because miR-26b inhibits MYB translation,
causing reduced KLF-1 activation and thus lowering
BCL11A expression, thereby increasing HbF produc-
tion (Figs.  5, 6, 7). Therefore these data highlight the
critical role played by potent negative regulators of HbF
such as MYB, KLF-1 and BCL11A and demonstrate
that miRNAs provide a viable therapeutically respon-
sive tier of HbF production for SCD treatment (Fig. 7),
importantly while sparring the undruggable nature
these transcription factors in non-erythroid cells
[73]. Overall, the K562 cell experimental repeats were
similar and although there was expected inter-indi-
vidual variation in the degree and timing of up- and/
or down-regulation of γ-globin and its key regulators
in the erythroid model, the trends remained true and
largely comparable. Despite the fact that several studies
have and continue to utilise K562 as a model to inves-
tigate various components of γ-globin expression [39,
53, 74–77], it could be argued that K562 cells are not
an ideal model for studying globin switching because
of their bias expression of γ-globin. We however, saw
this as an advantage in a number of ways: (1) the aim
of this study was not to demonstrate the switching in
expression of the globin genes (β to γ) but rather to
use a stable cell line model in conjunction with cord
blood-derived erythroid cells to demonstrate increases
in γ-globin and decreases its regulators (BCL11A, KLF-
1 and MYB) in response to HU, and for this purpose,
K562 cells would suffice as a model; (2) in choosing the
whether to use miRNA mimics or anti-miRNAs (miR-
inhibitors), the high expression of γ-globin in K562 was
considered; if our hypothesis of HU-induced miRNA-
mediated repression of MYB was correct, the use of
mimics would not only introduce unnaturally high lev-
els of miRNAs into this model (which we felt may in
fact result in some artefactual results merely because of
this unnatural state of aberrant concentration of miR-
NAs in the cells) but it would also be compounded by
any co-treatments with HU in causing γ-globin expres-
sion. This rationale led to the choice of anti-miRNAs,
which would go toward decreasing the already high lev-
els of γ-globin in K562 (via MYB) and also provide an
obvious opportunity of the rescue of miR-26b inhibi-
tion with HU co-treatment.
a
b
Fig. 5 Inhibition of candidate miRNAs down-regulates HbF in K562 
cells. The effect of anti-miRNAs (5 mM) on HbF protein levels in K562 
cells (western blot analysis—a; western blot densitometric illustra-
tion—b). Inhibition of miR-26b and miR-151-3p results in decreased 
HbF levels in comparison to the control anti-miRNA. HbF expression 
is partially recovered with HU treatment. All anti-miRNAs co-trans-
fections result in reduced HbF levels, particularly co-transfection of 
anti-miR-26b and anti-miR-494 resulting in near-complete transient 
knock-down of HbF
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Future work: implications for novel therapeutics in SCD
Future work regarding the post-transcriptional mecha-
nisms regulating the expression of various trans-acting 
factors, such as BCL11A, KLF-1 and MYB, could include 
experimental variations of the level of candidate miRNAs 
and examination of the effect on HbF levels and addi-
tional 3′-UTR luciferase assays on such regulators. The 
limitation on the number of primary erythroid cells could 
be overcome by the use of improved primary cell trans-
fection protocols or alternative sources of HSCs such as 
commercially available HSCs or bone marrow aspirates. 
Future work will look to replicate these results in primary 
erythroid cells and investigate other candidate miRNAs 
for interactions with key regulators of γ-globin expres-
sion. Another limitation of the present work the “promis-
cuous” nature of HU, as it could influence many aspects 
of cellular functions and almost certainly alter the global 
cellular transcriptome. Therefore, future studies should 
continue to evaluate the in  vivo impact of efficacious 
concentrations of HU on the erythroblast transcriptome 
and/or proteome, as well as the erythroid-specific micro-
nome of SCD patients (before treatment and at MTD) 
as global analysis of these epigenetic mechanisms could 
highlight multiple components of this complex system 
and possibly yield alternative (possibly miRNA-based) 
therapeutic approaches to hemoglobinopathies [78]. 
This is likely not implausible as several clinical trials in 
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Fig. 6 Time- and concentration-dependent luciferase activity in response to hydroxyurea treatment of anti-miR-26b transfected K562 cells. Inhibi-
tion of miR-26b results in a significant (p < 0.02) increase in luciferase activity and a sigmoidal pattern of action during a time course with HU treat-
ment, with the highest luciferase activity observed after 12 h of treatment (a). A concentration gradient of anti-miR-26b demonstrates an inverse 
relationship between anti-miR26b concentration and MYB-3′-UTR luciferase activity. This unequivocally demonstrates interaction between miR-26b 
and the 3′-UTR of MYB (b). The likely implication of this result is that the miR-26b-induced translational inhibition of MYB (a known activator of KLF-1) 
could result in down-regulation of KLF-1, which is known to directly induce BCL11A expression. In sum, miR-26b could explain the observed up-
regulation of γ-globin via a MYB/KLF-1/BCL11A pathway. * Significant difference, p < 0.05
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Fig. 7 Hydroxyurea mechanisms of HbF induction: regulators and 
miRNAs mediated actions. Proposed HU-induced miRNAs-mediated 
mode of indirect HbF regulation through critical regulators (MYB/KLF-
1/BCL11A) and possibly directly modulating HbF
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other diseases have demonstrated a promising future 
for miRNA-based therapeutics such as the liposome-
based human miR-34 mimic (MRX-34) miRNA-based 
drug against hepatocellular carcinoma (NCT01829971). 
MiRNAs have also been implicated in many cancers 
(colorectal, cervical, prostate, breast and lung) as either 
biomarkers and/or highlighted for potential therapeutic 
significance [79]. Closer to hemoglobinopathies, several 
miRNAs have been associated with specific phenotypes 
or key signalling pathways in SCD; miR-15a and miR-
16-1 with hereditary persistence of HbF [53], miR-148a
with DNMT-1 [72], miR-144 and tolerance of oxidative
stress and anemia severity [52], a mouse model show-
ing the correction of SCD via interference with the “fetal
switch” [80, 81], in vivo association of miR-26b and miR-
151-3p with HU treatment at MTD [44], miR-320 and
down-regulation of CD71 during terminal differentiation
of reticulocytes [51], miR-24 and inhibition of erythro-
poiesis via activin type I receptor ALK4 [82], a suite of
miRNAs including miR-451 in Plasmodium falciparum
parasite interactions with erythrocytes [83] and now in
this study, miR-26b direct interaction with MYB 3′-UTR
and the rescue of miR-26b inhibition with HU treatment.
It is however noteworthy to consider the myriad of 
challenges in miRNAs-based therapies including site-
specificity, delivery and treatment efficacies, off-targeting 
and side effects [84], undesired in vivo pharmacokinetics 
[85] and short half-life in peripheral blood before renal
clearance [86]. These challenges may also be com-
pounded by the rapid erythrocyte turnover and anemia
in SCD, the heterogeneous multi-organ complications
and the numerous genetic polymorphisms affecting dis-
ease severity, predisposition to specific phenotypes,
the vast variation in response to HU treatment and the
overall clinical course of the disease [60]. Although faced
with many challenges, novel methodologies such as exo-
some-based delivery systems provide sufficient evidence
in support of the continued efforts to develop improved
systems of delivery and target-specificity, desired in vivo
stability, reduced side- and off-target effects for miRNA-
based therapeutic approaches [87–89].
Conclusion
In the present article, the authors have demonstrated 
successful expansion and differentiation of umbilical 
cord blood-derived CD34+ HSCs into CD71+/CD235a+ 
erythroid cells and showed HU-mediated induction of 
γ-globin expression concomitant with the down-reg-
ulation of key negative regulators, BCL11A, MYB and 
KLF-1. Importantly, the experiments have demonstrated 
association between the induction of miR-15a and miR-
16-1 and HU-mediated down-regulation of MYB as well
as up-regulation of miR-148a, which targets DNMT-1.
Furthermore, the data have shown the direct interaction 
between miR-26b and the MYB 3′-UTR, possible indirect 
modulation of BCL11A via MYB activation of KLF-1, all 
of which were concomitant with HbF production in both 
erythroid and K562 cells. The results of this study dem-
onstrate the role of miRNAs in the modulation of HbF, 
directly and through critical regulators. The elucidation 
of the post-transcriptional regulation of HbF through 
miRNAs could incite investigation of therapeutic agents 
that would avoid global transcriptome changes but 
rather hone in on critical regulators with lineage-specific 
miRNA-mediated inhibition of negative regulation of 
HbF.
Methods
Umbilical cord blood
Umbilical cord blood was harvested during elective cae-
sareans at Mowbray Maternity Hospital (Cape Town, 
South Africa) from healthy females of black African ori-
gins, free of the sickle cell mutation. Cord blood (90–
140 ml) was collected in anticoagulant citrate phosphate 
dextrose adenine (CPDA-1)-containing bags (SSEM 
Mthembu, South Africa) and processed within 4  h of 
harvest.
Isolation of CD34+ hematopoietic cells
Cord blood samples were diluted using Iscove’s Modified 
Dulbecco Medium (Sigma, SA), layered on Ficoll-His-
topaque (1.077 g/ml) (Sigma, SA), centrifuged to collect 
the mononuclear cell layer (MNCL), then enriched for 
CD34+ hematopoietic stem cells (HSCs) using Dynabead 
magnetic separation technology according to manufac-
turer’s instructions (Life Technologies, SA).
Flow cytometry
The purity of the Dynabead-selected HSCs and differen-
tiated erythroid cells was determined using cell-surface 
antibodies and flow cytometry (FACSCalibur, BD Bio-
sciences, USA). Briefly, 5 × 104 HSCs were stained with
phycoerythrin-conjugated CD34 (CD34-PE) and fluo-
rescein isothiocyanate-conjugated CD45 (CD45-FITC) 
(BD Biosciences, USA) according to the manufacturer’s 
instructions and analysed. Subsequent to erythroid dif-
ferentiation, markers of the derived-erythroid cells were 
analysed on day 15 using CD34-PE, CD45-APC, CD71-
FITC and CD235a-PE (BD Biosciences, USA). The con-
trols included in the flow cytometry experiments were 
as follows: (i) No cells (cell suspension fluid: 1x PBS), 
(ii) Cells only, (iii) Cells and primary antibody only, (iv)
Cells and secondary antibody only. These were included
to ensure specificity in antigen–antibody interactions
in the experiments. During optimization, a separate
cell line, RAMOS (RA-1 CRL1596, ATCC) was used to
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Future work: implications for novel therapeutics in SCD
Future work regarding the post-transcriptional mecha-
nisms regulating the expression of various trans-acting 
factors, such as BCL11A, KLF-1 and MYB, could include 
experimental variations of the level of candidate miRNAs 
and examination of the effect on HbF levels and addi-
tional 3′-UTR luciferase assays on such regulators. The 
limitation on the number of primary erythroid cells could 
be overcome by the use of improved primary cell trans-
fection protocols or alternative sources of HSCs such as 
commercially available HSCs or bone marrow aspirates. 
Future work will look to replicate these results in primary 
erythroid cells and investigate other candidate miRNAs 
for interactions with key regulators of γ-globin expres-
sion. Another limitation of the present work the “promis-
cuous” nature of HU, as it could influence many aspects 
of cellular functions and almost certainly alter the global 
cellular transcriptome. Therefore, future studies should 
continue to evaluate the in  vivo impact of efficacious 
concentrations of HU on the erythroblast transcriptome 
and/or proteome, as well as the erythroid-specific micro-
nome of SCD patients (before treatment and at MTD) 
as global analysis of these epigenetic mechanisms could 
highlight multiple components of this complex system 
and possibly yield alternative (possibly miRNA-based) 
therapeutic approaches to hemoglobinopathies [78]. 
This is likely not implausible as several clinical trials in 
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Fig. 6 Time- and concentration-dependent luciferase activity in response to hydroxyurea treatment of anti-miR-26b transfected K562 cells. Inhibi-
tion of miR-26b results in a significant (p < 0.02) increase in luciferase activity and a sigmoidal pattern of action during a time course with HU treat-
ment, with the highest luciferase activity observed after 12 h of treatment (a). A concentration gradient of anti-miR-26b demonstrates an inverse 
relationship between anti-miR26b concentration and MYB-3′-UTR luciferase activity. This unequivocally demonstrates interaction between miR-26b 
and the 3′-UTR of MYB (b). The likely implication of this result is that the miR-26b-induced translational inhibition of MYB (a known activator of KLF-1) 
could result in down-regulation of KLF-1, which is known to directly induce BCL11A expression. In sum, miR-26b could explain the observed up-
regulation of γ-globin via a MYB/KLF-1/BCL11A pathway. * Significant difference, p < 0.05
 HU 
miR-26b
 GATA-1 MYB
KLF-1
regulators BCL11A
miRNAs?
γ-globin
Fig. 7 Hydroxyurea mechanisms of HbF induction: regulators and 
miRNAs mediated actions. Proposed HU-induced miRNAs-mediated 
mode of indirect HbF regulation through critical regulators (MYB/KLF-
1/BCL11A) and possibly directly modulating HbF
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other diseases have demonstrated a promising future 
for miRNA-based therapeutics such as the liposome-
based human miR-34 mimic (MRX-34) miRNA-based 
drug against hepatocellular carcinoma (NCT01829971). 
MiRNAs have also been implicated in many cancers 
(colorectal, cervical, prostate, breast and lung) as either 
biomarkers and/or highlighted for potential therapeutic 
significance [79]. Closer to hemoglobinopathies, several 
miRNAs have been associated with specific phenotypes 
or key signalling pathways in SCD; miR-15a and miR-
16-1 with hereditary persistence of HbF [53], miR-148a
with DNMT-1 [72], miR-144 and tolerance of oxidative
stress and anemia severity [52], a mouse model show-
ing the correction of SCD via interference with the “fetal
switch” [80, 81], in vivo association of miR-26b and miR-
151-3p with HU treatment at MTD [44], miR-320 and
down-regulation of CD71 during terminal differentiation
of reticulocytes [51], miR-24 and inhibition of erythro-
poiesis via activin type I receptor ALK4 [82], a suite of
miRNAs including miR-451 in Plasmodium falciparum
parasite interactions with erythrocytes [83] and now in
this study, miR-26b direct interaction with MYB 3′-UTR
and the rescue of miR-26b inhibition with HU treatment.
It is however noteworthy to consider the myriad of 
challenges in miRNAs-based therapies including site-
specificity, delivery and treatment efficacies, off-targeting 
and side effects [84], undesired in vivo pharmacokinetics 
[85] and short half-life in peripheral blood before renal
clearance [86]. These challenges may also be com-
pounded by the rapid erythrocyte turnover and anemia
in SCD, the heterogeneous multi-organ complications
and the numerous genetic polymorphisms affecting dis-
ease severity, predisposition to specific phenotypes,
the vast variation in response to HU treatment and the
overall clinical course of the disease [60]. Although faced
with many challenges, novel methodologies such as exo-
some-based delivery systems provide sufficient evidence
in support of the continued efforts to develop improved
systems of delivery and target-specificity, desired in vivo
stability, reduced side- and off-target effects for miRNA-
based therapeutic approaches [87–89].
Conclusion
In the present article, the authors have demonstrated 
successful expansion and differentiation of umbilical 
cord blood-derived CD34+ HSCs into CD71+/CD235a+ 
erythroid cells and showed HU-mediated induction of 
γ-globin expression concomitant with the down-reg-
ulation of key negative regulators, BCL11A, MYB and 
KLF-1. Importantly, the experiments have demonstrated 
association between the induction of miR-15a and miR-
16-1 and HU-mediated down-regulation of MYB as well
as up-regulation of miR-148a, which targets DNMT-1.
Furthermore, the data have shown the direct interaction 
between miR-26b and the MYB 3′-UTR, possible indirect 
modulation of BCL11A via MYB activation of KLF-1, all 
of which were concomitant with HbF production in both 
erythroid and K562 cells. The results of this study dem-
onstrate the role of miRNAs in the modulation of HbF, 
directly and through critical regulators. The elucidation 
of the post-transcriptional regulation of HbF through 
miRNAs could incite investigation of therapeutic agents 
that would avoid global transcriptome changes but 
rather hone in on critical regulators with lineage-specific 
miRNA-mediated inhibition of negative regulation of 
HbF.
Methods
Umbilical cord blood
Umbilical cord blood was harvested during elective cae-
sareans at Mowbray Maternity Hospital (Cape Town, 
South Africa) from healthy females of black African ori-
gins, free of the sickle cell mutation. Cord blood (90–
140 ml) was collected in anticoagulant citrate phosphate 
dextrose adenine (CPDA-1)-containing bags (SSEM 
Mthembu, South Africa) and processed within 4  h of 
harvest.
Isolation of CD34+ hematopoietic cells
Cord blood samples were diluted using Iscove’s Modified 
Dulbecco Medium (Sigma, SA), layered on Ficoll-His-
topaque (1.077 g/ml) (Sigma, SA), centrifuged to collect 
the mononuclear cell layer (MNCL), then enriched for 
CD34+ hematopoietic stem cells (HSCs) using Dynabead 
magnetic separation technology according to manufac-
turer’s instructions (Life Technologies, SA).
Flow cytometry
The purity of the Dynabead-selected HSCs and differen-
tiated erythroid cells was determined using cell-surface 
antibodies and flow cytometry (FACSCalibur, BD Bio-
sciences, USA). Briefly, 5 × 104 HSCs were stained with
phycoerythrin-conjugated CD34 (CD34-PE) and fluo-
rescein isothiocyanate-conjugated CD45 (CD45-FITC) 
(BD Biosciences, USA) according to the manufacturer’s 
instructions and analysed. Subsequent to erythroid dif-
ferentiation, markers of the derived-erythroid cells were 
analysed on day 15 using CD34-PE, CD45-APC, CD71-
FITC and CD235a-PE (BD Biosciences, USA). The con-
trols included in the flow cytometry experiments were 
as follows: (i) No cells (cell suspension fluid: 1x PBS), 
(ii) Cells only, (iii) Cells and primary antibody only, (iv)
Cells and secondary antibody only. These were included
to ensure specificity in antigen–antibody interactions
in the experiments. During optimization, a separate
cell line, RAMOS (RA-1 CRL1596, ATCC) was used to
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Commentary 
Epidemiology and burden of SCD 
Sickle cell disease is a life-long genetic disease that begins in 
childhood, affecting the structure of erythrocytes, altering the 
healthy biconcave shape to a crescent shape, leading to the 
blockage of veins, thereby resulting in organ damage [1]. There is 
strong correlation between the frequency of the HbS gene and the 
historical distribution and incidences of malaria due to the partial 
HbS-carrier resistance to Plasmodium falciparum malaria [2]. 
Indeed, Sickle Cell Anaemia mutation (HbS gene) appears to have 
occurred independently in 4 regions in Africa, defined by four 
haplotypes (Senegal, Benin, Bantu and Cameroon haplotypes)[3]. 
SCD is prevalent among indigenous populations in tropical regions 
of Africa and Asia; 305800 births with SCD are estimated to occur 
annually, nearly 67% of which take place in Africa. Sickle Cell 
Anaemia (SCA; the homozygousHbSS state) is by far the most 
prevalent and severe form of SCD [4]. Many countries in Africa have 
developed a national control program for SCD, however provisions 
of neonatal screening are rare [5] and development of specialized 
centres for lifelong medical care and surveillance have yet to 
become part of many SCD health systems, and in the absence of 
universal medical insurance coverage in many African countries, the 
chronic care of SCD patients is therefore dependent on financial 
support and care-giving by family member [6]. In addition, vaso-
occlusive painful events, silent and overt stroke that occur in SCD 
could potentially contribute to functional limitations and poor 
academic achievement of affected children. Indeed, it was reported 
in Cameroon that up to 37.5 % of participants' SCD-affected 
children had mild-to-severe cognitive deficits, and there was a 
significant effect on executive functions and attention [7]. Poor 
health status of children with SCD could also reduce caregivers' 
employability and worsen the socioeconomic burden on families. 
Indeed up to 24.3 % of caregivers in the USA missed two or more 
days of work per 3 days-hospital admission of their children [8], and 
the morbidity of a painful event continued after discharge from 
hospital [8,9]. Similar findings were also recently reported in 
Cameroon[6].  
The mortality rate associated with SCD has remained high in Africa, 
despite the use of appropriate interventions to manage the various 
forms of crises [10]. In the USA and Europe, who together account 
for less than 8% of the global disease burden of SCD, new-born 
screening, pneumococcal immunization, prophylactic penicillin and 
most importantly HU treatment, have decreased morbidity and 
mortality and thus increasing survival rates from childhood 
diagnoses to over 95% [4,11]. In stark contrast, as of 2010, sub-
Saharan Africa accounted for 75.5% of the global number of new-
borns with SCD, where most of these children die before age 5 due 
to a myriad of socio-economic factors and a poor public healthcare 
system [4]. The limited early detection and treatment initiatives that 
have been implemented in Africa result in high death rates before 
the age of 5 [10,12]. These statistics highlight the imperative 
necessity of research and translational medicine in to improve the 
burden through better care and potentially a cure of SCD in Africa.  
Treatment approaches 
There are five treatment approaches for SCD that are tailored to the 
clinical phenotype of a patient, namely supportive, symptomatic, 
preventative, abortive and curative approaches [13]. The supportive 
approach is the most common, aimed at the management of the 
patient and such an approach includes a balanced diet, hydration 
and folic acid supplementation. Blood transfusions, analgesia and 
antibiotics are typed as symptomatic approaches because their 
function is to alleviate specific SCD symptoms. The preventative 
approach is taken to preclude the occurrence of disease 
complications such as pneumonia and influenza vaccination, 
hydroxyurea for the induction of foetal haemoglobin (HbF) and 
blood transfusions to avert primary and secondary stroke episodes 
[14]. Nitric oxide (NO) is the only accepted agent for the abortive 
approach, reported to completely terminate of chronic pain episodes 
in some SCD patients [15]. Lastly, the curative approach is the 
ultimate goal for all genetic disorders, intended to correct the 
disease-causing mutation and prevent all complications. Currently, 
transplantation of haematopoietic stem cells (HSCs) is the only 
accepted curative treatment for SCD. Below, we briefly describe the 
3 current major strategies for effective treatment of SCD, namely 
blood transfusion, hydroxyurea (HU) and HSC transplantation.  
Blood transfusion: Blood transfusions improve the oxygen-carrying 
capacity and oxygen-delivery efficiency of blood to the tissues and 
decrease the blood concentration of sickle cells and improve 
perfusion of tissue microvasculature. Transfusions are typically used 
to ameliorate chronic anaemia and pain episodes [16], and are 
highly effective in patients with sporadic episodes of severe anaemia 
by preventing organ damage. Although transfusion can be applied 
as a preventative, abortive or curative approach for treatment of 
certain complications, they have many drawbacks. There are few 
blood transfusion services across the continent with the capacity to 
cope with the demand for regular transfusions [17,18]. 
Furthermore, widespread diseases such as HIV/AIDS and TB reduce 
the number of possible donors as well as the limited technical and 
financial support offered by the state's department of health. 
Although not specific to Africa, graft versus host disease (GVHD), 
even after alloimmunization [19], is one of the challenges 
surrounding transfusions. Other possible complications include 
transfusion-induced haemolytic reaction or autoimmune hyper-
haemolysis [20] and blood volume and iron overload [21]. This 
evidence suggests that although useful and effective in certain 
circumstances, blood transfusion alone is not a sufficient treatment 
for SCD nor is it curative. Therefore below, we discuss the use 
hydroxyurea as a drug treatment for SCD.  
Hydroxyurea: Hydroxyurea is an oral, cytotoxic, anti-metabolic and -
neoplastic drug for principal haematological disorders. The first 
clinical application of HU was in 1984 [22] and since then have been 
supported by numerous clinical trials demonstrating clinical efficacy 
and increase in survival rates and life expectancy [23], protection 
against cerebrovascular disease [24], long term drug safety, 
capacity to prevent organ damage, reduce morbidity and mortality 
in school-age children [25], toddlers [26] and infants [27]. The most 
notable evidence for the clinical efficacy of HU came from the 
Multicentre Study of Hydroxyurea (MSH) clinical trial [28]. The trial 
showed decreases in the frequency of painful episodes, acute chest 
syndrome, hospitalization and transfusions. Following FDA approval 
in 1998, 2007 saw HU receive approval from the European 
Medicines Agency (EMeA) as treatment for both adults and children 
with SCD. One year later, the National Institutes of Health Office of 
Medical Applications of Research (NIH-OMAR) and the Agency of 
Healthcare Research and Quality (AHRQ) both declared HU as an 
effective drug treatment for adults and children with SCD [29]. 
However, despite these results and the National Institutes of Health 
(NIH) recommendation for the use of HU in adults and children with 
SCD [30], HU is still underutilized [31]. This was confirmed by the 
NIH Consensus Development Conference statement [29] leading to 
studies investigating the barriers to the widespread use of HU. In 
surveys of the American Society of Paediatric Haematology and 
Oncologyand Florida and North Carolina's Haematologists and 
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Oncologists, it was reported that the most common barrier to the 
prescription of HU for SCD is compliance from the patients and their 
families [32,33]. Similar barriers to the use of HU in children have 
also been reported [34] with the age of the children being one of 
the major barriers to prescription, despite data from the 
Hydroxyurea to Prevent Organ Damage in Children with SCD 
confirming the safety of HU in young children [35]. Similarly, HU is 
still not included within national guidelines for use in children below 
age 5 in some West African countries such as Kenya where the 
disease burden is highest [36,37], and recent report suggest that 
less than 5% of SCD patients in Cameroon ever used HU 
[6].Furthermore, a recent review on the efficacy of HU in preventing 
SCD complications revealed that the majority of the studies were 
conducted in high-income countries with just 2 studies completed 
low-income countries, Tunisia and India [36]. This is illustrative of 
the apparent disproportion between regions of high disease burden 
and investment into medical research and intervention. Clinical trials 
investigating the effectiveness of HU in Africa are imperative as well 
as overcoming the barriers to the necessary utilization of HU in both 
children and adults with SCD and more importantly, further 
exploring curative modalities such as stem cell transplantation.  
Haematopoietic stem cell transplantation: Currently, allogeneic HSC 
transplantation is the most successful curative treatment for SCD 
[38]. This method was first reported in 1984 with the HSCs derived 
from bone marrow, transplanted and successfully curing a patient 
with SCD and acute myelogenousleukemia[39,40]. To date, 
approximately 250 individuals have received HSC transplantation for 
SCD worldwide [41]. Transplantations can be autologous or 
allogeneic. Autologous HSC transplantation is used depending on 
the severity of the presenting symptoms as this approach averts 
immune rejection. After comprehensive screening, the patient 
receives immunosuppressive and myeloblative treatment [41]. 
Although the myeloblative treatment has been associated with 
secondary toxicity-related complications such in infertility and graft 
versus host disease (GVHD) [41], immunosuppressants such as 
cyclosporine and methotrexate have been used to prevent GVHD 
[42]. Using the Worldwide Network for Blood and Marrow 
Transplantation and the World Health Organization (WHO), the total 
number of first-time HSC transplantation between 2006 and 2008 
were reported by WHO regional offices [43]. The findings were 
indicative of a general increase in the number of HSC transplants 
worldwide, with the highest in Asia. Of all 146 808 HSC transplants 
between 2006 and 2008, Europe and the Americas accounted for 
50.7 and 28.9% respectively, whereas both Africa and the eastern 
Mediterranean region accounted for 2.7%, most of which were 
conducted in the United Arab Emirates, Qatar and Egypt [43]. Using 
a linear regression, they showed strong correlations between rates 
of transplantation and government healthcare expenditure, gross 
national income per capita and overall infrastructure in the country 
[43]. As encouraging as the general hike in transplant rates is, the 
above correlations bid developing countries, particularly in Africa, 
more challenges to meet the extraordinary needs for HSC 
transplants. In contrast, Egypt has since 1989 initiated a Stem Cell 
Transplant (SCT) program for all haematological disorders, which by 
2007 had performed 1362 transplants, 80% of which were 
allogeneic [44]. The average 25 - 30% sibling HLA match is 
generally higher (about 40%) owing to the typical larger family size 
in most African communities. Egypt has 8 transplant centres 
performing about 210 transplants annually, the biggest being the 
Nasser Institute, which has completely shifted from bone marrow to 
peripheral blood as a stem cell source, a seemingly better option in 
the developing world. β-thalassemia major, being the most common 
haemolytic anaemia in Egypt, saw compelling economic support for 
establishing a SCT program, which now has an overall and disease-
free rates of 90 and 85%, respectively [44]. The SCT program in 
Egypt validates the feasibility of such programs in the third world 
and could be the focal point of a regional collaboration to initiate 
and develop this practice to cure SCD in Sub-Saharan African 
settings, and its successful transplant rates advocate for the 
establishment of similar programs across Africa.  
Advocacy for Haematopoietic stem cell 
transplantationcentres 
Every 2 years, Africa sees the birth of a number of SCD-affected 
children equal to the sum of the American and European 
populations affected by SCD, where most of these children die 
before age 5 [45]. One of the major obstacles to the management 
of SCD, particularly in developing countries, is the reluctance of 
governments and international healthcare agencies to accept that 
SCD is a worldwide health problem, comparable to that of 
communicable diseases and other major global disease such as 
diabetes and hypertension [46]. The Nasser Institute in Egypt 
serves as a model from which we advocate for the establishment of 
similar transplantation centres across the continent. Although the 
average cost of SCT in Egypt is 15 000 USD, this cost is completely 
sponsored by the Ministry of Health or medical insurance [44] due 
to a collaborative commitment between government and their 
private sector. We strongly urge such commitments to developing 
research, science and technology in order to build the necessary 
scientific and research capacity in Africa. We advocate for a joint 
effort from Cape and Cairo, to initiate a centre for HSC 
transplantation in Africa, with the respective governments, members 
of the private sector and pharmaceutical industry, leading 
researchers and clinicians as stakeholders. We propose an intra-
Africa collaboration and pooling of resources towards developing a 
transplantation centre that will be mandated with developing cost-
effective procedures for HSC transplants for haematological 
disorders like SCD and β-thalassemia; large-scale clinical trials and 
follow-up studies, initiating epidemiological studies of 
haematological disorders in Africa, studies on health-related quality 
of life (HRQL) and patient survival rates, commercialization and 
distribution of treatments and therapies across the continent and 
most importantly, building technological and research capacity in 
Africa through teaching and training laboratory technicians and 
researchers. Such an initiative would also strengthen collaborative 
relationships across research and academic institutions in Africa, 
leading to a combined database of patients, information and 
experimental procedures, which will go towards standardizing 
practices within the field. The centre could initiate research towards 
developing disease models and investigating manifestation of 
diseases and accounting for previously undocumented African 
polymorphisms, develop an Afrocentric pharmacogenomics 
knowledge base including methods of drug design, predictive 
responder indexes and toxicity studies. This centre could also give 
rise to other initiatives such as umbilical cord blood and stem cell 
banks and continue building scientific and technological 
infrastructure in Africa. Furthermore, it will lead to improving blood 
transfusion services across the continent, incite further investigation 
of drug treatments like HU through clinical trials such as the NIH's 
Novel use of HU in an African Region with Malaria (NOHARM) and a 
better understanding of disease-modifying polymorphisms within 
various African populations.  
Conclusion 
The data available on clinical trials and reports conducted outside of 
Africa is illustrative that a range of treatments are available and 
have been successful at curing SCD. What is required is the 
implementation of strategies to affordably avail these treatments in 
Africa, particularly HU and ultimately, HSC transplantation, through 
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a collective effort from researchers, physicians, state departments of 
health and the private sector. This approach is likely to foster 
collaborative healthcare and research networks across the 
continent, ensuring the continued development of scientific and 
technological capacity in Africa to effectively manage the high 
disease burden of haematological disorders such as SCD.  
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Chapter 3.3 – Results 
 
Southern African perspective of Sickle Cell Disease 
 
3.3.1. Pule GD, Mnika K, Jourbert M, Mowla S, Novitzky N, Wonkam A. Increasing 
burden of adult patients living with Sickle Cell Disease in Cape Town. Submitted to 
South African Medical Journal (in final editing, #10849) 2016. 
Abstract 
Background: An exponential increase of the number of Sickle Cell Disease (SCD) 
patients in paediatric services in Cape Town has been reported. The trend in 
adult/adolescent services has not been investigated.   
Objectives: The present study aims to evaluate the epidemiological trends and the 
profile of patients affected by SCD at the Haematology clinic at Groote Schuur Hospital. 
Methods: 1) Retrospective review of the number SCD patients over the past 20 years; 
2) cross-sectional analysis of clinical and haematological characteristics of SCD 
patients; 3) Molecular analysis of Hemoglobin S mutation, the haplotype in the β-globin-
Synopsis of Chapter 3.3 
Sickle Cell Disease (SCD) was historically largely restricted to tropical equatorial 
Africa, concomitant with malaria endemicity and as a result, similarities in 
anthropology and/or cultural practices have been used as proxy for generalizing 
genomic data. This chapter includes two publications that; 
i) Argues for the dissociation of the assumed congruence between genetics 
and anthropology or culture and seeks to contribute to understanding the 
origin and distribution of the HbS mutation among southern African 
population. 
ii) Confirms the increasing burden of adult SCD patients at Groote Schuur 
Hospital, as previously reported in paediatric patients at Red Cross War 
Memorial Hospital, and seeks to caution national health and academic 
institutions to adapt policies, health care and professional training, 
accordingly. 
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like gene cluster, the 3.7kb α-thalassemia gene deletion and 19 selected single 
nucleotide polymorphisms (SNPs) associated with HbF levels.   
Results: From 1995 to 2016, 81 SCD adolescent/adult patients were registered, mostly 
from others African countries (n = 61; 75.3%). There was over 200% increase in new 
cases (n = 47) in last quarter of the 2 decades investigated. Of the 58 regular attendees, 
data from 34 patients (58.6%) were analysed. The mean age was 26.1 ± 9.8 years; 
70.6% were male. Except four patients with sickle/β-thalassemia, all the patients had 
sickle cell anaemia (HbSS).  The co-inheritance of a single 3.7kb α-globin gene deletion 
was found in 42.3% (n = 11) of cases. The Bantu haplotype was the most observed 
(65.4% of chromosomes). Most HbF-promoting SNPs were not associated with variable 
levels of haematological indices. 
Conclusion: There is an increasing burden of adult SCD patients at Groote Schuur 
Hospital. National health and academic institutions need to adapt policies and health 
care professional training, accordingly. 
Nature of publication: Original full article 
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Abstract 
Background: An exponential increase of the number of Sickle Cell Disease (SCD) patients 
in paediatric services in Cape Town has been reported; the trend in adult/adolescent services 
has not been investigated.   
Objectives: To evaluate the epidemiological trends and the profile of patients affected by 
SCD at the Haematology clinic at Groote Schuur Hospital. 
Methods: 1) Retrospective review of the number of SCD patients over the past 20 years; 2) 
cross-sectional analysis of clinical and haematological characteristics of SCD patients; 3) 
Molecular analysis of Hemoglobin S mutation, the haplotype in the β-globin-like genes 
cluster, the 3.7kb α-thalassemia gene deletion and 19 selected single nucleotide 
polymorphisms (SNPs) associated with HbF levels.   
Results: From 1995 to 2016, 81 SCD adolescent/adult patients were registered, mostly 
coming from other African countries (n = 61; 75.3%). There was over 200% increase in new 
cases (n = 47) in last quarter of the 2 decades investigated. Of the 58 regular attendees, data 
from 34 patients (58.6%) were analysed. The mean age was 26.1 ± 9.8 years; 70.6% were 
male. Except four patients with sickle/β-thalassemia, all the patients had SCD (HbSS).  The 
co-inheritance of a single 3.7kb α-globin deletion was found in 42.3% (n = 11) of cases. The 
Bantu haplotype was the most observed (65.4% of chromosomes). Most HbF-promoting 
SNPs were not associated with variable levels of haematological indices. 
Conclusion: There is an increasing burden of adult SCD patients at Groote Schuur Hospital. 
National health and academic institutions need to adapt policies and health care professional 
training, accordingly. 
Keywords: Sickle Cell Disease; Groote Schuur Hospital; South Africa; sub-Saharan Africa 
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Background 
Sickle cell disease (SCD) is the first well documented molecular disease [1] and the most 
prevalent monogenic disease in the world. SCD is an accepted worldwide health problem that 
is comparable to other major global diseases such as diabetes and hypertension, including 
communicable diseases [2]. Sub-Saharan Africa (SSA) has the highest burden of disease with 
an excess of about 300 000 new affected births annually, which accounts for 80% of all 
annual global affected child births [3]. In spite of the high burden of disease in SSA, this is 
often associated with limited-to-poor medical resources, infrastructure and quality of care, 
thus estimates of neonatal and childhood mortality remain high, with up to 90% of affected 
children dying by five years of age [4]. SCD is caused by the polymerization and precipitation 
of the β-globin chains (HbS) during deoxygenation and dehydration of erythrocytes [5]. The 
altered structure of erythrocytes (normal biconcave shape to a crescent) is the basis of the 
vascular pathology of the disease, which includes abnormality of platelet and leukocyte 
adhesion and hyper-coagulation leading to microvascular occlusion, hemolysis, hypoxia, 
failed nitric oxide production and multi-organ damage [5]. The hallmark phenotypes of the 
disease include vaso-occlusive crises, stroke and acute chest syndrome, which are the basis 
for the typical episodes of acute pain [5-7]. The phenotype of SCD is influenced by both 
environmental and genetic factors. Variants at three principal loci; BCL11A, HBS1L-MYB 
intergenic polymorphism (HMIP) and the β-globin haplotype have been shown to account for 
10-20% of the variance of Fetal Hemoglobin (HbF) levels and associated with the 
amelioration of the SCD symptoms [8-10]. Other variants in the BCL11A erythroid-specific 
enhancer (rs1427407 and rs7606173) have been shown to account for 8% and 6.2% in HbF 
variance, respectively, among SCD patient cohorts in the USA [11, 12], Tanzania [13] and 
Cameroon [14]. The co-inheritance of α-thalassemia has also been associated with improved 
clinical manifestation of SCD [15-18]. Even though the multiple independent origin of the HbS 
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mutation has been recently questioned [19], the SCD mutation is classically associated with 
five-region defined β-globin gene haplotypes; Benin, Bantu or Central African (CAR), 
Cameroon, Senegal and Indian-Arab [20-23], four of which are from Africa and associated with 
malaria incidence [24].  
Because of the low incidence of malaria, the incidence of SCD in South Africa is equally 
extremely low; the HbS allele can be found in some indigenous South African ethnic groups 
(Venda and Shangaan) at an approximated frequency of 0.2% [25, 26]. However, this is 
changing with the socio-economically motivated influx of immigrants from other African 
countries, especially those within the equatorial malaria-endemic belt, resulting in study 
period by 300 - 400% increase of new cases of SCD over the past 10 years SCD at Red Cross 
War Memorial Children’s Hospital (RCWMH) in Cape Town [27]. The existence of similar 
trends in adult SCD patient services has not been investigated.  Following our previous report 
at RCWMH, we have reported in the present study the trend of new cases of adolescent and 
adult patients with SCD over the past 20 years, and studied the clinical, haematological and 
genetic profiles of a cohort of thirty-four of adolescent and adult SCD patients at the 
Haematology Unit at Groote Schuur Hospital (GSH), Cape Town.  
Methods  
Ethical approval 
The study was performed in accordance with the Helsinki declaration and with the approval 
of the University of Cape Town, Faculty of Health Sciences Human Research Ethics 
Committee (HREC REF: 132/2010). Informed and written consent was obtained from adult 
participants (18 years and older) and for the one patient (15 years old), informed consent was 
obtained from the guardian with assent from the participant. 
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Patients  
The haematology clinic runs weekly every Wednesday and most patients are seen at least 
once a month and every 3 months for the clinically stable patients, with the exception of 
crises related hospitalization. A retrospective review of the number of SCD patients attending 
the clinic over the past 20 years and a cross-sectional analysis of patients that regularly attend 
the clinic were performed. Clinical events and haematological indices were retrospectively 
collected from hospital records. The haematological measures were that reported at the first 
visit to the hospital. 
Molecular methods 
DNA extraction 
DNA isolated using from the peripheral blood using the AllPrep DNA/RNA/miRNA 
universal kit (QIAGEN, USA) according to manufacturer’s instructions.  
Genotyping 
HbS mutation and β-globin haplotypes 
PCR and DdeI restriction analysis were used to confirm the presence of the HbS mutation 
using 100 ng DNA [28]. To determine the haplotype background, published primers and 
methods [29] genotyping five restriction fragment length polymorphic (RFLP) regions in the 
β-globin gene cluster were used to analyse the XmnI (5'Gγ), HindIII (Gγ), HindIII (Aγ), 
HincII (3˙'Ψβ) and HinfI (5'β) for the β-globin haplotype background [19].  
SNPs 
Using a reported method [9], SNaPshot genotyping, capillary electrophoresis and direct cycle 
sequencing were used to assay five selected HbF-associated variants: rs8176703, rs372091, 
rs2334880, rs1427407, rs7606173. In addition, 14 other variants were analysed using the 
iPLEX Gold Sequenom Mass Genotyping Array (Inqaba Biotec, South Africa): 
X12_123681790, X16_391593, rs10468869, rs10756993, rs113267280, rs11754265, 
84
rs141494605, rs148706947, rs183437571, rs192197462, rs570013781, rs59329875, 
rs62573842, rs6466533, rs6590706, rs67104793, rs7163278 and rs76901220. 
Statistical analysis 
Descriptive statistics were obtained for all quantitative data using SPSS (IBM, USA version 
21.0). A chi-squared test, with 1 degree of freedom, was used to perform the Hardy-Weinberg 
Equilibrium (HWE) test on the SNPs genotypes with all variants in HWE (p>0.05). 
Results 
Patients’ origin and trends 
A total of 128 patients’ files from 1995 to March 2016 were reviewed. Among them, 47 
patients were diagnosed with some form of α- or β-thalassemia (Figure 1). Of the remaining 
81 patients affected by SCD, 61 (75.3%) were from other Sub-Saharan African countries. 
Over the last quarter (2011 – 2016) of the last two decades, there was an approximately 200% 
increase of new cases of SCD registered at the haematological clinic of GSH (n = 47) (Figure 
2). Figure 3A and B shows the number of patients seen at GSH and country of origin 
respectively, with 16.4% (n=21) South African patients, most of which are of Mixed/Indian 
ancestry (n=15) and 21.9% (n=28) from Congo.  
Of the 58 patients that regularly attend the Haematology clinic, 34 (58.6%) consented to be 
included the study (Figure 1). Over 75% of the patients at GSH are referrals from Red Cross 
War Memorial Paediatric Hospital, some coming from neighbouring secondary level 
hospitals in Cape Town and a minority of internal referrals of relatives of attending patients.  
Clinical and haematological profile 
The mean age was 26.1 ± 9.8 years (range: 15 – 51 years), of which 70.6% were male. The 
co-inheritance of a single 3.7kb α-globin gene deletion was 42.3% (n=11).  
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Table 1 summarizes the haematological and clinical events recorded for all patients. 
Information obtained from the anamnesis indicated that the majority of the patients were 
diagnosed relatively late (mean age at diagnosis:  6.8 ± 7.1 years; range: 1-39 years), as a 
result of the presentation of the initial clinical manifestations of SCD, mainly pain episodes.  
Clinical management 
With regards to treatment, 33% of the patients in the cohort had received at least one blood 
transfusion; about 8% (n=5) of the patients have been enrolled in a hyper-transfusion 
program, ranging from fortnight to monthly transfusion regimen to manage complications 
such as stroke, chronic painful crises and non-healing chronic leg ulcer. The frequency of the 
transfusions is largely dependent on symptom severity and availability of blood units from 
the Western Cape Blood Transfusion Service (Cape Town, South Africa).  
Of the patient cohort, 85% (n=88) were at maximum tolerated dose (MTD) with dosage 
ranging between 500 -1000 mg per day. From our patient survey, 30 – 50% of the 
participants were fully compliant with HU treatment; 20 – 30% reporting partial compliance 
(tended to forget to take the treatment 2 – 3 times a week) and some patients refusing the 
treatment. Reasons for refusal included potential cancer development in the future, family 
planning particularly for men afraid of treatment-related infertility and self-perceived 
improvement of symptoms without the treatment.  
Genetic characteristics 
Sickle cell genotypes; β-globin haplotypes and co-inheritance of α-thalassemia 
The description of the HbS allele frequency, β-globin haplotype background and α-globin 
gene deletion for the patients is given in Table 1. Genotyping for the HbS mutation revealed 
that 85.2% (N=23) of the patients were homozygous for the mutation (HbSS) with the rest 
being heterozygous (HbAS) with a possibility of β0-thalassemia (HbS/β0) (N=4), all of which 
were South African with Mixed and Indian ancestry. Figure 4 shows the distribution of the 
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SCD β-globin gene haplotypes: the Bantu and Atypical haplotypes accounted for 65.4% and 
26.9%, respectively, whereas the Senegal and Benin haplotypes each were 3.8% with no 
observation of the Cameroon and Indian-Arab haplotypes. In combination, the Bantu/Bantu 
haplotype represented 50% of the patients (Table 1). The heterozygous 3.7kb α-globin gene 
deletion was observed in 42.3% of the patients. 
Frequency of genetic variants associated with HbF levels 
Table 2 shows the observed alleles and minor allele frequency (MAF) of genetic variants 
previous associated with HbF, some recently in a Sardinian population [30]. All variants were 
in Hardy Weinberg Equilibrium (p > 0.05) with the exception of 4 loci (X12_123681790, 
rs141494605, rs183437571 and rs192197462) that presented monomorphic alleles in all 
patients. Tests of association between the variants and all haematological indices including 
Hb levels were conducted however, no significant associations were observed except for 
rs6466533 and the SCD haplotype combinations. The CC genotype (rs6466533) was 
associated with higher platelet counts compared to the heterozygous TC genotype (p < 0.05). 
Similarly, the Bantu/Bantu haplotype combination was associated with higher platelet counts 
compared to the Atypical/Atypical genotype (p < 0.05). Table 3 shows the MAF of the above 
variants in African populations; Esan (Nigeria), Luhya (Kenya), Mandinka (Gambia) and 
Mende (Sierra Leone); American (including African American), Europe and both East and 
South Asian populations.  
Discussion  
To the best of our knowledge, this is the first study describing the clinical and genetic 
backgrounds of SCD patients at Groote Schuur Hospital and reporting on adult patients with 
SCD in South Africa. The results of this study indicate the similar trend of a rapid increase in 
the number of cases of SCD that was previously reported in at Red Cross War Memorial 
Children’s Hospital in Cape Town [27]. This was also the result of migration from sub-
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Saharan Africa countries where SCD is most prevalent. Related to this was a specific 
administrative difficulty in taking care of some patients that lack up-to-date and correct 
paperwork for immigrants and asylum seekers. This was an indirect indication that most 
patients arrived as adults in South Africa, contrary to what was observed in the second part of 
the last decade at RCWMH, where most patients were South African born. It is therefore 
expected the adult population of SCD are GSH will continue to grow as a compounded effect 
of future referrals from neighbouring paediatric hospitals and arrival of new adult patients 
from migrant populations, as migration particularly into SSA continues to be a reality of 
many seeking political asylum, economic opportunities and better healthcare. Concomitant 
with the migration, the improved clinical management and healthcare of paediatric SCD 
patients is expected to grow the pool of adults patients living with SCD, and increased the 
number of patients that will survives well beyond the reproductive age, therefore likely 
increasing, and the frequency of the HbS allele in the population.  
Indeed, newborn screening and comprehensive clinical care programs, which are also 
possible in South Africa,  have reduced SCD-related premature childhood deaths by 70% in 
high-income nations like the USA [31, 32] and most patients can survive into adulthood [33]. A 
similar increasing trend of SCD in countries previously not affected by the disease has been 
observed in Ireland [34], Italy [35], Germany [36], England [37] or France [38]. Therefore the 
evidence that SCD burden is comparable to that of communicable diseases and other major 
global diseases such as hypertension and diabetes [2] will have increasing resonance.  The 
marked increase in patients between 2001 and 2005 could also be associated with the ending 
of a civil war, transitional government and political instability in Congo, which had spread 
into neighbouring states. The latter increase (2011 – 2016) is more likely due to economic 
and health-motivated migration. The increase of SCD in both paediatric and adult settings 
will impose new burden on the healthcare system in South Africa concomitant with the new 
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need for training at all levels of medical education, as well as the need for policies from 
health authorities for the prevention, management and care of haemoglobinopathies.   
The number of annual vaso-occlusive crises was similar to that reported in Cameroon and 
likewise the mean number of vaso-occlusive crises per year [9]. As specific challenge faced by 
the health care professional was the compliance with HU treatment, supportive medication 
such as folic acid and clinic attendance are the major challenges at Groote Schuur Hospital. 
There as several barriers to HU treatment; the financial implications of taking days off at 
work to attend the clinic and receive the treatment (maximum one month’s supply), 
misconceptions about the treatment and possible carcinogenic effects as well as potential 
impotence in male patients [39]. Most patients fail to comply with clinic appointments simply 
because they feel better and thus see no need to go to the hospital.  
The novel aspect of this paper is the report on the genetic background of four key modifiers 
of HbF; variants at the BCL11A erythroid-specific enhancer, β-globin haplotypes and α-
thalassemia 3.7kb gene deletion and several other known HbF-promoting polymorphisms. It 
is imperative to gain a better understanding of genetic variants affecting the predisposition to 
specific complications such as stroke, acute chest syndrome and polymorphisms affecting 
susceptibility to pain as well as the pharmacogenomics of the commonly prescribed 
treatments such as hydroxyurea, malaria prophylaxis and pain medication. The dominance of 
the Bantu haplotype in this cohort is in accordance with the Congolese origin of most 
patients. Indeed, the Bantu haplotype is most prevalent below the equatorial malaria belt 
across Southern African countries [19]. Most variants were not associated with haematological 
indices except the CC genotype at rs6466533 and Bantu/Bantu haplotype combination with 
platelet counts, likely due to the modest sample size. The differences in MAF of the recently 
identified HbF-promoting loci in a Sardinian population [30] among African populations from 
the Human 1000 Genome Project (1000G) (Table 3) emphasises the necessity of large-scale 
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genomic analyses on various populations across the continent as there is vast variations 
between any two African populations. 
It should be underlined that the intention of this paper is not to stigmatize SCD nor immigrant 
patients, but to inform and prepare medical care providers and healthcare officials of the 
increasing need for management of haemoglobinopathies in South Africa. This trend is not 
restricted to South Africa, with countries such as Italy [40], the Republic of Ireland [34], 
England [41] and Germany [36] that have been affected by the reality of population movement 
and new burden of diseases, developing neonatal screening programmes and establishing 
SCD centres in response to similar increases in SCD prevalence. 
Limitations 
The final sample size of patients included in the present study was limited because of poor 
patients compliance to clinic attendance, self-transfers to other hospitals and the shortened 
period of recruitment. The sample size did not allow for robust statistical analyses to reveal 
potent markers of specific phenotypes or clinical measures. A handful of patients had HbF 
levels performed using HPLC (High performance liquid chromatography) before initiation of 
hydroxyurea treatment. This haematological measure would have been ideal to check for 
association with genetic variants as baseline HbF. 
Conclusion 
Over the past 10 years the number of adult patients living with SCD has increased 
considerably, imposing the creation of a weekly out-patients service at Groote Schuur 
Hospital.  The genic profile is similar to that of many other SCD patients from other sub-
Saharan Africa countries where most patients are originally from.  The trend has implication 
for medical education through academic and training institutions and policy action via the 
national health ministries for the prevention and care as well as research in 
hemoglobinopathies in South Africa.  This paper demonstrates the changing distribution of 
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the HbS allele and prevalence of the disease in Southern Africa and aims to enlighten all 
stakeholders: patients, care providers and health ministries towards better management of 
SCD. 
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Table 1. Description of hematological indices, clinical events and β-globin gene of the study 
cohort 
Variables Categories Mean +/- 
SD 
Value range Number of 
observations 
Gender Female 29.4%  10 
Male 70.6%  24 
Age (years)  26.1 ± 9.8 15 - 51 34 
Hematological indices Hb (g/dl) 9.1  ± 1.8 5.6 – 14.0 27 
MCV (fl) 91.5  ±  
31.9 
53.6 – 146.4 27 
WBC (109/l) 8.1 ± 3.0 3.0 – 13.6 27 
Platelets (109/l) 334  ±  
166.5 
133 – 737 27 
Neutrophils (109/l) 4.6 +/- .,1 2.0 – 10.3 27 
Clinical events Age of diagnosis (years) 6.8  ±  7.1 1 – 39 30 
Vaso-occlusive crisis (No. /year) 1.5  ±  1.2 0 – 5 30 
Stroke 13.3%  4/30 
Leg ulcers 16.7%  5/30 
Hospitalizations (No. /year) 2.1  ±  1.4 0 - 5 30 
Treatment Blood transfusions 33.3%  10/30 
Hydroxyurea (mg/day) 544.1  ±  
144 
500 – 1000 30 
β-globin genotype HbSS 85.2%  23/27 
HbAS& 14.8%  4/27 
β-globin haplotype Bantu/Bantu 50.0%  13/26 
Bantu/Senegal 7.7%  2/26 
Bantu/Benin 7.7%  2/26 
Bantu/Atypical 15.4%  4/26 
Atypical 19.2%  5/26 
α-globin gene deletion αα/αα 57.7%  15/26 
αα/α3.7 42.3%  11/26 
&: HbAS with possibility of β0 (HbSβ0); β-globin haplotypes numbers given by combination  
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Table 2. Genetic variants previous associated with HbF 
SNP Chromosome loci Alleles MAF Number of 
observations 
rs8176703 136135863& G/A 0,130 27 
rs372091 11:5496926 G/A 0,148 27 
rs2334880 16:71619734 C/T 0,400 25 
rs1427407 2:60490908 C/A 0,204 27 
rs7606173 2:60498316 C/G 0,426 27 
X12_123681790 X12_123681790 A* - 31 
X16_391593 X16_391593 T/C 0,015 33 
rs10468869 18:51795403 A/G 0,400 30 
rs10756993 9:18839726 C/A 0,016 31 
rs113267280 6:41952511 T/G 0,016 31 
rs11754265 6:135356216 C/G 0,172 29 
rs141494605 16:216593 T* - 27 
rs148706947 16:342218 C/T 0,047 32 
rs183437571 19:13121899 C* - 30 
rs192197462 14:57116065 A* - 30 
rs570013781 16:149539 G/A 0,016 31 
rs59329875 20:44547672 C/T 0,296 27 
rs62573842 9:32264314 A/G 0,250 30 
rs6466533 7:79163576 T/C 0,283 30 
rs6590706 11:133465011 A/G 0,217 30 
rs67104793 3:142444839 A/DEL.A 0,190 29 
rs7163278 15:93345162 T/C 0,121 29 
rs76901220 ss131769967& G/A 0,016 31 
 
* monomorphic; & no chromosome location provided in dbSNP, reference ID provided.  
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Figure 1. Patient recruitment flow chart 
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Figure 2. Frequency of Sickle Cell Disease at Groote Schuur Hospital. 
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Figure 3. Number of patients by nationality (A) and the distribution of countries of birth for 
patients at Groote Schuur Hospital (B). There was one patient from each of the following 
countries; Zaire, Somalia, Hong Kong and the UK. 
 
 
Figure 4. Distribution of SCD haplotypes. Haplotypes given by number and percentage of 
chromosomes. 
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Abstract 
The partial carrier-resistance to Plasmodium falciparum malaria conferred by the sickle cell 
(HbS) mutation has resulted in the local amplification and positive selection of Sickle Cell 
Disease in malaria-endemic regions and particularly in sub-Saharan Africa (SSA). Recently, 
genome-wide association study revealed three linkage disequilibrium (LD) tags of known 
functional mutation associated with resistance to malaria; rs8176703 (9q34.2; ABO), 
rs2334880 (16q22.2; MARVELD3) and rs372091 (11p15.5; HBB). The present study 
investigated the β-globin gene haplotypes, and malaria-associated variants among three 
cohorts of Bantu-speaking individuals from Malawi, Zimbabwe and South Africa compared 
to reports from other SSA populations. The data illustrate a south-ward frequency decrease of 
malaria-associated variants in SSA linked to the evolutionary dynamics of various African 
populations genomes through selective pressure of malaria. These selected genomics 
differences, among “Bantus” from various part of Africa emphasize the evidence of the 
dissociation between genetics, anthropology and culture, that may have implications in 
precision medicine. The present study also shown a prevalent Benin haplotype, which is 
mostly found in West Africa, among Southern African Blacks and very low Bantu haplotype; 
and this results illustrate the value of investigating the origin and age of the HbS mutation in 
Southern African populations within Africa. 
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Introduction  
Sickle Cell Disease (SCD) is a monogenic, hematological and multi-organ disorder affecting 
the structure of erythrocytes by altering the normal biconcave shape to a crescent [1]. The 
sickling results from the polymerization and precipitation of the β-globin chains (HbS) during 
deoxygenation and dehydration of erythrocytes [2]. The vascular pathology of the disease 
includes platelet and leukocyte adhesion abnormality and hypercoagulation leading to 
microvascular occlusion, hemolysis and hypoxia and ultimately, multi-organ damage.  
There is strong correlation between the frequency of the HbS gene and the historical 
distribution and incidences of malaria [3] because of the partial carrier-resistance to 
Plasmodium falciparum malaria. The geographical co-occurrence of SCD and malaria and 
the partial carrier-resistance is believed to have resulted in the local amplification and 
positive selection of SCD in malaria-endemic regions [4,5]. Besides HbS mutation, three tag 
SNPs were identified in a genome-wide association study (GWAS) associated with resistance 
to severe malaria; rs8176703 (9q34.2; ABO), rs2334880 (16q22.2; MARVELD3) and 
rs372091 (11p15.5; HBB) [6]. These variants were found to have genome-wide significance 
and be in linkage-disequilibrium (LD) with functional mutations associated with resistance to 
severe malaria in patients and controls from Ghana.  The ABO locus has previous indication 
of a protective effect conferred by the blood group O against severe malaria [7-9]. The 
variant rs2334880, was one of the novel resistance loci identified and was mapped to 6.4kb 
upstream of the MARVEL domain-containing protein 3 gene (MARVELD3; MIM 
ID*614094), which forms part of multiple tight-junction of epithelial and vascular endothelial 
cells [10-12] and is strongly associated with severe malaria [13]. The endemicity of malaria 
in sub-Saharan Africa (SSA) and the associated HbS mutations, has resulted in the highest 
SCD burden with nearly 80% of the approximately 300 000 new affected births that occur in 
SSA annually [14]. 
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The HbS mutation is believed to have evolved independently in 5 regions of the world, 
classically associated with five region-defined haplotypes, four of which are African, based 
on conserved patterns of polymorphisms across the β-globin gene cluster, namely Benin, 
Central African (CAR) or Bantu; Cameroon; Senegal and Indian-Arab [4,15,16]. A recent 
review of the global distribution and frequencies of these haplotypes has provided a glimpse 
into population dynamics and migration within and out of Africa that has prompted the 
hypothesis of a single origin of HbS mutation [17]. In this context, the study of malaria 
associated variants among Southern African populations, specifically among South African 
Blacks that have been living outside the malaria-endemic equatorial belt for 3-5000 years 
[18,19], provides new insight into the within-Africa migration patterns, the origin of the HbS 
mutation, and some perspectives into the dissociation between genetics and anthropology, 
with regards to differential allele frequencies related to various conditions such as malaria, 
susceptibility and resistance among Bantu-speaking groups from various parts of Africa. 
In this present study, we investigated the β-globin gene haplotypes and malaria-associated tag 
variants among three cohorts of healthy Southern African populations from Malawi, 
Zimbabwe and South Africa and compared the frequencies of these variants to that of other 
SSA populations. Methods  
Ethics Approval 
The study was performed with the approval of the University of Cape Town, Faculty of 
Health Sciences Human Research Ethics Committee (HREC REF: 132/2010 and HREC REF: 
1094/2009).  
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Populations 
One hundred and fifty-eight DNA samples (50 Zimbabweans; 58 Malawians and 50 South 
Africans) all of Bantu origin were randomly selected for the Division of Human Genetics bio-
repositories, Faculty of Health Sciences, University of Cape Town. These participants were 
randomly sampled from a cohort of unrelated and apparently healthy individual, initially 
recruited for a population genetics study. 
Genotyping 
HbS mutation and β-globin haplotypes 
Using the participants from the three southern African populations, PCR and Dde I restriction 
analysis were used to confirm the absence of the HbS mutation [20] and published primers 
and methods [21] genotyping five restriction fragment length polymorphic (RFLP) regions in 
the β-globin gene cluster were used to analyse the XmnI (5'Gγ), HindIII (Gγ), HindIII (Aγ), 
HincII (3˙'Ψβ) and HinfI (5'β) loci for the HbS haplotype background (Suppl. Table S1) [17].  
Malaria Associated SNPs 
Using a reported method [22], SNaPshot genotyping (based on the incorporation of a single 
ddNTP to an extension primer designed to anneal 1 bp upstream of the target SNP) and 
capillary electrophoresis was used to assay the allele frequencies and relative geographical 
distribution of polymorphisms at novel malaria resistance loci, 1q32 within the ATP2B4 gene 
and 16q22.2 neighbouring the MARVELD3 gene, rs8176703, rs372091 and rs2334880. [6]. 
Genotyping results were confirmed using Sanger sequencing. 
Data analysis and Bioinformatics analysis using data extracted from the 1000G 
Genotyping at the characterised loci conformed to Hardy-Weinberg Equilibrium (HWE) (P-
values > 0.05). Leveraging the moderated sample size and the accurate publicly phased data 
from 1000 Genomes Project, we compared the Minor allele frequencies (MAF) of all SNPs to 
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those of other African and non-African populations, and 2) analysed the diversity of the beta 
globin haplotype in five other African populations. We have used a custom python script to 
extract the data of five African populations from 1000 Genome project phase3 on 
chromosome 11 in a 100 kb region around HBB. The data included 108 samples from Yoruba 
(YRI) in Nigeria, 99 from Esan (ESN) in Nigeria, 113 from Gambia (GWD) in Western 
Divisions in the Gambia, 99 Luhya (LWK) in Webuye, Kenya and 85 from Mende (MSL) in 
Sierra Leone. Plink software [23] was used to compute the haplotype blocks in each of those 
populations. Each inferred haplotype blocks, was utilized in plink to estimate the haplotype 
frequency within the specific population. Similarly, the LD blocks were computed using 
Plink and the LD pattern was visualized using Haploview [24]. From a custom R script, we 
have made use of 20 haplotypes from each population to plot the haplotype bifurcation at the 
variant rs334.  Results 
Sickle Cell genotype frequencies 
The description of the HbS allele frequency, β-globin haplotype background and selected 
malaria-related SNPs for the study cohorts is given in Table 1. All participants from South 
Africa (100%, n=50); and the majority from Zimbabwe (88%, n=50) and Malawi (93.5%, 
n=62) were determined to be homozygous unaffected (HbAA), with the rest being 
heterozygous for the sickle mutation (HbAS).  
Haplotypes in the β-globin gene cluster 
SCD exists in Africa on disparate haplotype backgrounds [25] and are described by a specific 
pattern of five SNPs across the β-globin gene cluster [17]. This pattern confers four 
haplotypes associated with the HbS mutation in Africa; Benin, Bantu/Central African 
Republic (CAR), Senegal and Cameroon, with the fifth haplotype arising in the 
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Indian/Arabian peninsula (Arab/Hindu) [26, 27]. Any recombination of the defining SNPs 
results in recombinant haplotypes referred to as “atypical”. The SCD haplotypes were 
described using a previously published method and the global distribution of the haplotypes 
reviewed [17]. The haplotypes were described based on the analysis of chromosomes from 
the South Africa, Zimbabwe and Malawi cohorts (78, 64 and 70 chromosomes respectively), 
the most prevalent of the β-globin gene haplotypes was the atypical form; 67.95%, 65.63% 
and 51.43% respectively. Specifically, Atypical I was common across all 3 populations at 
similar frequencies, (32.1% South Africa; 38.1% Zimbabwe and 38.9% Malawi) (Suppl. 
Table S3). The two second most prevalent haplotypes were the Benin and Cameroon forms. 
In combination, the Atypical/Atypical haplotype was most frequent in the South Africa and 
Zimbabwe cohorts (41.03% and 37.50%, respectively) whereas the Benin/Atypical was the 
most frequent combination in Malawi (41.18%). Figure 1 shows the distribution of the SCD 
β-globin gene haplotypes amongst the study cohorts compared to the haplotypes reported in 
SCD patients in other African countries [17]. 
Targeted Malaria-related variants 
Variants at novel malaria resistance loci, 1q32 within the ATP2B4 gene and 16q22.2 
neighbouring the MARVELD3 gene, were selected to probe the allele frequencies and 
relative geographic distribution around and below the equatorial malaria belt. This approach 
was driven by the hypothesis that, such resistance loci even at the level of single nucleotide 
polymorphisms, which confer clinically significant resistance to severe malaria would 
undergo strong positive selection in malaria-endemic regions and to a gradual lesser extent, 
regions around the equatorial belt. Therefore, the allele frequencies of three variants at 
resistance loci [6] were investigated among three sub-Saharan African populations (Malawi, 
Zimbabwe and South Africa) at varying proximity to the equatorial malaria endemnicity belt. 
SCD unaffected populations were selected in order to eliminate the possible effect of co-
108
8 
 
inheritance of malaria resistance loci and the HbS allele, as a result of the HbS allele-
conferred partial resistance to P. falciparum. The genotype frequencies for the rs8176703 
(GG), rs372091 (GG) and rs2334880 (CT) among South African, Malawian and Zimbabwean 
populations were largely similar. However, when comparing MAFs at these loci with other 
populations from the Human 1000 Genome Project 1000Genomes Phase III, there was an 
apparent gradient of the MAF for rs8176703 and rs372091, highest in countries within the 
equatorial malaria belt (Gambia, Nigeria and Kenya) and lowest in the sub-equatorial 
populations investigated in this study (Table 2, Figure 2); however, this pattern was not 
observed in the MAF at rs2334880. When comparing the measure of frequency 
differentiation among the genotyped SNPs and the corresponding frequencies of these tag-
SNPs in the 1000 Genomes data, the frequency of the genotyped SNPs were highest among 
the Southern African populations and the African populations (Esan, Luhya, Yoruba, Mende 
and Mandinka) (Figure 3). The frequencies were lowest between American, Asian and 
European populations. Table 3 and Figure S1 show the frequency of the HbS allele across 
African populations [14, 28-36]. When investigating the LD between these variants in the 
1000 Genomes data, the variants were found to be in linkage equilibrium with their 
respective functional mutations. 
Pattern of Linkage Disequilibrium and Haplotype blocks at rs334 in African 
populations 
We have computed the haplotype blocks, block of linkage disequilibrium and the haplotype 
frequency in a 100 kb region around HBB, targeting the variant rs334 in that region which is 
well known of alleles A/T, encoding the Hb A form of (adult) hemoglobin and the sickling 
form of hemoglobin, Hb S, respectively. The results in Figures 4 and 5 show differing pattern 
of LD between Western and Eastern African Bantu.  
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Discussion 
The present data aims to confirm the evolutionary dynamics of various African genomes 
through selective pressure of malaria, prompt the persecution of the dissociation between 
genetics and anthropology and culture, and lastly contribute to understanding the origin and 
evolution of the HbS mutation as well as migration of southern African populations within 
and out of Africa. 
South-ward frequency decrease of malaria-associated SNPs in SSA  
The high frequency of the homozygous HbAA genotype in the study cohorts was expected as 
the participants were neither confirmed nor suspected SCD patients, and were all from 
Southern African population where malaria has low prevalence or is inexistent. As a result of 
the known partial resistance conferred by the HbS allele to malaria Plasmodium falciparum 
infection, the HbS allele is highly prevalent in malaria endemic regions particularly around 
the tropical equatorial belt in sub-Saharan Africa [3,4]. Therefore, this study investigated the 
effect of the low environmental pressure from malaria in Malawi, Zimbabwe and, to a greater 
extent, South Africa, on the frequency of three genetic backgrounds associated with SCD; 
namely the HbS allele, conservation of the five loci in the β-globin gene cluster that confer 
the SCD haplotype and lastly, variants associated with resistance to malaria [6]. To confirm 
the accepted notion of low HbS allele frequency in populations outside malaria-endemic 
regions (figure S1; Table 3), was the frequency gradient of the HbS allele in the Zimbabwe 
(12%) and Malawi (6%) cohorts compared to the South Africa cohort (0%), in the present 
study.  
In addition to the HbS mutation, whose association with malaria is extensively studied, the 
second objective was to investigate and validate three variants identified in a genome-wide 
association study (GWAS) as LD-tags of known functional mutations associated with malaria 
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resistance; rs8176703 (9q34.2; ABO locus), rs2334880 (16q22.2; MARVELD3 locus) and 
rs372091 (11p15.5; HBB locus) [6]. LD-tag SNPs were investigated over the known 
functional mutations as the populations studied were largely unexposed to malaria and devoid 
of the HbS mutation, a variant that has been positively selected in regions of high malaria 
endemnicity. Furthermore, given that these variants were proposed as LD-tag SNPs, they 
could be genotyped as proxy for the functional mutations. In this study, the MAFs of these 
three variants were determined and compared to those in Gambia, Nigeria and Kenya (1000 
Genomes data) and showed a decreasing gradient of MAF for two of the loci (rs8176703 and 
rs372091), which are tags for the functional mutations at ABO and β-globin, were highest 
within the equatorial malaria belt and lowest in all three study cohorts. However, there was 
no such gradient for the rs2334880 variant, with similar MAF across all six populations, 
therefore not specifically linked with malaria endemicity, which is concomitant with results 
from an independent study where this variant failed to replicate its association [2,3]. This 
trend suggests that although all three variants were highlighted as LD-tags for known 
functional mutations and have been associated with resistance to severe malaria, only two 
(rs8176703 and rs372091) are largely restricted to the equatorial malaria belt and possibly 
confer greater resistance to severe malaria as compared to the less equator-bound variant 
(rs2334880). The lack of LD between these tag SNPs and their respective functional 
mutations in other African populations is possibly because LD may differ between 
populations and therefore may have affected the power of these tag SNPs in association with 
the causal mutations and thus severe malaria. 
It is however noteworthy that the ATP2B4 [1] and FREM3 [2] loci were not genotyped in 
this study due to a limitation of resources and challenges with assay optimization. 
Furthermore, several other loci have been associated with malaria-resistance and were not 
included in the present study. Future work should consider determining the frequency and 
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effect of not only LD-tag SNPs but include functional mutations at several loci to improve 
our understanding of the malaria-resistance genotype profile of Southern African populations, 
largely unexposed to malaria. 
Haplotype blocks at rs334 in African populations 
The differing pattern of LD between Western and Eastern African Bantu can be explained by 
the fact that Eastern African Bantu undergone admixture due to the various contacts with sea 
bone migrants in their past history [37]. However, the result in Suppl. Table S4 suggests 
similar pattern of beta globin haplotype diversity at the variant rs334 across all the five 
African populations (Western and Eastern Bantu). This illustrates the importance of 
investigating the origin and age of the HbS mutation following the past southern Bantu 
migration, admixture and population sub-structure. 
Implications for genetics, anthropology and culture 
Taken in sum; the frequency of HbS mutation and the decreasing MAF gradient of the 
targeted SNPs from the tropical malaria endemic regions towards the South suggest that the 
specific combination and pattern of multiple malaria resistant variants could allow the broad 
determination of the regional origins of an individual as Western, Central or Southern 
African. Although the vast majority of differentiated loci among Bantu populations are no 
more differentiated than would be expected from population drift, the modest data presented 
here, supports the proposed notion of dissociation between genetic background and ethno-
linguistic attributes and classifications as demonstrated with populations that can loosely be 
defined as “Bantu” having disparate genetic backgrounds, particularly in loci that may be 
under positive selection due to the fitness benefit they confer, in this case resistance to severe 
malaria.  
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Within the context of Africa; that could have major implications in future research and 
practice on precision medicine; as gene-based treatment could be population specific, but not 
based on the ethno-linguistic classification, rather on target genomic variants. Despite genetic 
diversity, the three populations studied here can be loosely labelled as “Bantu” or “Bantu-
speaking”, as is an individual from the Ewondo tribe in Cameroon, and rightly so. This is 
primarily due to several indicators of a common language root; for instance (i) “muntu”  for 
“human” is the same in Xhosa (South African Bantu language) and Ewondo, (ii) the Ewondo 
and Xhosa tribes also share similar cultural and rite of passage practices such as the ritual of 
male circumcision and the burial of the umbilical cord or placenta of new-born as part of 
welcoming the new-born and introduction to the ancestors; (iii) and religious beliefs such as 
the “cult of ancestry” and reincarnation are common amongst Bantu-speakers. Despite these 
and many other shared cultural, linguistic and anthropological attributes, the present data 
further supports the notion that Bantu-speakers from Central and West Africa are no more 
genetically similar to those in Southern Africa, as previously illustrated with differential 
prevalence of HIV resistant genes amongst SSA populations [38, 39] and now with malaria 
associated variants. Given the vast genetic diversity within the continent and amongst any 
two SSA populations, the present research further emphasizes the need to redefine the 
classifications of various groups in Africa by region-defined genomic attributes as this 
approach could better serve the progress towards gene-based therapies, genetic profiling and 
diagnoses specific to targeted population groups based on common genetic tag loci, as 
opposed to the classical ethno-linguistic population classification approach. The present data 
among Bantu-speakers from Central and West Africa and Southern Africa, genetic 
relatedness at malaria-associated loci may be very different from genome-wide genetic 
relatedness, since the latter depends only on demographic processes whereas the former may 
additionally be driven by selection of specific haplotypes. Therefore, emphasizing the point 
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that the loose labelling of some African populations as “Bantu-speakers” and more so 
assuming genetic relatedness, is an inappropriate presumption, with particularly when this 
notion is stretched within the African continent and even beyond for individuals not of 
African descent. 
SCD β-globin haplotype: insights into the migration of Southern African Blacks 
The third question of this study was to investigate the degree of conservation of the five SCD 
haplotype-conferring loci in populations both largely unaffected by the disease and void of 
the environmental pressure of malaria. The most apparent, although not surprising result, was 
the high frequency of the Atypical haplotype in all the study cohorts leading to the hypothesis 
that in such populations, the five loci of the β-globin gene cluster may be under less 
evolutionary pressure to remain conserved. This could be due to several reasons; there is no 
apparent clinical benefit to retaining an otherwise unfavourable haplotype in the absence of 
malaria and potentially its strongest environmental positive selector, malaria. Furthermore, 
this could be as a result of genetic drift and recombination at the β-globin gene cluster. The 
next frequent haplotype in all study cohorts was the Benin form, suggesting that the Southern 
African Bantu-speakers migrated southwards post-occurrence of the HbS mutation and is 
consistent with their West African origins [17]. The data showing the classification of the 
HbS haplotypes in these Southern African populations and the degree of similarity among the 
haplotype distributions in South Africa, Zimbabwe and Malawi is novel. This is because 
these populations have historically been largely unaffected by malaria and suggest some 
insight into the evolutionary dynamics at the β-globin loci with regards to recombination of 
the classical HbS haplotypes and expansion of the Atypical form in malaria-devoid regions in 
Africa. 
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This result also confirms to anthropological data detailing the most significant events of the 
geographic expansion of the Bantu Niger-Kordofanian-speakers out of Cameroon and Nigeria 
[18,40]. It was previously hypothesised that the migration path was first through rainforest 
equatorial Africa and later into Eastern and Southern Africa. This is supported by the 
widespread distribution of Bantu-related linguistic groups and the presence of Niger-
Kordofanian genetic ancestry in many African populations.  However, the present result with 
a prevalent Benin haplotype and very low Bantu haplotype that is characteristic of SCD 
patients from Central and West Africa [17] could be due to a myriads of possible reasons that 
remain to be investigated: (i) the migration through East Africa of modern Southern African 
Bantu-speaking populations was transient with limited admixture with populations found 
locally in East Africa; (ii) some Bantu haplotypes may have been lost during recombination 
events at the β-globin gene locus potentially leading to the expansion of the highly prevalent 
Atypical form; (iii) during the early migration events through the equatorial rainforests, the 
migrating populations from Central, East and West Africa encountered largely unoccupied 
regions, therefore expanding the Benin, Cameroon and Senegal haplotypes; (iv) the Bantu 
haplotype could be a recent haplotype of SCD, only recently expanding in Central Africa and 
subsequently in some parts of North and South America through slave trade; and lastly (v) 
the continuous socio-economically motivated migration from Central, East and West Africa 
into Southern African countries could have led to the relatively higher frequencies of the 
Benin, Cameroon and Senegal haplotypes although unlikely as this has become a significant 
migration phenomenon only in the past two to three decades. Beyond the concept of the 
dissociation between genetic background and ethno-linguistic attributes and classifications, 
the present data also complements previous studies on migrations of Southern African 
populations from West and/or Central Africa [41]. 
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Conclusion 
This data has alluded to the frequency and distribution of (likely) positively selected 
polymorphisms at two novel resistance loci for severe malaria in three SCD-unaffected sub-
Saharan African populations to probe the possibility of a frequency gradient of such 
polymorphisms in a decreasing fashion away from the equatorial malaria belt. The data is 
indicative of the importance of the inclusion of Southern African populations when studying 
the age and origin of the HbS mutation, whose precise origin remains to be fully elucidated 
[17]. Future studies should include Khoi and San populations, some of which may not have 
been exposed to malaria. Furthermore, these data also provide genetic evidence indicating the 
independent and continuous waves of migration of West and East African Bantu-speaking 
groups into Southern Africa. Beyond the modest data presented here, the high proportion of 
atypical haplotypes in Southern African populations, together with the data from diverse 
populations on the African continents could suggest various level of  genetic diversification 
of African populations, whether attributable to recent and/or more ancient admixture, that did 
not probably result from a single North to South migration path nor a specific era, but rather 
through several independent and associated, multi-directional migration events.  It can be 
anticipated that modern day continuous immigration, will further reinforce the African 
genomic diversity, by allowing the redistribution of gene pools previously restricted to 
specific geographical location, such as malaria-related mutations, across the continent.  
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Table 1. Frequencies of the HbAA; β-globin haplotypes and malaria-related SNPs 
  South Africa 
N (%) 
Zimbabwe 
N (%) 
Malawi 
N (%) 
β-globin mutation HbAA 50 (100) 44 (88.0) 58 (93.5) 
HbAS 0 (0.0) 6 (12.0) 4 (6.5) 
β-globin haplotypes# Atypical 53 (68.0) 42 (65.7) 36 (51.4) 
Benin 13 (16.6) 8 (12.5) 19 (27.1) 
Bantu 4 (5.1) 2 (3.1) 4 (5.7) 
Cameroon 5 (6.4) 10 (15.6) 5 (7.1) 
Senegal 3 (3.9) 2 (3.1) 6 (8.7) 
β-globin haplotype 
recombinants* 
Atypical/Atypical 16 (41.0) 12 (38.0) 8 (23.5) 
Benin/Atypical 13 (33.3) 8 (25.0) 14 (41.2) 
Bantu/Atypical 4 (10.3) 2 (6.3) 2 (5.9) 
Senegal/Atypical 2 (5.1) 1 (3.1) 4 (11.8) 
rs8176703 GG 35 (0.97) 48 (0.96) 48 (0.98) 
AG 1 (0.03) 2 (0.04) 1 (0.02) 
AA 0 (0.0) 0 (0.0) 0 (0.0) 
rs372091 GG 34 (0.94 42 (0.93) 48 (0.98) 
AG 1 (0.03) 3 (0.07) 1 (0.02) 
AA 1 (0.03) 0 (0.0) 0 (0.0) 
rs2334880 CC 7 (0.23) 10 (0.21) 14 (0.29) 
CT 19 (0.63) 23 (0.48) 24 (0.50) 
TT 4 (0.13) 15 (0.31) 10 (0.21) 
* β-globin haplotype recombinants: the pair of haplotypes inherited in 2 separate 
chromosomes in an individual. # β-globin haplotype frequencies are given as the number of 
chromosomes presenting with a specific haplotype 
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Table 2. Minor allele frequencies of study cohorts and several populations from the 
1000Genomes Project 
 
* study populations from current study. Other data was sourced from the 1000G project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Variants 
Region rs8176703 rs372091 rs2334880 
South Africa* 0,013 0,023 0,472 
Malawi* 0,01 0,01 0,457 
Zimbabwe* 0,02 0,033 0,552 
African 0.398 0.068 0.398 
African Caribbean (Barbados) 0.359 0.047 0.359 
Southwest US (African 
American) 
0.311 0.041 0.311 
Nigeria (Esan) 0.399 0.141 0.399 
Kenya (Luhya) 0.470 0.071 0.470 
Kenya (Yoruba) 0.407 0.125 0.407 
Mende (Sierra Leone) 0.400 0.024 0.400 
Gambia (Mandinka) 0.403 0.013 0.403 
America 0.102 0.001 0.102 
Europe 0.160 1.000 0.160 
East Asia 0.009 1.000 0.009 
South Asia 0.019 1.000 0.019 
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Table 3. HbS allele frequencies by country in Africa 
Country Study years Population Age group HbS allele 
frequency 
Reference 
Angola 1950-2010 18,994 All ages 0.137 [14] 
Benin 1950-2010 9,219 All ages 0.159 [14] 
Botswana 1950-2010 1,977 All ages 0.003 [14] 
Burkina Faso 1950-2010 
1997-1999 
 
16,250 
 
9201 
All ages 
New-borns 
Median 9 
years 
0.056 
0.0025 
0.0013 
[14, 30, 31] 
Burundi 1950-2010 8,519 All ages 0.040 [14] 
Cameroon 1950-2010 19,957 All ages 0.120 [14] 
Cape Verde 1950-2010 513 All ages 0.026 [14] 
Central African 
Republic 
1950-2010 4,506 All ages 0.077 [14] 
Chad 1950-2010 11,509 All ages 0.051 [14] 
Comoros 1950-2010 691 All ages 0.018 [14] 
Congo 1950-2010 3,760 All ages 0.145 [14] 
Democratic Republic 
of the Congo 
1950-2010 67,829 All ages 0.165 [14] 
Djibouti 1950-2010 879 All ages 0.001 [14] 
Equatorial Guinea 1950-2010 693 All ages 0.192 [14] 
Eritrea 1950-2010 5,204 All ages 0.003 [14] 
Ethiopia 1950-2010 84,996 All ages 0.003 [14] 
Gabon 1950-2010 1,501 All ages 0.280 [14] 
Gambia 1950-2010 
2003 
1,751 
 
536 
All ages 
New-borns 
10-72 
months 
0.075 
0.012 
0.003 
[14, 29] 
Ghana 1950-2010 
2002 
24,339 
1266 
842 
All ages 
0-4 years 
5-10 years 
0.087 
0.0039 
0.0012 
[14] 
Guinea 1950-2010 10,324 All ages 0.168 [14] 
Guinea‐Bissau 1950-2010 1,647 All ages 0.041 [14] 
Kenya 
 
1950-2010 
1998-1999 
 
1998-2008 
40,835 
 
2,774 
782 
282 
415 
3,677 
All ages 
New-borns 
0-3 years 
0-11 
months 
12-23 
months 
3-5 years 
6-13 years 
0.038 
0.016 
0.006 
0.01 
0.0035 
0.0024 
0.0009 
[14, 27, 28] 
 
Lesotho 1950-2010 2,064 All ages 0.001 [14] 
Liberia 1950-2010 4,102 All ages 0.046 [14] 
Madagascar 1950-2010 20,146 All ages 0.061 [14] 
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Malawi 1950-2010 15,690 All ages 0.033 [14] 
Mali 1950-2010 13,362 All ages 0.057 [14] 
Mauritania 1950-2010 3,359 All ages 0.050 [14] 
Mozambique 1950-2010 23,418 All ages 0.027 [14] 
Namibia 1950-2010 2,212 All ages 0.010 [14] 
Niger 1950-2010 15,885 All ages 0.080 [14] 
Nigeria 1950-2010 
1970-1972 
158,255 
534 
259 
637 
All ages 
New-borns 
1-4 years 
5-14 years 
0.171 
0.021 
0.004 
0.002 
 
[14, 26] 
Rwanda 1950-2010 10,277 All ages 0.023 [14] 
Sao Tome and 
Principe 
1950-2010 165 All ages 0.094 [14] 
Senegal 
 
 
Senegal (rural 
kegoudou) 
1950-2010 
2002-2003 
 
12,866 
 
432 
All ages 
New-borns 
2-10 years 
Newborn 
0.067 
0.005 
None 
0.01 
[14, 24, 25] 
Sierra Leone 1950-2010 5,837 All ages 0.164 [14] 
South Africa 1950-2010 50,523 All ages 0.003 [14] 
Sudan 1950-2010 43,182 All ages 0.043 [14] 
Swaziland 1950-2010 1,195 All ages 0.006 [14] 
Tanzania, United 
Republic of 
1950-2010 45,028 All ages 0.074 [14] 
Uganda 1950-2010 33,798 All ages 0.082 [14] 
Zambia 1950-2010 
1967-1971 
13,254 
2,845 
2,200 
2,306 
All ages 
0-11 
months 
1-3 years 
3-12 years 
0.112 
0.013 
0.009 
0.005 
[14, 23] 
Zimbabwe 1950-2010 12,645 All ages 0.021 [14] 
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Figure 1. Distribution of SCD haplotypes amongst three southern African SCD-
unaffected populations (South Africa, Zimbabwe and Malawi) and SCD populations 
across the continent (with adaptation of previously reported from [17])
 
Figure 2. Minor frequencies of malaria-restriction SNPs amongst southern African 
populations and three populations from the 1000Genomes Project within the malaria-
endemic central Africa. A: rs8176703; B: rs372091; C: rs2334880
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Figure 4. Haplotype bifurcation diagrams. 
The root of each diagram is a core haplotype at the variant rs333, identified by a white 
circle. The diagram is bi-directional, portraying both proximal and distal LD for 
derived (each top) and ancestral allele (each bottom). The breakdown of LD on the core 
haplotype background is portrayed at progressively longer distances, depending on 
whether allele is present or not. The thickness of the lines corresponds to the number of 
samples with the indicated long-distance haplotype. (A) ESN (B) YRI (C) GWD (D) 
MSL and (E) LWK. 
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Figure 5. Pattern of Linkage Disequilibrium. 
A linkage disequilibrium (LD) block of polymorphisms in a tight region around rs333. 
(A) ESN (B) YRI (C) GWD (D) MSL and (E) LWK. 
 
Supplementary Table 1 
Restriction endonuclease cutting patterns that represent each of the five β-globin gene 
haplotypes 
 ENZYMES 
 
HAPLOTYPES XmnI 
(5′Gϒ) 
HindIII 
(Gϒ) 
HindII (Aϒ) HincII (3′ᵠβ) HinfI (5′β) 
ARAB-INDIAN + + - + - 
BANTU/CAR - + - - - 
BENIN - - - + - 
CAMEROON - + + + + 
SENEGAL + + - +  
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Supplementary Table 2 
Restriction endonuclease cutting patterns that represent each of the five most common 
Atypical β-globin gene haplotypes 
   ENZYMES   
ATYPICAL 
TYPES 
XmnI 
(5′Gϒ) 
HindIII 
(Gϒ) 
HindII (Aϒ) HincII (3′ᵠβ) HinfI (5′β) 
I - - - + + 
II - + - - + 
III - + - + + 
IV - - - - + 
V - + - + - 
 
Supplementary Table 3 
Frequency of various forms of Atypical β-globin haplotypes in Southern African populations 
 HAPLOTYPE FREQUENCY BY POPULATION N (%) 
 
ATYPICAL TYPES South Africa Zimbabwe Malawi 
I 17 (32.1) 16 (38.1) 14 (38.9) 
II 13 (24.5) 10 (23.8) 9 (25.0) 
III 4 (7.5) 5 (11.9) 6 (16.7) 
IV 4 (7.5) 2 (4.8) 3 (8.3) 
V 4 (7.5) 3 (7.1) 2 (5.6) 
 
 
Supplementary Figure 1 
HbS allele frequency in Africa (adapted from [14])
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Chapter 4. Academic Discussion and Conclusions 
 
Sickle Cell Disease (SCD) is the oldest monogenic disease, first reported in 1910 
(Herrick, 2001) but since then grew into a worldwide health problem with a disease 
burden comparable to that of communicable diseases and major global diseases such 
as diabetes and hypertension (Weatherall, 2010). The genetic basis for the disease is a 
single nucleotide substitution (T>A) in the 17th position of the β-globin gene on 
chromosome 11p (Bunn, 1997), leading to a glutamine to valine peptide change thereby 
creating a hydrophobic motif in the deoxygenated sickle hemoglobin (HbS) (Brittenham, 
Schechter & Noguchi, 1985). This results in the polymerization and growth of the β1 and 
β2 chains of the HbS molecules as they crystalize within the erythrocytes and alter the 
intracellular architecture, cellular conformation and oxygen-carrying capacity of the 
cells. This process is the pathophysiological basis of the disease and all associated 
symptoms as the aberrantly-shaped sickle cells cause occlusion of micro-vessels, 
resulting in denaturation of hemoglobin, decreased oxygen delivery to tissues, regional 
hypoxia and increased HbS polymerization and erythrocyte rigidity (Gladwin et al., 
2012). Vaso-occlusive crises (VOC) is therefore a hallmark phenotype of the disease, 
including acute chest syndrome (ACS) and cerebrovascular complications such as 
silent and overt stroke. 
Sickle cell anemia (SCA) is the most common and severe form of SCD, accounting for 
approximately 70% of the disease cases in African populations (Serjeant et al., 2005). 
The burden of disease in sub-Saharan Africa well exceeds that of any other region in 
the world sitting at 80%, with an estimated 305 800 annual new affected births (Modell 
& Darlison, 2008). Although the disease is most rampant in sub-Saharan Africa, it is not 
to the exclusion of North America and Europe with 2 600 and 1 300 annual new affected 
births. The high incidence of SCA in sub-Saharan Africa is largely ascribed to the 
positive selection conferred by malaria as a result of the geographical co-occurrence of 
SCD and malaria (Flint et al., 1998; Williams et al., 2005). It is accepted that the primary 
reason for this amplification of the HbS allele frequency in malaria endemic regions is 
the partial-carrier resistance to Plasmodium falciparum malaria, even though the precise 
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mechanisms of resistance are not yet fully elucidated. Similarly, other genetic variants 
associated with SCA such as HbC and β-thalassemia have undergone similar selection.  
The disease exists on a variable genetic haplotype background of five independent, 
region-specific disease haplotypes based on the permutation of five SNPs in the β-
globin gene cluster: Benin, Bantu/Central African Republic (CAR), Senegal, Cameroon 
and the Indian-Arab haplotypes (Pagnier et al., 1984; Labie et al., 1985; Elion et al., 
1992). These haplotypes are said to be multi-centric origins of the HbS gene and have 
also been associated with disease severity and clinical course of patients (Steinberg, 
2009; Alsultan et al., 2012). Early child mortality is a common feature of SCD with 
approximately 10% of affected children suffering from cerebrovascular accidents 
(Ohene-Frempong et al., 1998). One other frequent complication that is associated with 
vaso-occlusion is pulmonary hypertension (Collins & Orringer, 1982). Early diagnosis 
has been shown to decrease disease-related mortalities (Gaston et al., 1986; Vichinsky, 
1991) and significantly improve survival rates in the Caribbean (Lee et al., 1995), United 
States (Quinn et al., 2004), the United Kingdom (Telfer et al., 2007) as well as in Africa 
(Rahimy et al., 2009).  
The key to improved clinical management and therapeutic interventions lies in a 
comprehensive understanding of the genetic heterogeneity of the disease, the 
molecular processes involved in drug-induced disease amelioration and a firm 
knowledge base of the effects of the vast genetic variation in African patients on 
predispositions to symptoms, drug-metabolism and quantitative trait loci such as HbF. 
To our knowledge, this thesis is the first to collectively address all these 3 key aspects 
of SCD in African patients and unequivocally demonstrate a functional model of the 
miR-26b/MYB post-transcriptional signalling pathway for the induction of HbF by HU 
treatment. The significance of this work will be discussed within the context of the 
currently available data on the genetic modifiers of HbF and mechanisms of HU-induced 
HbF expression in SCD in the following parts; (i) genetics of HbF; (ii) alternative 
treatment approaches for SCD and (iii) SCD in Southern Africa. 
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4.1. Genetics of fetal hemoglobin 
 
Persistent fetal hemoglobin (HbF) is a heritable quantitative trait locus (QTL) and has 
been shown to ameliorate symptoms of SCA in adult patients. Research efforts have 
thus been directed towards building a comprehensive understanding of the genomic 
modifiers of HbF in the search for therapeutically amenable polymorphisms with 
significant bearing on this QTL. Three principal loci have been elucidated; BCL11A, the 
intergenic region between HBS1L and MYB (HMIP1/2) and the β-globin haplotype. 
Together, these have been shown to account for 10 – 20% variance in HbF levels 
(Menzel et al., 2007; Creary et al., 2009; Thein et al., 2009); amongst various SCD 
patient populations including the USA and Brazil (Lettre et al., 2008), Tanzania (Makani 
et al., 2011) and Cameroon (Wonkam et al., 2014). 
In this study, we investigated additional HbF-promoting loci with the intention of 
identifying key regulatory loci of persistence of HbF in adult SCD patients of African 
descent. The envisaged implications of this approach was to (i) prompt a revision of the 
central dogma; multiple independent origins of β-globin haplotypes, and interrogation of 
the geographic nomenclature of haplotypes; (ii) elucidate polymorphisms that are critical 
in HbF production in an African population and (iii) highlight other variants that may be 
of significance in European or African American populations but bear neither genomic 
nor clinical significance in our African study cohort.  
This intention was made clear with the work on β-globin haplotypes in a 2-part study of 
a cohort of SCD patients from Cameroon in which the β-globin haplotypes of the 
patients were investigated as well as an extensive review of the literature for the global 
distribution of β-globin haplotypes. After the evaluation of 1082 chromosomes, no 
significant association between haplotypes and clinical events, anthropometric 
measures, hematological indices or HbF levels. However, we reported what appeared 
to be peculiar at first sight; a 74% (n = 799) frequency of the Benin haplotype in the 
cohort and only 19% (n = 207) with the Cameroon haplotype background (Bitoungui et 
al., 2015). This was usual as the expectation would be the predominance of the 
Cameroon haplotype in SCD patients from Cameroon. Equally unexpected was the 
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relatively high frequency of the Cameroon haplotype in Sudan compared to Cameroon 
(Elderdery et al., 2012) coupled with the wide representation of all African β-globin 
haplotypes in Sudan. These observations, however unusual, could be attributed to the 
geographic nomenclature of haplotypes (naming in accordance with the region of the 
first observation). This system is flawed in that it fails to reflect the accurate locale of 
origin of the haplotypes. Furthermore, the current central dogma, that is the hypothesis 
of multiple independent origins, also raises the question of how several identical 
mutations could have occurred in a short period of time in Africa after the appearance of 
malaria, despite the low mutation rate of nuclear DNA (Currat et al., 2002). Therefore, 
taken in sum, it is perhaps provocative and ambitious, but not unreasonable, to 
hypothesize that there could be a single origin of the HbS mutation in the region of East 
Africa/Sudan, with additional haplotypes generated by diverse structural mechanisms 
such as gene conversion, expanded and spread to the rest of the continent through 
traditional migratory patterns. This assertion may be supported by recent phylogenetic 
analysis of African ancestry pointing to the Nubian tribe of Sudan as the 2 most 
ancestral mitochondrial sequences (Elhassan et al., 2014). The expansion out of Africa 
and rise of the Indian-Arab haplotype could possibly be a product of human migration 
out of Africa through the Arab peninsula from Dhofar Oman (Rose et al., 2011). To the 
best of our knowledge, the present study represents the largest study of β-globin 
haplotypes in a single African country, and is the most comprehensive review of the 
global distribution of β-globin SCD haplotypes thus far.  
HbF is the most significant biological modifier of SCD and influenced by cis- and trans-
acting genomic variations. In a recent study, in this group of Cameroonian SCD 
patients, robust genetic associations between HbF levels and BCL11A and HBS1L-
MYB intergenic locus were demonstrated (Wonkam et al., 2014). This was congruous 
with previous reports in African American, Afro-Brazilian (Lettre et al., 2008) and 
Tanzanian SCD patients (Makani et al., 2011). In this study, we showed significance 
association between variants at the BCL11A enhancer (rs1427407 and rs7606173) and 
HbF levels in Cameroonian patients (Pule et al., 2015). These variants explained 8% 
and 6.2% variance in HbF, respectively, and confirmed a stronger effect of these 
extragenic polymorphisms on HbF levels compared to intragenic variants. The present 
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article is the first report on the importance of the SNPs rs1427407 and rs7606173 
among West African SCD patients and the results are consistent with those reported 
among African Americans (Bauer et al., 2013) and patients from Saudi Arabia and India 
(Sebastiani et al., 2015) and Tanzania for rs1427407 (Mtatiro et al., 2015). What is 
probably of greater significance beyond the associations are the implications on future 
therapeutic interventions. This is because the major clinical caution of exploring 
decreased expression of BCL11A as a route toward promoting HbF production comes 
from the deleterious functional implications of altered expression levels of this 
developmental-stage specific transcription factor as reduced BCL11A levels display 
neurodevelopmental abnormalities including intellectual disabilities and brain (Peter et 
al., 2014; Balci et al., 2015; Funnell et al., 2015). This thus amplifies the significance of 
the genetic variation at the BCL11A erythroid-specific enhancer and confirmed effect on 
HbF levels. The on-going pre-clinical trials for hemoglobinopathies (SCD and β-
thalassemia) at Sangamo BioSciences 
(www.sangamo.com/pipeline/hemoglobinopathies) is the exact embodiment of the 
significance of these results. The therapeutic intervention utilises genomic editing of 
autologous hematopoietic stem cells to introduce favourable variants at the BCL11A 
enhancer and re-transplantation as a curative approach. The present study has thus 
contributed to the knowledge base of the effect of the erythroid-specific enhancer on 
HbF and beyond that, demonstrated the applicability of clinical trials such as this 
(discussed above) for African SCD patients. 
However, not all polymorphisms have clinical significance across many populations. 
Recently a genome-wide association study (GWAS) of HbF in Tanzania revealed 8 
novel loci with genome wide significance in SCA patients (HbS/β0) (Mtatiro et al., 2014) 
and whole genome sequencing of the general population in Sardinia provided further 
insight into regulation of HbF and several novel variants (Danjou et al., 2015). Similarly, 
4 variants (rs2310991; rs4282891; rs76901216 and rs76901220) in the promoter 
sequence of the HU-inducible small guanosine triphosphate (GTP)-binding protein and 
secretion-associated and RAS-related (SAR1a) protein have been associated with HbF 
(both baseline and HU-induced) in African American patients (Kumkhaek et al., 2008). 
We replicated all 3 studies in patients from Cameroon (n = 484; 484 and 453, 
138
 
 
 
respectively) and observed no association between any of the variants and clinical 
events, anthropometric measures, hematological indices or HbF levels; and 6 of a total 
of 21 loci were monomorphic in our cohort. In fact, the Tanzanian GWAS failed to show 
association in a British cohort from the same study (Mtatiro et al., 2014) due to the 
different ancestries between the East Africa (Tanzania) and the largely Caribbean/West 
African descents (United Kingdom), citing the considerable heterogeneity of both the 
genetic and environmental factors affecting the manifestation of SCD within African 
populations (Wonkam et al., 2014), even more so between populations in different 
continental settings. It is therefore likely that, the differences in ancestry between 
Tanzanian patients (majority of which carry the Bantu/CAR haplotype) and Sardinian 
populations (mostly if not all HbAA and without the selection pressure of malaria) 
compared to Cameroonian SCD patients (largely Benin and Cameroon haplotypes), 
could explain the incongruence in association results amongst the studies. HbF 
regulation is a highly heterogeneous system and subject to regulatory and signalling 
pathways that develop differently across different populations (Solovieff et al., 2010). 
Therefore, replication of association studies across different populations, particularly of 
varied genetic backgrounds and environmental settings, is imperative to understanding 
the complex processes of HbF production and genetic polymorphisms predisposing 
patients to persistence of adult HbF, more so in sub-Saharan Africa where the burden of 
disease is highest. 
 
4.2. Alternative treatment approaches to Sickle Cell Disease 
 
Currently, HU is the only pharmacologic drug for treatment of SCD patients. HU 
received FDA approval for treatment of both adults and children with SCD in 1998 and 
by the European Medicines agency in 2007. In addition, the National Institutes of Health 
Officer of Medical Applications of Research and the Agency of Healthcare Research 
and Quality both declared HU as an effective drug treatment for adults and children with 
SCD (Brawley et al., 2008; Lanzkron et al., 2008; Strouse et al., 2008). Since its first 
clinical application for hemoglobinopathies in 1984, HU has demonstrated swift and 
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vivid increases in HbF levels and low bone marrow toxicity (Platt et al., 1984a). Several 
clinical trials since have further elucidated the clinical efficacy of HU in decreasing the 
frequency of painful episodes, acute chest syndrome (ACS), hospitalization and 
transfusion (Charache et al., 1995), increase in survival rates and life expectancy 
(Steinberg et al., 2003; Voskaridou et al., 2010), protection against cerebrovascular 
disease (Zimmerman et al., 2007), long-term drug safety, capacity to prevent organ 
damage and reduced morbidity and mortality in school-age children (Kinney et al., 
1999), toddlers (Hankins et al., 2005; Thornburg et al., 2009) and infants (Wang & 
Thompson, 2010). Despite this evidence, some potential short and long-term potential 
adverse effects such as male impotence (Berthaut et al., 2008; DeBaun, 2014; Smith-
Whitley, 2014), susceptibility to infections (Shemisa et al., 2014; Amoako et al., 2014; 
Hirst et al., 2012; Owusu et al., 2015), potential teratogenic effect (Charache et al., 
1995; Flanagan et al., 2010) and cutaneous adverse reactions (Chaine et al., 2001) 
have also been associated with HU. Therefore, the fear of such side effects is 
concerning to some health professionals (Brandow et al., 2010; Oyeku et al., 2013), 
parents and patients (Zumberg et al., 2005; Lanzkron et al., 2008; Haywood et al., 
2009; Thornburg et al., 2010; Strouse & Heeney, 2012) and constitutes the biggest 
potential barriers to compliance in some settings (Hampton, 2008; Lebensburger et al., 
2013). As a consequence, HU remains underutilized (Zumberg et al., 2005; Lanzkron et 
al., 2008), despite the studies that have reported on the overall drug safety (Steinberg et 
al., 2003) and limited evidence regarding potential HU-induced leukemogenic (Segal et 
al., 2008) or teratogenic effects (Ballas et al., 2012).  
Despite this plethora of knowledge on HU and its clinical applications, there remains 
several questions on its molecular mechanisms of HbF induction. To our knowledge, as 
part of this thesis, we have provided the first comprehensive systematic review of the 
known mechanisms of HU-induced HbF production in SCD, citing several key signalling 
pathways (Pule et al., 2015) and elucidated a novel HU-induced miRNA-mediated post-
transcriptional pathway for HbF expression (Pule et al., 2016). Furthermore, to define a 
perspective on the overall management and treatment of SCD in sub-Saharan Africa, 
we provided a commentary on the availability of various treatment approaches for SCD 
in Africa compared to the West, proposing a collaborative cross-continent effort from 
140
 
 
 
government, private sector and research institutes towards improving access to good 
medical care for patients (Pule & Wonkam, 2014). 
To fully understand the progress to date on known mechanisms of HU induction of HbF, 
we began with an extensive and comprehensive review, consulting a total of 562 
articles. After careful scrutiny and strict selection criteria, 361 abstracts were reviewed 
for further elimination and from this a total of 129 articles were eventually included in the 
review. This formed the basis of the current knowledge on HU. It is noteworthy that 
although we recognise other disease modulating effects of HU outside of HbF induction 
such as stress hematopoiesis, endothelial nitric oxide release or reduction of leukocyte 
counts, the focus of the review was particular to HbF production including genomic 
polymorphisms that predispose hereditary persistence of HbF in adulthood. Therefore, 3 
signalling levels were reported; (i) epigenetic and transcriptional events, eluding to DNA 
remodelling and methylation pathways; (ii) signal transduction pathways, including 
Giα/JNK/Jun, cGMP/cAMP and a myriad of erythroid-related transcriptional factors, and 
(iii) post-transcriptional and translational regulation through miRNAs. Key epigenetic 
and transcriptional events regulating response to HU treatment included DNA 
remodelling events through the BCLL1A, SOX-6 and Mi-2/nucleosome remodelling and 
deacetylase complex and differential methylation at regulatory sites like the 5’ locus 
control regions and 3’ hypersensitivity sites flanking the globin genes in the β-globin 
cluster. Such epigenetic modifications have proven to play a significant role in the fetal 
switch (γ- to β-globin) and thus may hold some insight to future therapeutic 
interventions. Several signal transduction pathways such as the Giα/JNK/Jun, 
cGMP/cAMP, MAPKs and stress signals like superoxide and hydroxyl radicals were 
also implicated in HU-induced HbF production. The intertwinement of these pathways 
were collated into a signalling network of various HU-activated signal transduction 
pathways for HbF production (Pule et al., 2015). This network also included miRNAs as 
a pivotal post-transcriptional and translation regulatory tier in HbF production, 
erythropoiesis and erythrocyte physiology. Further investigation of translation-altering 
agents and the global disease-specific miRNA profiles of SCD patients in understudied 
and highly heterogeneous populations, such as in Africa, promises to yield mechanistic 
insight into the disease phenotype and differential response to HU treatment. 
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In line with this very hypothesis, we then investigated the potential post-transcriptional 
regulation of HbF through miRNAs and elucidated a novel HU-induced miR-26b/MYB-
BCL11A pathway for γ-globin expression using erythroid cells derived from umbilical 
cord blood CD34+ hematopoietic stem cells (HSCs) and K562 cells (Pule et al., 2016). 
We showed that HU causes down-regulation of BCL11A, KLF-1 and MYB was 
associated with a 7-fold up-regulation in HbF in both cell models. HU also differentially 
regulated several miRNAs including miR-15a, miR-16-1, miR-148a and miR-151-3p, 
however the increased production of HbF was particularly associated with miR-26b 
expression. The inhibition of the miRNAs, specifically miR-26b, unequivocally 
demonstrated the causative effect of HU on the induction of HbF through miRNA-
mediated inhibition of MYB expression. The pathway between MYB (activator of KLF-1), 
KLF-1 (activator of BCL11A) and BCL11A (potent repressor of HbF) was altered by HU-
induced expression of miR-26b, which was shown to directly target the 3’ untranslated 
regions (UTR) of MYB. Therefore, this demonstrates the potential of miRNAs as a 
viable therapeutically responsive tier of HbF production for SCD treatment, which may 
spare the undruggable nature of transcription factors such as BCL11A in non-erythroid 
cells.  
The use of K562 cells as an erythroid cell model remains contentious despite the fact 
that several studies have and continue to utilise this cell line as a model to investigate 
various components of γ-globin expression (Sankaran et al., 2011; Hahn & Lowrey, 
2014; Trakarnsanga et al., 2014; Zhu et al., 2014; Finotti et al., 2015; Aimola et al., 
2016). The main bone of contention is their bias expression of γ-globin. We however, 
saw this as an advantage in 2 ways: (i) the aim of this study was not to demonstrate the 
switching in expression of the globin genes (β to γ) but rather to use a stable cell line 
model in conjunction with cord blood-derived erythroid cells to demonstrate the 
associated increases in γ-globin and decreases in its regulators (BCL11A, KLF-1 and 
MYB) in response to HU, (ii) in choosing the whether to use miRNA mimics or anti-
miRNAs (miR-inhibitors), the high expression of γ-globin in K562 was considered. If our 
hypothesis of HU-induced miRNA-mediated repression of MYB was correct, the use of 
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mimics would not only introduce unnaturally high levels of miRNAs into this model 
(which we felt may in fact result in some artefactual results merely because of this 
unnatural state of aberrant concentration of miRNAs in the cells) but it would also be 
compounded by any co-treatments with HU in causing γ-globin expression. This 
rationale led to the choice of anti-miRNAs, which would go toward decreasing the 
already high levels of γ-globin in K562 (via miR-26b/MYB) and also provide an obvious 
opportunity for HbF rescue (with HU co-treatment) after miR-26b inhibition. Therefore, 
future studies should continue to evaluate the in-vivo impact of efficacious 
concentrations of HU on the erythroblast transcriptome, proteome, as well as the 
erythroid-specific micronome of SCD patients (before and after HU treatment) as the 
global analysis of these epigenetic mechanisms could highlight multiple components of 
this complex and heterogeneous regulatory system and possibly yield alternative 
(possibly miRNA-based) therapeutic approaches to hemoglobinopathies. 
Considering the scientific and clinical progress made in the past 106 years since the 
first report of SCD in 1910, we interrogated the available treatment approaches for SCD 
in Africa and examining the issue of investing in HSC transplantation in Africa (Pule & 
Wonkam, 2014). We reported on 5 broad treatment approaches (Ballas et al., 2012): (i) 
supportive, which is the most common and included a balanced diet, hydration and folic 
acid; (ii) blood transfusions, analgesia and antibiotics characterise the symptomatic 
approach as they specifically serve to alleviate a target symptom(s); (iii) the 
preventative approach is taken to preclude the occurrence of disease complications 
such as pneumonia and influenza vaccination for infections, HU for low HbF levels and 
blood transfusions to avert primary and secondary stroke episodes; (iv) although widely 
contentious, nitric oxide treatment is considered an abortive approach, reported to 
terminate chronic pain episodes and lastly (v) HSC transplantation as the sole curative 
treatment for SCD. We reported that despite accounting for >80% of the burden of 
disease, sub-Saharan Africa still faces major barriers to quality care and management 
of patients, which include safe and reliable blood transfusion services, clinical and 
laboratory expertise and equipment for accurate diagnosis, vaccinations and pain 
management drugs and stigmatization of the disease. SCD is becoming a worldwide 
health problem, with a burden comparable to that of communicable diseases and other 
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major global diseases such as diabetes and hypertension (Weatherall, 2008). 
Therefore, we strongly advocate for a commitment to collaboration among all 
stakeholders: health ministries, governments, private sector and pharmaceutical 
companies to develop cost-effective procedures for HSC transplants for 
hemoglobinopathies like SCD and β-thalassemia; conduct large-scale clinical trials and 
follow-up studies; perform studies on the epidemiology; health-related quality of life 
(HRQL) and patient survival rate; and most importantly, build technological and 
research capacity in Africa through teaching and training laboratory technicians and 
researchers. 
 
4.3. Sickle Cell Disease in Southern Africa 
 
The frequency of the HbS mutation has a strong correlation with the historical 
distribution of incidences of malaria, primarily due to the partial carrier-resistance to 
Plasmodium falciparum malaria parasite (Williams et al., 2005). Therefore, the 
geographical co-occurrence of the HbS mutation and malaria, taken in sum with the 
conferred partial carrier-resistance is believed to have resulted in the local amplification 
and positive selection of SCD in malaria-endemic regions (Flint et al., 1986; Flint et al., 
1998). Therefore, in sub-Saharan Africa, SCD has largely remained within the confines 
of the tropical equatorial malaria belt and its burden rarely experienced in southern 
Africa. As a result, similarities in anthropology and/or cultural practices have been used 
as proxy for generalizing genomic data. 
In this part of the study, we interrogated the commonly assumed congruence between 
genetics and culture/language/anthropology and sought to understand the origin and 
distribution of the HbS mutation and other SCD-related polymorphisms among southern 
African populations. Furthermore, we studied and confirmed the increasing burden of 
adult SCD patients at Groote Schuur Hospital (Cape Town), as previously reported in 
paediatric patients at Red Cross War Memorial Hospital (Cape Town) (Wonkam et al., 
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2012), with the primary aim being to caution national health and academic institutions to 
adapt policies, health care and professional training, accordingly. 
Within our 3 southern African study cohorts; Malawi, Zimbabwe and South Africa, we 
investigated the effect of the low environmental pressure from malaria in Malawi, 
Zimbabwe and, to a greater extent, South Africa, on the frequency of three genetic 
backgrounds associated with SCD; namely the HbS allele, conservation of the five loci 
in the β-globin gene cluster that confer the SCD haplotype and lastly, variants 
associated with resistance to malaria. Although we only interrogated about 100 
chromosomes from each cohort, the increasing frequency gradient of the HbS allele 
from 0% (South Africa), 6% (Malawi) and 12% (Zimbabwe), is proof of the concept that 
the HbS allele frequency increases with proximity to the tropical equatorial malaria belt. 
A similar trend was also observed for 2 of the 3 polymorphisms previously associated 
with malaria-resistance (Timmann et al., 2012), suggesting that although all three 
variants have been associated with resistance to severe malaria, only two (rs8176703 
and rs372091) are largely restricted to the equatorial malaria belt and thus possibly 
confer greater resistance to severe malaria as compared to the less equator-bound 
variant (rs2334880). The most apparent, although not surprising result, was the high 
frequency of the Atypical haplotype in all the study cohorts leading to the hypothesis 
that in such populations, the five loci of the β-globin gene cluster may be under less 
evolutionary pressure to remain conserved. This could be due to several reasons: there 
is no apparent clinical benefit to retaining an otherwise favourable haplotype in the 
absence of SCD and potentially its strongest environmental positive selector, malaria. 
Furthermore, this could be as a result of genetic drift and recombination at the β-globin 
gene cluster 
Although the vast majority of differentiated loci among Bantu populations are no more 
differentiated than would be expected from population drift, the modest data presented 
here, supports the proposed notion of dissociation between genetic background and 
ethno-linguistic attributes and classifications as demonstrated with populations that can 
loosely be defined as “Bantu” having disparate genetic backgrounds, particularly in loci 
that may be under positive selection due to the fitness benefit they confer, in this case 
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resistance to severe malaria. Despite the several shared cultural, linguistic and 
anthropological attributes such as common language roots, rite of passages and 
religious belief; our data further supports the notion that Bantu-speakers from Central 
and West Africa are no more genetically similar to those in Southern Africa, as 
previously illustrated with differential prevalence of HIV resistant genes amongst SSA 
populations (Kinomoto et al., 2005; Jenabian et al., 2015) and now with malaria 
associated variants. Given the vast genetic diversity within the continent and amongst 
any two SSA populations, the present data further emphasizes the need to redefine the 
classifications of various African groups by region-defined genomic attributes. This 
approach is likely to better serve the progress towards precision medicine, as opposed 
to the classical ethno-linguistic population classification approach. What remains 
apparent is the fact that the evident gene admixture and diversification of African 
populations did not result from a single North to South migration path nor a specific era, 
but rather through several independent and associated, multi-directional migration 
events further fortified by modern day immigration and continentalisation that continues 
to distribute previously restricted gene pools across the continent. 
As a testament of the distribution of previously locale-specific gene polymorphisms, we 
provided the first report describing the clinical and genetic backgrounds of SCD patients 
at Groote Schuur Hospital (GSH) and reporting on adult patients in South Africa. This 
study is a follow-up of a previous report at Red Cross War Memorial Children’s Hospital 
in Cape Town, showing rapid increase in the number of paediatric cases of SCD 
(Wonkam et al., 2012). From 128 patients’ files from 1995 to March 2016 reviewed in 
this study, 47 patients were diagnosed with some form of α- or β-thalassemia and of the 
remaining 81 patients affected by SCA (HbSS), 61 (75.3%) were from other Sub-
Saharan African countries. A key finding of this study was the marked 200% increase in 
the number of new cases of SCD patients at the GSH hematology clinic between 2011 
and 2016. The marked increase in patients between 2001 and 2005 could be 
associated with the ending of a civil war, transitional government and political instability 
in Congo, which had spread into neighbouring states whereas the 2011 – 2016 increase 
is more likely due to economic and health-motivated migration. This trend is expected to 
continue, compounded by future referrals from neighbouring paediatric hospitals, arrival 
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of new migrant patients, and the improved clinical management and healthcare of 
paediatric patients as the percentage of patients surviving to reproductive age continues 
to increase. However, the increasing prevalence of SCD is not unique to South Africa as 
similar trends have been reported in Ireland (Gibbons et al., 2015), Italy (Colombatti et 
al., 2013), Germany (Zur, 2016), England (Pizzo et al., 2015) and France (Habibi et al., 
2015). The novelty of this work is specifically the report on the genetic background of 
critical modifying loci of HbF; polymorphisms at the BCL11A erythroid-specific 
enhancer, β-globin haplotypes and α-thalassemia 3.7kb gene deletion. To improve 
clinical management and pharmacological accuracy in treatment, it is imperative to 
understand the genetic variants affecting the predisposition to specific complications 
such as stroke, acute chest syndrome, variants associated with susceptibility to pain, 
pharmacogenomics of the commonly prescribed treatments such as HU, malaria 
prophylaxis and vaccinations for infections. It warrants declaration that the intention of 
this study was not to, in any way, stigmatize SCD or immigrant patients but rather to 
provide necessary awareness to academic and training institutions, national health 
ministries and agencies about the changing distribution of the HbS allele and 
prevalence of SCD in Southern African countries, particularly in South African hospitals 
in order to better inform policies, regulations and management of SCD. 
 
Study limitations 
Limitations of molecular studies 
 
A limitation of the molecular studies was the use of two methods for HbF measurement: 
alkaline denaturation test (ADT) and, later when it became available, high performance 
liquid chromatography (HPLC) during the prospective patient recruitment in Cameroon. 
Although significant associations with HbF levels were present in both sub-sets of the 
patient cohort (after disaggregation of patient samples based on the HbF assessment 
technique (ADT vs HPLC)) and all association analysis in all the studies reported in this 
thesis were corrected for the electrophoresis technique, the use of HPLC for the whole 
cohort would have allowed more precise statistical approximation of the effect of various 
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polymorphisms on clinical events, disease course and hematological indices of SCD. 
Although the sample sizes used in the studies reported in this thesis were sufficient for 
the assertions and conclusions drawn from their results, more robust patient numbers, 
particularly in the cohorts used for the southern African perspective of SCD, would 
assist in the development of a more accurate model for the expansion and distribution 
of the HbS allele in southern Africa. Validation of novel variants associated with HbF 
levels in non-African populations is clearly important as it has been demonstrated by 
two of the manuscripts included in this thesis. However, the assessment of tag or 
targeted SNPs may be insufficient to replicate associations across populations. This 
may be because LD differs across different populations and therefore tag SNPs may 
very well be dissimilar between any two populations. The study of the burden of SCD in 
Cape Town was limited due to its retrospective nature as clinical and phenotype 
information were collected from patient files; thus the cohort was not emphatically 
phenotyped. A comparison among other populations within and outside of Africa with 
(and without) malaria exposure would be the ideal experiment to further demonstrate 
the inheritance of HbS-related polymorphisms in HbAA individuals. The experiments in 
this thesis were hypothesis-testing and have succeeded in providing interesting 
preliminary data that requires exploration in other populations and at scale. 
 
Limitations of functional studies 
 
One of the limitations of the functional studies was the limited number of CD34+ 
hematopoietic stem cells (HSCs) from umbilical cord blood samples. Post expansion 
and differentiation of primary erythroid cells, meant that there was often a limitation on 
the number and variety of experiments that could be carried out. Although we were able 
to demonstrate the inter-individual variation in response to HU, the use of non-clonal 
populations of erythroid cells introduced variables into the ex vivo model. The results 
from the ex vivo model should be validated in CD34+ HSCs in peripheral blood as well 
as bone marrow aspirates from SCD patients with varying clinical severity in order to 
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develop our understanding of the relation between patients’ miRNome and the clinical 
course of the disease. 
 
Implications of research 
 
There are several implications of the aspects of the research presented here as well as 
of the thesis as a whole: (i) The interrogation of genetic polymorphisms that modulate 
the hereditary persistence of the disease-ameliorating HbF in a cohort of African 
patients with severe clinical events such as stroke and vaso-occlusive crises will 
improve our understanding of the genomics and clinical management of African 
patients. Furthermore, the provocative hypothesis of a single origin of the HbS mutation 
in Africa, expansion and diversification of haplotypes will initiate an academic dialogue 
on the geographic nomenclature that forms the central dogma of SCD haplotypes; (ii) 
The work presented on the erythroid specific enhancer of BCL11A represents one of the 
most significant contributions of the work presented to our understanding of the 
heterogeneity and complexity of HbF regulation. The outcome of the BCL11A enhancer 
pre-clinical trial in the USA could be a giant leap in SCD treatment; (iii) The systematic 
review and comprehensive synthesis of the known mechanisms of the HbF-promoting 
effect of HU will serve as a reference for future studies on the progress made to date in 
building an understanding of the molecular pathways involved in HU treatment, and a 
guide for future areas of research towards developing novel therapeutic approaches; 
(iv) In the same way, we developed a HU-induced post-transcriptional miRNAs-
mediated pathway of HbF induction through silencing of potent negative regulators such 
as MYB, KLF-1 and BCL11A, and in the process putting forth miRNAs as candidate 
targets for future therapeutic interventions in SCD; (v) The exploration of the effect of 
malaria on SCD-related polymorphisms will contribute to our understanding of the 
epidemiology of SCD in sub-Saharan Africa, particularly in and around the tropical 
equatorial malaria belt of central Africa; Lastly, the report of the expansion and 
distribution of the HbS allele in southern Africa, regions that were historically devoid of 
the mutation, will provide the necessary awareness to governments, healthcare 
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providers and teaching institutions to adapt health policies and practices to this 
increasing prevalence of SCD. 
 
Conclusions and perspectives 
 
The present study is the first to collectively address 3 pertinent components of SCD in 
sub-Saharan Africa: (i) the genomic modifiers of the persistence of HbF in adult patients 
from Cameroon; (ii) collate the current knowledge base of mechanisms of HU-induced 
HbF and unequivocally demonstrate a functional model of the miR-26b/MYB post-
transcriptional signalling pathway for the induction of HbF by HU; and (iii) provide 
evidence of the increasing prevalence of the HbS allele in southern Africa, particularly 
South Africa, a country historically devoid of SCD. The sum of the work presented in 
this thesis has significantly contributed to our understanding of the genetics and 
treatment of SCD. 
This work has also highlighted the clinical significance of the erythroid specific BCL11A 
enhancer and its account for variance in HbF levels. A review of the global distribution 
of β-globin haplotypes has yielded a provocative hypothesis of a single African origin of 
the HbS mutation and interrogation of the geographic nomenclature used in defining 
SCD haplotypes. Epigenetic and transcriptional events, signal transduction pathways 
and post-transcriptional pathways were highlighted as broad categories of reported 
molecular processes that involved HU induction of HbF. Furthermore, an umbilical cord 
blood-derived erythroid model was used to show HU-induced HbF production through 
down-regulation of negative regulators, BCL11A, KLF-1 and MYB, by miRNA-mediated 
action with miR-26b-silencing of MYB central to HbF induction. Closer to home, the data 
presented in this thesis confirmed the evolutionary dynamics of various African 
genomics in response to selection pressure from malaria, and strongly prompted the 
dissociation of the assumed congruence between the genetics and 
cultural/linguistic/anthropological heritages of African populations. Furthermore, we 
provided evidence of the increasing burden of adult SCD patients in South Africa, 
cautioning national health institutions to adapt policies accordingly. 
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Taken in sum, the data presented is a comprehensive account of SCD in sub-Saharan 
Africa, comprising the following: components of SCD haplotype distribution, collation of 
the knowledge base on HU mechanisms of HbF induction; elucidation of a novel post-
transcriptional miRNAs-mediated regulatory pathway for HbF induction by HU; 
interrogation of the evolutionary dynamics of African genomes and congruence between 
genetics and anthropological heritages; and a report on the expansion of SCD into 
southern Africa. The anticipated outcomes of this collective body of work are an 
expanded understanding of the effect of genomic modifiers on the disease-ameliorating 
HbF, the distribution of such polymorphisms across the continent and the emphasis on 
the potential role of post-transcriptional therapeutic targets in SCD treatment. 
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Hydroxyurea induces γ-globin expression through microRNAs-mediated actions in human 
hematopoietic and K562 erythroleukemia cells. 
 
D.G. Pule1, S. Mowla2, N. Novitzky2, A. Wonkam1.  
 
1) Human Genetics, Clinical Laboratory Sciences, University of Cape Town, Cape Town, Western Cape, South Africa; 2) 
Hematology, Clinical Laboratory Sciences, University of Cape Town, Cape Town, Western Cape, South Africa. 
 
Background: Hydroxyurea is the only available drug treatment for Sickle Cell Disease (SCD); but the 
mechanism of fetal hemoglobin (HbF) induction is poorly understood. In particular, the role of microRNAs 
in the post-transcriptional regulation of HbF, through potent regulators such as MYB, BCL11A and KLF-1, is 
understudied. 
Objectives: We have investigated the role of microRNAs in the post-transcriptional regulation of HbF in 
erythroid cells treated with hydroxyurea. 
Methods: As models, we used 1) hematopoietic stem cells derived from umbilical cord blood (HSCs) and 2) 
the K562 human erythroleukemia cell line. Both primary erythroid and K562 cells were treated with 
hydroxyurea and changes in BCL11A, KLF-1, GATA-1, MYB, β- and γ-globin gene expression and 7 targeted 
miRNAs, previously shown to be modified by hydroxyurea or associated with basal γ-globin expression 
were also investigated. 
Results: We differentiated CD34+ stem cells into erythroid precursors using a single-phase expansion and 
differentiation protocol. BCL11A was down-regulated and there was a marked 7-fold increase (p < 0.003) in 
γ-globin expression in both primary human erythroid and K562 cells. Down-regulation of GATA-1 was also 
consistent with the above findings. Similarly, KLF-1 was down-regulated in both cell models, corresponding 
to the repressed expression of BCL11A and β-globin gene (p < 0.04). In both cell models, most miRNAs was 
significantly up-regulated by hydroxyurea with some level of variation. Down-regulation of, another potent 
negative regulator of γ-globin and direct target of the up-regulated miR-15a and miR-16-1, provides a post-
transcriptional tier of HbF regulation. We also demonstrated that the inhibition of miR-26b; miR-151-3p and 
miR-451 resulted in an apparent decrease in HbF. 
Conclusions: The data provide evidence of a microRNAs-mediated post-transcriptional mechanism for γ-
globin regulation under hydroxyurea treatment. These findings will add a unique piece to our understanding 
of HbF regulation and incite further investigation of the post-transcriptional regulatory network for HbF 
expression. 
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